The New England Comparative Effectiveness Public Advisory Council
Public Meeting – October 29, 2014

Controversies in the Management of Patients with Type 2 Diabetes

Final Report – December 2014

Authored by:

ICER
INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW
# Table of Contents

Executive Summary .................................................................................................................................................. 4

1. Introduction ......................................................................................................................................................... 18

2. Background ......................................................................................................................................................... 20

3. Coverage Policies............................................................................................................................................... 31

4. Clinical Guidelines and Policy Statements .................................................................................................... 40

5. Evidence Review............................................................................................................................................... 46

6. Economic Evaluation ...................................................................................................................................... 64

7. Questions and Discussion................................................................................................................................. 83

References............................................................................................................................................................... 95

Appendix A: Literature Search and Synthesis Strategy ....................................................................................... 106

Appendix B: Results of Obesity-Related Sensitivity Analyses ............................................................................ 108

Appendix C: Summary Evidence Tables ............................................................................................................. 109

Appendix D: Results of Medicaid Sensitivity Analyses ....................................................................................... 126

Appendix E: Meeting Agenda and List of Participants ....................................................................................... 127

Appendix F: CEPAC Conflict of Interest Policy for Voting Members ............................................................... 129
About ICER
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. ICER receives funding from government grants, non-profit foundations, health plans, provider groups, and health industry manufacturers. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide the foundation for a more effective, efficient, and just health care system. More information about ICER is available at www.icer-review.org.

About CEPAC
The New England Comparative Effectiveness Public Advisory Council (CEPAC), an independent, regional body of practicing physicians, methodological experts, as well as patient/public members, provides objective, independent guidance on the application of medical evidence to clinical practice and payer policy decisions across New England. Led by the Institute for Clinical and Economic Review, CEPAC was originally funded by a federal grant from the Agency for Healthcare Research and Quality (AHRQ), but is now supported by a broad coalition of state Medicaid leaders, integrated provider groups, public and private payers and patient representatives. For more information on CEPAC, please visit cepac.icer-review.org.
Executive Summary

Abstract

On October 29, 2014 the New England Comparative Effectiveness Public Advisory Council (CEPAC) held a public meeting in Providence, RI on “Controversies in Type 2 Diabetes Management.” The Council reviewed evidence summarized by the Institute for Clinical and Economic Review (ICER) on the comparative clinical effectiveness and comparative value of multiple pharmacological options for second- and third-line treatment in patients with inadequate glycemic control on metformin monotherapy or the combination of metformin and a sulfonylurea, the most widely accepted initial medication choices for type 2 diabetes. The drug classes assessed in the review include: sulfonylureas, insulin, and two relatively new classes of medications, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. CEPAC also reviewed the evidence on multiple forms of insulin and methods for insulin delivery, as well as the potential benefits of continuous blood glucose monitoring in this population. Following their votes, CEPAC then explored how best to apply the evidence to practice and policy with a distinguished Policy Expert Roundtable of clinical experts, health plan representatives, and a patient advocate from across New England.

In evaluating the evidence on different insulin formulations, CEPAC determined that NPH insulin (intermediate-acting human insulin) is functionally equivalent to long-acting insulin analogs, and has “high” comparative value. A Cochrane review of eight randomized control trials (RCTs) comparing NPH insulin to insulin analogs found no significant between-group differences in glycemic control, changes in body weight, or adverse events, with the exception of a reduction in nonsevere hypoglycemia for insulin analogs. NPH insulin is also much less expensive—average wholesale prices are approximately one-third of those for insulin analogs. The results of ICER’s economic modeling suggest that for every 1,000 patients treated with insulin, a switch from insulin analogs to NPH insulin would result in approximately $1.7 million in cost savings. In New England, reducing the percentage of patients using insulin analogs from the current estimate of 80% to 50% would result in over $100 million in savings.

In assessing the evidence on second-line treatment options, CEPAC determined that the available evidence was inadequate to determine the superiority of DPP-4 inhibitors when added to metformin compared to metformin+sulfonylurea. The Council also considered the evidence inadequate for DPP-4 inhibitors when used as a third-line option with metformin and a sulfonylurea, in comparison to metformin+sulfonylurea+insulin. In the case of GLP-1 receptor agonists, the Council voted that this drug class is more effective than sulfonylureas and insulin as either a second- or third-line treatment option, but has low comparative value due to substantially higher treatment costs (details of cost-effectiveness analysis included in full report). A systematic review by the Canadian Agency for Drugs and Technologies in Health (CADTH) of RCTs assessing the effectiveness of different second-line agents found statistically significant reductions in HbA1c versus placebo across all major drug classes analyzed, with the greatest reductions for GLP-1 receptor agonists and insulin. Another CADTH systematic review of randomized control trials comparing third-line pharmacotherapy added to metformin and a sulfonylurea for type 2 diabetes found statistically significant reductions in HbA1c across all drug combinations, with the most significant reduction with insulin. The addition of a GLP-1 receptor agonist was associated with reductions in HbA1c similar to those of insulin, but with significant weight loss compared to other combination therapies.

CEPAC also concluded that the evidence is inadequate to determine the comparative effectiveness of insulin pump therapy versus multiple daily injections or continuous glucose monitors versus self-monitoring of blood glucose, as data are very limited on the benefit of these management tools in the type 2 diabetes population.
Background

The management of type 2 diabetes has received significant attention over the past decade due to the increasing prevalence of this condition and the rise in costs associated with its treatment. Approximately 29 million Americans have diabetes, of whom 95% have the type 2 form (CDC, 2014a). In 2012, the annual cost of managing diabetes was estimated to total $245 billion, including both direct medical costs and lost productivity resulting from complications (CDC, 2014a). This estimate represents a 41% increase in diabetes-related expenditures since 2007 (ADA, 2013).

The primary aims of treatment for type 2 diabetes are to control blood sugar levels and manage the patient’s risk of major complications. Close monitoring of blood sugar and glycated hemoglobin (HbA1c) levels are a key aspect of type 2 diabetes management, following multiple randomized controlled trials (RCTs) that have demonstrated the benefit of tight glycemic control in reducing the risk of microvascular complications in patients with diabetes (King et al., 1999; DCCT, 1987).

For patients unable to manage their type 2 diabetes with lifestyle modifications alone, oral medications or insulin therapy are necessary to achieve target blood glucose levels. There is general consensus that metformin – a biguanide that works by decreasing the amount of glucose absorbed from food and the amount of glucose produced by the liver – is the most effective first-line medication option available for most patients (Holman, 2007; Roumie, 2012). However, for many patients with type 2 diabetes additional medications are required to control blood glucose, and a second or sometimes third pharmacologic option will be added to the treatment regimen. A number of questions remain, however, regarding management options for patients with more complex disease, including: the relative advantages and risks associated with different pharmacologic combination therapies, including newer drug classes like dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists; the best strategies for initiating insulin treatment; the comparative clinical effectiveness and value of different types and delivery methods of insulin; and the role of more intensive glucose monitoring in comparison to conventional monitoring approaches.

In this report for the New England Comparative Effectiveness Public Advisory Council (CEPAC), we examined the evidence on the following second- and third-line medications: sulfonylureas, GLP-1 receptor agonists, DPP-4 inhibitors, and insulin. We also reviewed the comparative effectiveness and costs associated with different insulin formulations, as well as devices to support insulin delivery and glycemic control in the type 2 diabetes population, including insulin pumps and continuous glucose monitors.
Evidence Review

We conducted a review of published evidence on the comparative effectiveness and value of certain treatment options for the management of type 2 diabetes, which was framed according to multiple scoping domains of policy interest in New England. Given the very broad scope of this review, we relied on published and authoritative systematic reviews as a starting point for each research domain and supplemented these findings with any additional RCTs, comparative cohort studies, or case series that have been published following the literature searches for each of these reviews.

Long-acting Insulin Analogs versus NPH Insulin

Evidence from a Cochrane review (Hovarth, 2009) as well as subsequent clinical studies found no substantial differences between long-acting insulin analogs (insulin glargine or detemir) compared with intermediate-acting human (NPH) insulin in glycemic control, changes in body weight, or adverse events, with the exception of a reduction in nonsevere hypoglycemia (i.e., symptomatic or nocturnal events) for insulin analogs. Because the true level of harm associated with nocturnal and daytime nonsevere hypoglycemic episodes remains unknown, the overall comparative net health benefit of analog versus human insulin appears comparable or perhaps incremental. The degree of certainty about net benefit is moderate, given that the evidence base has produced relatively consistent findings.

Second-line Pharmacotherapy

There have been few head-to-head comparative trials of DPP-4 inhibitors, sulfonylureas, GLP-1 receptor agonists, and insulin as second-line agents for patients with continuing hyperglycemia on metformin. A systematic review (CADTH, 2013a) of RCTs found statistically significant reductions in HbA1c versus placebo across all major drug classes analyzed, with the greatest reductions for GLP-1 receptor agonists and insulin. Although severe hypoglycemic events were uncommon across all treatment combinations (1% or less), the insulins and sulfonylureas were associated with higher rates of severe hypoglycemia. Insulins and sulfonylureas were associated with increases in body weight, whereas GLP-1 receptor agonists and DPP-4 inhibitors were associated with weight-loss and weight-neutral outcomes, respectively. Subsequently published studies have produced similar findings.
Third-line Pharmacotherapy

Another CADTH systematic review (CADTH, 2013b) comparing third-line pharmacotherapy added to metformin and a sulfonylurea for type 2 diabetes found statistically significant reductions in HbA1c across all drug combinations, with the most significant reduction from insulins. The addition of a GLP-1 receptor agonist was associated with reductions in HbA1c similar to those of insulin, but with significant weight loss compared to other combination therapies. Basal insulin and DPP-4 inhibitors were associated with a significant excess risk of overall hypoglycemia relative to placebo. Severe hypoglycemia was relatively rare even for three-drug combinations, and many comparisons could not be made due to a lack of events in one or both study arms.

Insulin Pump Therapy versus Multiple Daily Injections

A recent systematic review and meta-analysis conducted by the Agency for Healthcare Research and Quality (AHRQ) (Golden, 2012) compared insulin pumps with multiple daily injections (MDI) and found no differences in glycemic control or weight gain, as well as insufficient evidence on hypoglycemic events, mortality, and other clinical outcomes. Although recent trials have provided some evidence of clinical benefit, these have suffered from methodological concerns and use of nonstandard outcomes. Findings from the evidence base of eight RCTs suggests a moderate level of certainty that insulin pumps provide a comparable net health benefit to multiple daily injections in patients with type 2 diabetes.

Continuous Glucose Monitors versus Self-Monitoring of Blood Glucose

Data are extremely limited with regard to the potential added benefits from real-time continuous glucose monitors compared to traditional self-monitoring of blood glucose in patients with type 2 diabetes. Given that neither the original AHRQ review (Golden, 2012) nor our subsequent search identified any comparative studies of continuous versus conventional glucose monitoring in type 2 diabetes patients who are taking insulin, the evidence appears insufficient to determine whether continuous monitoring provides added clinical benefit for these patients.
Economic Outcomes of Management Options for Type 2 Diabetes

We conducted a formal cost-effectiveness analysis of second- and third-line pharmacotherapy using a published, validated outcomes model. Because there are no clear clinical differences between insulin analogs and NPH, however, our approach was to simply document the budgetary impact of use of varying distributions of analog versus human insulins in New England. We did not attempt to model the economic impact of either insulin pumps or continuous glucose monitors given the dearth of evidence in patients with type 2 diabetes.

Cost-Effectiveness Model: Pharmacotherapy

We used the U.K. Prospective Diabetes Study (UKPDS) Outcomes Model, version 1.3 (Clarke, 2004) to estimate the lifetime clinical and economic effects of type 2 diabetes and its treatment. While the model is based on data collected entirely in the U.K., predictive equations from the study have been extensively validated against U.S.-based studies such as the Framingham Heart Study and the Wisconsin Epidemiology Study of Diabetic Retinopathy (Kothari, 2002). The model generates estimates of the incidence of major diabetes-related complications (e.g., heart failure, myocardial infarction) based on risk equations specific to certain demographic (e.g., age, race/ethnicity, BMI) and clinical (e.g., duration of diabetes, HbA1c, cholesterol) characteristics. Costs include those of treatment, management of diabetes in the absence of complications, and the initial as well as subsequent annual costs of managing complications. Estimates of quality of life (utilities) were based on data obtained during the UKPDS study itself. Details on all parameter estimates and sources of information can be found in the full report.

Second-Line Pharmacotherapy

All modeled regimens had comparable effects on the rate of diabetes-related complications, although the addition of GLP-1 receptor agonists to metformin resulted in a lower rate of heart failure than the other alternatives. This combination also resulted in the greatest gains in both unadjusted and quality-adjusted life expectancy (i.e., QALYs), but was also by far the most costly, resulting in cost-effectiveness estimates of over $20 million per diabetes death averted and nearly $700,000 per QALY gained versus metformin+sulfonylurea. The addition of DPP-4 inhibitors to metformin resulted in lower effectiveness and higher costs relative to metformin+sulfonylurea. Clinical gains with metformin+basal insulin were modest; the difference in treatment costs by insulin type resulted in vastly different cost-effectiveness estimates, however (e.g., $160,000 vs. $1 million per QALY gained for NPH insulin and insulin analogs, respectively). The cost-effectiveness of second-line pharmacotherapy combinations is presented in Table ES1 on the following page.
Table ES1. Cost-effectiveness of second-line treatments added to metformin for type 2 diabetes.

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Life Expectancy (years)</th>
<th>QALYs</th>
<th>Severe Diabetes Death (%)</th>
<th>Severe Hypoglycemia (%)*</th>
<th>Total Costs</th>
<th>vs. MET+SULF</th>
</tr>
</thead>
<tbody>
<tr>
<td>MET Alone (Ref)</td>
<td>11.01</td>
<td>8.33</td>
<td>21.5</td>
<td>N/A</td>
<td>$70,494</td>
<td>---</td>
</tr>
<tr>
<td>MET+SULF</td>
<td>11.11</td>
<td>8.43</td>
<td>20.5</td>
<td>1.0</td>
<td>$76,956</td>
<td>---</td>
</tr>
<tr>
<td>MET+GLP-1</td>
<td>11.17</td>
<td>8.49</td>
<td>20.3</td>
<td>No events</td>
<td>$117,184</td>
<td>$20,114,146</td>
</tr>
<tr>
<td>MET+DPP-4</td>
<td>11.10</td>
<td>8.42</td>
<td>20.8</td>
<td>&lt;0.1</td>
<td>$104,026</td>
<td>†</td>
</tr>
<tr>
<td>MET+Insulin Analog</td>
<td>11.13</td>
<td>8.45</td>
<td>20.4</td>
<td>0.9</td>
<td>$101,839</td>
<td>$24,883,051</td>
</tr>
<tr>
<td>MET+NPH Insulin</td>
<td>11.13</td>
<td>8.45</td>
<td>20.4</td>
<td>0.9</td>
<td>$80,817</td>
<td>$3,861,003</td>
</tr>
</tbody>
</table>

*Not from model; pooled findings from RCTs in CADTH review
†Less effective, more expensive
MET: Metformin; SULF: Sulfonylurea; GLP-1: Glugacon-like peptide-1 agonist; DPP-4: Dipeptidyl peptidase-4 inhibitor

Third-Line Pharmacotherapy

As with second-line pharmacotherapy, third-line combinations had comparable impacts on development of all diabetes-related complications with the exception of heart failure, where lower rates were generated for the combination of metformin, a sulfonylurea, and a GLP-1 receptor agonist. In comparison to the referent combination of metformin+sulfonylurea+NPH insulin, the GLP-1 receptor agonist combination averted six diabetes-related deaths per 1,000 treated and resulted in a slight improvement in quality-adjusted life expectancy (six days). Costs were significantly higher, however, resulting in incremental costs per diabetes death averted and per QALY gained of approximately $5 million and $1.8 million, respectively. Cost-effectiveness ratios could not be generated for DPP-4 inhibitor- or insulin analog-based regimens due to equivalent or lower effectiveness and higher cost. Cost-effectiveness findings for third-line pharmacotherapy can be found in Table ES2 on the following page.
Table ES2. Cost-effectiveness of third-line treatments added to metformin+sulfonylurea for type 2 diabetes.

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Life Expectancy (years)</th>
<th>Diabetes Death (%)</th>
<th>Severe Hypoglycemia (%)*</th>
<th>Total Costs</th>
<th>vs. MET+SULF+NPH</th>
</tr>
</thead>
<tbody>
<tr>
<td>MET+SULF (Ref)</td>
<td>9.02</td>
<td>24.6</td>
<td>N/A</td>
<td>$ 81,773</td>
<td>---</td>
</tr>
<tr>
<td>MET+SULF+NPH Insulin</td>
<td>9.21</td>
<td>23.6</td>
<td>1.1</td>
<td>$ 91,025</td>
<td>---</td>
</tr>
<tr>
<td>MET+SULF+GLP-1</td>
<td>9.23</td>
<td>23.0</td>
<td>1.5</td>
<td>$ 122,181</td>
<td>$ 5,192,565</td>
</tr>
<tr>
<td>MET+SULF+DPP-4</td>
<td>9.13</td>
<td>23.8</td>
<td>2.6</td>
<td>$ 111,048</td>
<td>$ 1,771,354</td>
</tr>
<tr>
<td>MET+SULF+Insulin Analog</td>
<td>9.21</td>
<td>23.6</td>
<td>1.1</td>
<td>$ 108,717</td>
<td>⬤</td>
</tr>
</tbody>
</table>

*Not from model; pooled findings from RCTs in CADTH review
†Less effective, more expensive
‡Equally effective, more expensive
MET: Metformin; SULF: Sulfonylurea; GLP-1: Glugacon-like peptide-1 agonist; DPP-4: Dipeptidyl peptidase-4 inhibitor

Budgetary Impact Model: Insulin Analogs vs. NPH Insulin

Our intent was to document the one-year budgetary impact of changes in the distribution of NPH insulin versus insulin analogs in type 2 patients using insulin as add-on therapy to other antidiabetic drugs. In keeping with assumptions made for the cost-effectiveness analysis, we assumed no difference in major clinical outcomes by insulin type; we do present estimates of the numbers of patients who would experience nocturnal hypoglycemia at different distributions, however. While the clinical significance of this outcome remains uncertain, it was the one variable that differed materially in head-to-head RCTs of NPH and insulin analogs. Annual costs of NPH and insulin analogs were estimated based on typical add-on dosing (0.3 U/kg) for an individual weighing 89kg.

Based on our estimates, of the 11 million adults currently residing in New England, approximately 1.4 million (12%) have type 2 diabetes. Of these individuals, slightly more than 200,000 are currently using insulin to help manage their condition, with 80% of users receiving insulin analogs. Reductions in the proportion of individuals receiving insulin analogs would increase the number experiencing nocturnal hypoglycemia, as the rate of these events with NPH insulin is nearly double that of insulin analogs. If 65% of patients were receiving insulin analogs, an additional 18 patients per 1,000 treated would experience nocturnal hypoglycemia (an increase of 9%). If this distribution were to be reversed (i.e., 65% of patients receiving NPH insulin), the number would grow by an additional 56 patients over baseline (a 27% increase).
As shown in Figure ES1 below, the high percentage of insulin analog recipients, coupled with prices that are approximately threefold higher for insulin analogs versus NPH (i.e., $2,661 vs. $986 annually) results in annual expenditures in the region of nearly $500 million, 92% of which is driven by insulin analog costs. Simply put, for every 1,000 patients treated with insulin, a switch from insulin analogs to NPH insulin would result in approximately $1.7 million in cost savings.

**Figure ES1. Budgetary impact of shifts in the distribution of insulin analog vs. NPH insulin use in New England.**

<table>
<thead>
<tr>
<th>Baseline (80%)</th>
<th>65%</th>
<th>50%</th>
<th>35%</th>
<th>20%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Analog</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NPH</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**CEPAC Votes on Comparative Clinical Effectiveness and Value**

During CEPAC public meetings, the Council deliberates and votes on key questions related to the review of the evidence produced by ICER. At the October 29, 2014 meeting, CEPAC discussed and placed votes on questions concerning the comparative clinical effectiveness and comparative value of second- and third-line treatment options for type 2 diabetes, as well as devices to support insulin delivery and the monitoring of blood glucose.

When voting on comparative value, CEPAC was asked to assume the perspective of a state Medicaid program that must make resource decisions within a relatively fixed budget for care. CEPAC is not given prescribed boundaries or thresholds for budget impact or incremental cost-effectiveness ratios to guide its judgment of low, reasonable, or high value. However, CEPAC did make use of a series of value categories designed by ICER to assist the Council in assigning an overall value rating (see Table ES3 on the following page). CEPAC members who vote “no” on comparative clinical
effectiveness are designated to a special “low” value vote category for lack of evidence to demonstrate comparative clinical effectiveness. Because all of the voting questions asked whether a particular drug or device was equivalent to or better than a comparator, CEPAC did not have the option to vote for two of the categories shown in the value matrix below, as these categories refer to a drug or device that has “worse outcomes”.

Table ES3. Evidence Categories for Ratings of Low, Reasonable/Comparative, and High Value.

<table>
<thead>
<tr>
<th>Low Value</th>
<th>Reasonable/Comparable Value</th>
<th>High Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Worse outcomes; Higher or equivalent cost</td>
<td>Worse outcomes; Lower cost</td>
<td>Comparable outcomes; Lower cost</td>
</tr>
<tr>
<td>Comparable outcomes; Higher costs</td>
<td>Comparable outcomes</td>
<td>Promising but inconclusive evidence of better outcomes; Lower cost</td>
</tr>
<tr>
<td>Promising but inconclusive evidence of better outcomes; Higher cost</td>
<td>Promising but inconclusive evidence of better outcomes; Comparable cost</td>
<td>Better outcomes; Lower or comparable cost</td>
</tr>
<tr>
<td>Better outcomes; Too high a cost</td>
<td>Better outcomes</td>
<td>Better outcomes; Slightly higher cost</td>
</tr>
<tr>
<td></td>
<td>Reasonable higher cost</td>
<td></td>
</tr>
</tbody>
</table>

**Human insulin vs. insulin analogs**

1. Is the evidence adequate to demonstrate that NPH insulin (intermediate-acting human insulin) is functionally equivalent to long-acting insulin analogs for most patients with type 2 diabetes?

9 yes (100%)  0 no (0%)

2. If yes, from the perspective of a state Medicaid program, would you judge the value of NPH insulin compared to long-acting insulin analogs to be high, reasonable, or low?

9 high (100%)  0 reasonable (0%)  0 low (0%)
Combination therapy with Metformin plus DPP-4 inhibitor or sulfonylurea

3. Is the evidence adequate to demonstrate that combination therapy with metformin + DPP-4 inhibitor is superior to metformin + sulfonylurea for most patients with type 2 diabetes for whom metformin monotherapy provides inadequate glycemic control?

1 yes (11%) 8 no (89%)

4. Is the evidence adequate to demonstrate that combination therapy with metformin + GLP-1 receptor agonist is superior to metformin + sulfonylurea for most patients with type 2 diabetes for whom metformin monotherapy provides inadequate glycemic control?

6 yes (67%) 3 no (33%)

5. If yes, from the perspective of a state Medicaid program, would you judge the value of metformin + GLP-1 receptor agonist compared to metformin + sulfonylurea to be high, reasonable, or low?

0 high (0%) 0 reasonable (0%) 6 low (100%)

Combination therapy with Metformin plus sulfonylurea + either DPP-4 inhibitor or insulin

6. Is the evidence adequate to demonstrate that combination therapy with metformin + sulfonylurea + DPP-4 inhibitor is superior to metformin + sulfonylurea + NPH insulin for most patients with type 2 diabetes with inadequate glycemic control?

0 yes (0%) 9 no (100%)

Combination therapy with Metformin plus sulfonylurea + either GLP-1 receptor agonist or insulin

7. Is the evidence adequate to demonstrate that combination therapy with metformin + sulfonylurea + GLP-1 receptor agonist is superior to metformin + sulfonylurea + NPH insulin for most patients with type 2 diabetes with inadequate glycemic control?

6 yes (67%) 3 no (33%)
8. If yes, from the perspective of a state Medicaid program, would you judge the value of metformin + sulfonylurea + GLP-1 receptor agonist compared to metformin + sulfonylurea + NPH insulin to be high, reasonable, or low?

<table>
<thead>
<tr>
<th></th>
<th>high (0%)</th>
<th>reasonable (0%)</th>
<th>low (100%)</th>
</tr>
</thead>
</table>

**Insulin pumps vs. multiple daily injections**

9. Is the evidence adequate to demonstrate that any clinical subpopulation of patients with type 2 diabetes does better with insulin pumps compared to multiple daily injections?

<table>
<thead>
<tr>
<th></th>
<th>yes (0%)</th>
<th>no (100%)</th>
</tr>
</thead>
</table>

**Self-monitoring of blood glucose vs. Continuous glucose monitors**

10. Is the evidence adequate to demonstrate that any clinical subpopulation of patients with type 2 diabetes does better with continuous glucose monitors compared to self-monitoring of blood glucose?

<table>
<thead>
<tr>
<th></th>
<th>yes (0%)</th>
<th>no (100%)</th>
</tr>
</thead>
</table>

**Recommendations to Guide Practice and Policy in New England**

Following CEPAC’s deliberation on the evidence and subsequent voting, the Council engaged in a moderated discussion with a Roundtable composed of clinical experts, a patient advocate, and regional health insurers. The participants in the Roundtable discussion are shown in Table ES4 on the following page.
The Roundtable discussion explored the implications of CEPAC’s votes for clinical practice and medical policy, considered real life issues critical for developing best practice recommendations in this area, and identified potential avenues for applying the evidence to improve patient care. The main themes and recommended best practices from the conversation are summarized in the sections below. The Policy Expert Roundtable discussion reflected multiple perspectives and opinions and therefore none of the recommendations that follow should be taken as a consensus view held by all participants.

1. Clinicians should make treatment decisions with a consideration of the psycho-social context in which medications are being used. Health care teams that integrate nurse case managers, community health workers, behavioral health providers, pharmacists, and diabetes educators are ideal for providing comprehensive management of the condition and ensuring that different treatment approaches are feasible given each patient’s unique circumstances.

2. Consideration of pharmacotherapy for patients with type 2 diabetes should be only one component of a broader management plan that emphasizes lifestyle changes and behavioral support.

3. To the extent possible, clinicians should determine appropriate HbA1c targets based on individual factors.

4. Based on the best available evidence, clinicians and payers should consider aligning patient education, practice standards, and payment policies to start patients who require insulin on human formulations first, unless there are contraindications or other factors suggesting that initiation on insulin analogs would be preferred.
5. Health plans and provider organizations should promote the use of high value drug treatment options while crafting approaches that are flexible enough to allow for personalized care that can meet individual patient needs. Specifically:

- **First-line therapy:** Nearly all patients requiring pharmaceutical treatment should be started on metformin as first-line therapy, and the use of metformin should be optimized before considering the addition of other options.

- **Second-line therapy:** For many patients who do not reach adequate blood sugar control with metformin monotherapy, second-line therapy with sulfonylureas is a reasonable choice. Although CEPAC voted that GLP-1 receptor agonists offer incremental clinical benefits related to reduced weight gain and incidence of hypoglycemia – benefits that will be of greater potential importance for some patients than others – CEPAC felt that the balance of the clinical benefits versus the high per-patient incremental cost made GLP-1 receptor agonists a “low value” second-line therapy compared to sulfonylureas. The evidence was not considered adequate to demonstrate clinical advantages of DPP-4 inhibitors over less-expensive sulfonylureas as second-line therapy.

- **Third-line therapy:** For patients who need additional therapy after metformin plus sulfonylureas, the evidence suggests that adding NPH insulin is a reasonable choice. As with second-line treatment, CEPAC voted that GLP-1 receptor agonists offer incremental clinical benefits versus NPH insulin related to reduced weight gain and incidence of hypoglycemia, benefits that will be of greater potential importance for some patients than others. Here too, CEPAC felt that the balance of the clinical benefits versus the high per-patient incremental cost made GLP-1 receptor agonists a “low value” third-line therapy compared to NPH insulin. The evidence was inadequate to demonstrate clinical advantages of DPP-4 inhibitors over less-expensive NPH insulin as a third-line therapy.

6. The policy and clinical community should support the development of evidence and future research in the following areas:

- Further study of insulin pumps and continuous glucose monitors is needed to understand if certain patient subpopulations with type 2 diabetes may benefit from these technologies. For future research to be relevant, additional regulation may be required from the FDA since at present, devices change and are upgraded so frequently that conducting meaningful long-term studies is impossible. CEPAC members recognized the challenge to developing a robust evidence base for devices as it is more difficult to perform a blinded study and there may be issues regarding confounding.
• Further research is needed to understand the heterogeneity of treatment effects, specifically for identifying patient subpopulations whose risk of significant hypoglycemia should lead to initial treatment with insulin analogs, GLP-1 receptor agonists, or DPP-4 inhibitors. Many important patient subpopulations are excluded from clinical trials, so little is known at present about treatment effects in patient groups that are not well studied.

• The research community should develop study designs that reflect patient preferences and analyze treatment regimens that are feasible for patients to maintain. Further studies should also be framed around more patient-centered questions, like the percentage of patients that achieve reductions in HbA1c levels without experiencing an adverse event. Conceptualized this way, research will more helpfully inform treatment decisions by addressing the questions that matter most to patients.

• Additional long-term studies are also needed that analyze primary rather than intermediate outcomes. Patient and clinical communities want to know the effect new medications have on mortality, myocardial infarction, stroke, and other long term complications of diabetes (e.g. retinopathy, neuropathy). Evidence on long-term outcomes exist for sulfonylureas, but are still lacking for newer medications.
1. Introduction

To make informed health care decisions, patients, clinicians, and policymakers must consider many different kinds of information. Rigorous evidence on the comparative clinical risks and benefits of alternative care options is always important; but along with this information, decision-makers must incorporate other considerations. Patients and clinicians must weigh patients’ values and individual clinical needs. Payers and other policymakers must consider information about current patterns of utilization, and the impact of any new policy on access, equity, and the overall functioning of systems of care. All decision-makers, at one level or another, must also take into account the costs of care, and make judgments about how to gain the best value for every health care dollar.

The goal of the New England Comparative Effectiveness Public Advisory Council (CEPAC) is to provide a forum in which all these different strands of evidence, information, and public and private values are discussed together, in a public and transparent process. Funded by a consortium of state Medicaid agencies, private payers, and integrated provider groups, and backed by a diverse set of New England state policymakers, the mission of CEPAC is to provide objective, independent guidance on how information on comparative effectiveness can best be used across New England to improve the quality and value of health care services. The Council is an independent body composed of clinicians and patient or public members from each New England state with skills in the interpretation and application of medical evidence in health care delivery. CEPAC members are not selected for their expertise in the topic being addressed, but rather to provide an objective view of the evidence. At each meeting, CEPAC members make a determination of whether or not the evidence is adequate to demonstrate the comparative clinical effectiveness and value of the clinical interventions being addressed (see Section 7). Representatives of state public health programs and of regional private payers are included as ex-officio members of CEPAC. The latest information on CEPAC, including conflict of interest policies and guidelines for submitting comments, is available online: cepac.icer-review.org.

The Institute for Clinical and Economic Review (ICER) manages CEPAC and is responsible for developing evidence reviews for CEPAC consideration. ICER is a trusted non-profit organization that evaluates scientific evidence on the value of medical tests, treatments, and delivery system innovations and helps translate that evidence into action to improve patient care and control costs. By working collaboratively with patients, clinicians, manufacturers, insurers and other stakeholders, ICER develops tools to support patient decisions and medical policy that share the goals of empowering patients and improving the value of health care services. More information about ICER is available at www.icer-review.org.
ICER has produced this evidence review and policy analysis in response to increasing stakeholder interest in the management of type 2 diabetes, driven in large part by the rising prevalence of this condition, its significant clinical burden, and escalating out-of-pocket and overall costs of treatment in New England and across the country.

Increasing costs are in part due to the emergence of novel therapies and management tools for diabetes, including newer and costlier forms of insulin, insulin pump therapy, new classes of oral and injectable medications, and devices for the intensive monitoring of blood glucose. For patients unable to manage their type 2 diabetes with lifestyle modifications alone, oral medications or insulin therapy are necessary to achieve target blood glucose levels. Though metformin is widely accepted as an appropriate first-line medication for type 2 diabetes, a number of questions remain regarding management options for patients with more complex disease, including: the relative advantages and risks associated with different pharmacologic combination therapies, including newer drug classes like dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists; the best strategies for initiating insulin treatment; the comparative clinical effectiveness and value of different types and delivery methods of insulin; and the role of more intensive glucose monitoring in comparison to conventional monitoring approaches.

To address these concerns, ICER has undertaken a systematic literature review to examine the evidence on different management approaches for patients with type 2 diabetes. This report will support CEPAC’s deliberation and attempts to answer some of the key issues confronting patients, physicians, provider organizations, payers, and other policymakers. This review summarizes the evidence on different management approaches for type 2 diabetes and provides an overview of existing clinical guidelines and payer coverage policies impacting the delivery of care in New England and nationally. Several systematic reviews used in our assessment have found remarkably consistent treatment effects among individual drugs within a class (CADTH 2013a; CADTH 2013b); following the approach used in these reviews, we have also conducted our analyses at the class level. ICER also used a simulation model to explore the potential clinical and economic impact of various management strategies. The overall purpose of this report is to help enhance the use of evidence in practice and policy, and comments and suggestions to improve the work are welcome.
2. Background

2.1 The Condition

The management of type 2 diabetes has received significant attention over the past decade due to the increasing prevalence of this condition and the rise in costs associated with its treatment. Approximately 29 million Americans have diabetes, of whom 95% have the type 2 form (CDC, 2014a). In 2012, the annual cost of managing diabetes was estimated to total $245 billion, including both direct medical costs and lost productivity resulting from complications (CDC, 2014a). This estimate represents a 41% increase in diabetes-related expenditures since 2007 (ADA, 2013).

Diabetes mellitus is a metabolic disorder that is characterized by hyperglycemia (high blood sugar) in the context of the body’s resistance to insulin and a relative insufficiency of insulin production in the pancreas. Insulin is a hormone that is required to control blood glucose levels by supporting the movement of blood glucose into cells to be used as energy. The two main forms of diabetes are type 1 (formerly termed insulin-dependent diabetes) and type 2 (formerly termed non-insulin dependent diabetes). Type 1 diabetes occurs when the body’s immune system causes beta cells in the pancreas to be destroyed, reducing or completely eliminating the secretion of insulin. Individuals with type 1 diabetes require insulin-replacement therapy, either delivered by injection or pump, to survive. Type 1 diabetes accounts for about 5% of all diagnosed cases of diabetes, and its onset typically occurs in childhood.

Unlike type 1 diabetes, the type 2 form is categorized by insulin resistance, a condition in which the body is not using insulin effectively. Typically, liver cells react to the presence of insulin by suppressing the release of glucose. However, insulin resistance causes the liver to release glucose, which then accumulates in the blood rather than being absorbed and used by cells, leading to hyperglycemia. The body responds by producing more insulin, but eventually, the insulin-producing beta cells in the pancreas are unable to produce enough hormone to overcome insulin resistance. Type 2 diabetes develops gradually, and is generally considered to be caused by a combination of lifestyle factors, such as obesity, sedentary lifestyle, and alcohol consumption, as well as genetic factors (CDC, 2014b). A number of risk factors are associated with type 2 diabetes, including age, family history, excess weight, inactive lifestyle, high blood pressure, and certain ethnicities such as African American, Hispanic/Latin American, American Indian and Alaska Native, Asian-American, and Pacific Islander (CDC, 2014b). Though more common in adults, type 2 diabetes is becoming increasingly prevalent in younger populations due to the rise in childhood obesity. Presentation of type 2 diabetes symptoms varies, but may include thirst, frequent urination, hunger, weight loss, and fatigue (ADA, 2004).
Chronic hyperglycemia caused by diabetes can increase the risk of several serious complications, many of which can be delayed or prevented with appropriate treatment. Complications include:

- Retinopathy – an inflammatory condition of the eyes that can lead to blindness if untreated
- Neuropathy – nerve damage which may result in numbness in the hands, feet, legs, or arms
- Diabetic ketoacidosis – life-threatening condition brought on by the body burning fat for energy in the absence of sufficient glucose
- Kidney disease - progressive condition that can lead to kidney failure and dialysis
- Macrovascular complications - high blood pressure, cardiovascular disease, and stroke
- Hyperosmolar Hyperglycemic Nonketotic Syndrome (HHNS) – a condition characterized by severe dehydration that may lead to seizures, coma, or death
- Gastroparesis – disorder in which the vagus nerve is damaged, resulting in delayed or stopped passing of food through the stomach.

2.2 Management Options for Type 2 Diabetes

The primary aims of treatment for type 2 diabetes are to control blood sugar levels and manage the patient’s risk of major complications. Close monitoring of blood sugar and glycated hemoglobin (HbA1c) levels are a key aspect of type 2 diabetes management. Multiple randomized controlled trials (RCTs) have demonstrated the benefit of tight glycemic control in reducing the risk of microvascular complications in patients with diabetes. The UK Prospective Diabetes Study (UKPDS) assessed patients over a period of ten years and found that intensive glycemic control (median HbA1c = 7%) reduced the risk of microvascular disease by 25% compared to standard treatment (median HbA1c = 7.9%) in patients with type 2 diabetes (King et al., 1999). The Diabetes Control and Complications Trial (DCCT) also investigated the relationship between glycemic control and microvascular complications, finding that tighter glycemic control (mean HbA1c ~7%) in patients with type 1 diabetes was associated with a ~60% reduction in retinopathy, neuropathy, and nephropathy compared to patients in the standard group (HbA1c ~9%) (DCCT, 1987). As such, conventional practice standards emphasize lowering HbA1c levels to less than 7% for most patients with type 2 diabetes (AACE, 2013; Skylar et al., 2003).

The benefits of treating to specific thresholds have also recently been questioned, however (Teoh, 2011). Both the UKPDS and DCCT trials found an increased risk of hypoglycemia associated with intensive glycemic control due to the primary mechanism of action of some diabetes medications (described in more detail below). Hypoglycemia involves a wide range of symptoms, including dizziness, shakiness, confusion, hunger, and weakness brought on by dangerously low levels of blood glucose (below 70 mg/dl) (NIH, 2014). Hypoglycemia is a common occurrence for many
patients with diabetes, and is usually treated easily without complication (Briscoe et al., 2014). If left untreated, however, hypoglycemia can reach severe levels and result in seizures, comas, or death in very rare circumstances (Briscoe et al., 2014).

Healthy lifestyle changes (improved diet and level of exercise) are also a standard part of type 2 diabetes management, and for some individuals with early stage disease modifications in behavior are sufficient to achieve healthy blood glucose levels and/or delay the onset of complications (Ripsin, 2009). Given the progressive nature of type 2 diabetes, however, many patients will eventually require antidiabetic medications to help control blood sugar levels and manage other aspects of the condition.

There is general consensus that metformin – a biguanide that works by decreasing the amount of glucose absorbed from food and the amount of glucose produced by the liver – is the most effective first-line medication option available for most patients (Holman, 2007; Roumie, 2012). Metformin is generally regarded as safe as it does not result in weight gain or hypoglycemia (too-low blood sugar), side effects commonly associated with some other diabetes management options. However, for many patients with type 2 diabetes additional medications are required to control blood glucose, and a second or sometimes third pharmacologic option will be added to the treatment regimen. Additional management options include sulfonylureas, GLP-1 receptor agonists, DPP-4 inhibitors, and insulin. These agents are described below, and a summary table comparing the different medications can be found on page 29.

Part of the complexity of managing type 2 diabetes is the number of treatment approaches available. After consultation with external stakeholders regarding those aspects of type 2 diabetes treatment associated with the most variation and controversy, we have limited the scope of our review to a discussion of the second- and third-line medications listed above. Numerous other pharmacologic treatment options are available, including thiazolidinediones, meglitinides, and alpha-glucosidase inhibitors. In addition, bariatric surgery and other interventions seeking to modify risk factors for the progression of type 2 diabetes and its complications are also important considerations for many patients, but for practical reasons these other management options have not been included within the scope of this review.

**Pharmacological options**

**Sulfonylureas**

Sulfonylureas have been used in the treatment of type 2 diabetes for over 50 years (Aquilante, 2010). These oral medications work by binding to channels on pancreatic cells, increasing the release of insulin from the pancreas to control blood glucose levels. Sulfonylureas are available in a
number of generic and branded forms, and include different generations of agents (full details available in Table 1 on page 29). Sulfonylureas are generally used at earlier stages of the condition, given their reliance on functioning beta cells in the pancreas to stimulate the release of insulin (Aquilante, 2010). They may be used as first-line agents or in combination with metformin, thiazolidinediones, and other anti-hyperglycemic medications. The most common adverse effects include weight gain (though in some formulations this effect is less pronounced), water retention, and hypoglycemia (Micromedex® Healthcare Series, v. 2.). Hypoglycemia is of particular concern given the medication’s main mechanism of action. Sulfonylureas interact with a number of medications that may decrease their effectiveness, including beta blockers, calcium channel blockers, oral contraceptives, and thyroid medications (Micromedex® Healthcare Series, v. 2.). Sulfonylureas should also be avoided during pregnancy (Micromedex® Healthcare Series, v. 2.).

**Glucagon-like Peptide 1 (GLP-1) receptor agonists**

GLP-1 receptor agonists are part of new group of injectable drugs that control blood glucose with three different mechanisms: 1) by mimicking natural GLP-1 hormones to increase insulin secretion; 2) by suppressing pancreatic glucagon secretion (glucagon typically raises blood glucose levels); and 3) by slowing gastric emptying, or the passage of food from the stomach to the small intestine (Garber, 2011; Shyangdan, 2011). GLP-1 receptor agonists can be used as a monotherapy, or in combination with sulfonylureas, metformin, thiazolidinediones, or insulin glargine, a long-acting basal insulin analog (described in more detail later in this section). Available versions of GLP-1 receptor agonists include exenatide (Byetta®, Bydureon®, and Bydureon Pen®, AstraZeneca plc) and liraglutide (Victoza®, Novo Nordisk A/S), albiglutide (Tanzeum™, GlaxoSmithKline plc), and dulaglutide (Trulicity™, Eli Lilly and Company). Byetta was approved in 2005 and is administered twice daily prior to morning and evening mealtimes. Bydureon, approved in 2012, is a newer long-acting formulation that only requires a weekly injection. Victoza is injected once daily and received FDA approval in 2010. Tanzeum and Trulicity are newer formulations, both receiving FDA approval in 2014. Potential advantages of GLP-1 receptor agonists include their selective effects on insulin (i.e., insulin secretion is only stimulated when blood glucose levels are elevated, thereby reducing the risk of hypoglycemia when taken alone), glucagon suppression in the presence of glucose, and the promotion of weight loss given their mechanism of action (Garber, 2011; Bydureon® package insert, 2014). The most common side effects include nausea, diarrhea, and vomiting (Cernea, 2011). Serious adverse events may include pancreatitis, though a direct association with GLP-1 receptor agonist treatment is not well established (Cernea, 2011; Egan et al., 2014). Available GLP-1 receptor agonists also include black box warning labels for thyroid tumors due to studies done in animals suggesting a correlation (Micromedex® Healthcare Series, v. 2.). This effect in humans remains unknown, but the drug is contraindicated in individuals with a family or personal history of certain thyroid cancers (Micromedex® Healthcare Series, v. 2.).
Dipeptidyl peptidase-4 inhibitors (DPP-4 Inhibitors)

DPP-4 inhibitors, or gliptins, are a relatively new class of oral anti-hyperglycemic medications, first approved by the FDA in 2006. Like GLP-1 receptor agonists, DPP-4 inhibitors target the hormones that decrease blood glucose levels. Specifically, DPP-4 inhibitors interrupt DPP-4 enzymes, which destroy beneficial GLP-1 hormones and glucose-dependent insulinotropic polypeptide (GIP) (see above). By inhibiting the action of DPP-4 enzymes, the DPP-4 inhibitors allow GLP-1 hormones to promote the release of insulin and the suppression of glucagon in a glucose-dependent manner, leading to better blood glucose control (Karagiannis, 2014). DPP-4 inhibitors can be used as a monotherapy or as an adjunctive therapy with metformin, sulfonylurea, insulin, or thiazolidinedione (Dicker, 2011; Onglyza® package insert, 2013). Several DPP-4 inhibitor agents are available, including sitagliptin (Januvia®, Merck), saxagliptin (Onglyza®, AstraZeneca plc) and linagliptin (Tradjenta®, Boehringer Ingelheim Pharmaceuticals). The most common side effects include upper respiratory infection, nasopharyngitis, and headaches (Reid, 2012). DPP-4 inhibitors do not increase risk of severe hypoglycemia or weight gain (Reid, 2012). Links have also been established between DPP-4 inhibitors and pancreatitis, though a direct association is not well established (Cernea, 2011).

Insulin

Insulin therapy is designed to mimic the normal release of insulin from pancreatic beta cells in patients with uncontrolled hyperglycemia. Coming in many different forms, insulin can either be human synthetic, meaning that it is based on recombinant human DNA and therefore identical to the structure of natural insulin, or an insulin analog, which molecularly alters insulin to allow for more predictable cell absorption (UCSF, 2014). Both versions come in different formulations that affect the drug’s onset and duration of action. Insulin can be short- or rapid-acting (bolus), which involves administering insulin at different times in relation to meals, or it can be long- or intermediate-acting (basal) to seek consistent blood glucose levels throughout the day. Fast-acting insulin formulations include regular human insulin (HumuLIN R®, Eli Lilly and Company; Novolin R®, Novo Nordisk, A/S) and analogs insulin aspart (NovoLog®, Novo Nordisk, A/S), insulin glulisine (Apidra®, Sanofi-Aventis U.S. LLC), and insulin lispro (Humalog®, Eli Lilly and Company). Long- or intermediate acting insulin formulations include neutral protamine Hagedorn (NPH) (Humulin N®, Eli Lilly and Company; Novolin N®, Novo Nordisk, A/S) and analogs insulin detemir (Levemir®, Novo Nordisk, A/S) and insulin glargine (Lantus®, Sanofi-Aventis U.S. LLC). Insulin is also available in a range of concentrations. High concentration formulations (i.e., U-500) allow for a large dose of insulin to be administered using a small volume of the medication (Clark, 2010). Pre-mixed formulations, which combine rapid- and long-acting insulin, are also available to improve patient convenience and minimize multiple daily injections (Qayyum, 2008). Analog insulins are both newer and costlier, but offer some patient advantages such as more flexible dosing, since human insulin has more varied duration of action and can take longer to have an effect after administration.
Some long-acting analogs may also reduce the risk of nocturnal hypoglycemia (Horvath, 2007). Table 2 on page 30 describes the key differences between insulin types in greater detail. There are no generic versions of insulin available, although a biosimilar (i.e. generic formulation of biopharmaceutical product) for insulin glargine recently received first approval in Europe (Hull, 2014).

Insulin can be incorporated at different stages in the management of type 2 diabetes, but is commonly added as a second- or third-line treatment option after the failure of oral anti-hyperglycemic medications to control blood glucose levels. ICER’s literature review focused on long-acting insulins, as these are most often employed when patients are using insulin in combination with other medications. Hypoglycemia and weight gain are the most common adverse effects associated with insulin therapy.

**Impact of diabetes pharmacotherapy on macrovascular outcomes**

As noted previously, intensive glycemic control appears to have a beneficial impact on microvascular complications such as retinopathy and nephropathy. However, the impact of diabetes pharmacotherapy on long-term macrovascular outcomes such as stroke and myocardial infarction (MI) remains a controversial topic. As previously discussed, patients with diabetes are already at an increased risk of adverse cardiovascular outcomes, and findings from some RCTs and observational studies have fueled debate over whether certain medications pose an excess risk of these events. Sulfonylureas in particular have been associated with a modest increase in stroke, acute MI, or death compared to treatment alternatives (Roumie et al., 2012; Muis et al., 2005; Bell, 2006; Monami et al., 2013; Morgan et al., 2014a; Morgan et al., 2014b; Morgan et al., 2014c). Insulin has also been implicated as potentially increasing the risk of cardiovascular disease and cancer (Currie et al. 2012; Smith et al. 2012; Mellbin et al., 2011) although some studies have not shown increased risk of these outcomes (ORIGIN Trial, 2012). Several studies have also found an increased risk of adverse cardiac events, including heart failure, with certain formulations of thiazolidinediones (Erdmann et al., 2009), calling into question their most appropriate role in therapy. A recent publication describes a protocol for the use of the FDA’s Mini-Sentinel surveillance database to assess these risks for multiple types of antidiabetic agents (Fireman, 2012). Results are expected to be presented in 2015.

**Devices for diabetes management**

**Insulin delivery – pumps**

Insulin can be administered through a variety of mechanisms, including a syringe, a pen, or a pump. Syringes are the conventional method of insulin delivery, involving a subcutaneous injection with a
needle. Pens also deliver insulin subcutaneously, but come pre-filled or with cartridges to help manage dosing. Insulin pumps are small devices that can be programmed to provide both continuous doses of insulin throughout the day and/or fast-acting doses around meal time through a catheter. Pumps are designed to improve patient convenience and glycemic control, and minimize the need for multiple daily injections of insulin (a diabetes management approach requiring the injection of long-acting insulin once or twice daily, in addition to fast-acting insulin near mealtimes for optimal glycemic control). A variety of insulin pumps are available, each with different technological features and accompanying supplies, including tubing, cartridges, dressing, and syringes. The annual costs of pump therapy can be significant, in part because of frequent market upgrades that make certain technology obsolete and require the purchase of new supplies. Popular models of insulin pumps and supplies can cost over $7,000 at the outset of treatment, with significant additional annual costs to replace supplies required for ongoing care (Rosenthal, 2014).

Glucose monitors

Glucose monitoring is a core part of diabetes management to ensure adequate control of glucose levels, though its role and frequency, particularly for patients on oral medications alone, is controversial (Boutati, 2009). Patients receiving insulin replacement therapy can self-monitor blood sugar levels to determine glycemic control and establish any needed short-term adjustments to therapy. The required frequency of self-monitoring depends on individual factors, including medication choice and risk of hypoglycemia, but typically takes place four times daily for patients using insulin (Babar, 2013; Benjamin, 2002). Self-monitoring of blood glucose involves pricking the finger using a lancet and test strips to manually determine the concentration of glucose in a sample of blood (Benjamin, 2002). Alternatively, individuals can monitor glycemic control with meters that come in a range of models, each with different capabilities and features. Blood glucose meters are small computerized devices that provide automated blood glucose readings. Individuals are still required to prick their finger and provide a blood sample using a test strip, though many versions offer convenience features to support ease of use. Continuous glucose monitors (CGMs) have been developed that use sensors applied subcutaneously to measure and record blood glucose levels in real time throughout the day and signal an alarm if blood sugar concentration is too high or too low. CGMs are more costly than conventional techniques, costing an estimated $4,335 annually (Huang, 2010). Whether they improve outcomes in patients with type 2 diabetes has been challenged (Jeitler et al., 2008).

Diabetes Management and Rising Costs of Care

The cost of diabetes management has increased substantially in the past decade, in large part due to treatment upgrades that make older versions of medications and devices unavailable or difficult to access. As previously discussed, manufacturers of insulin pumps, glucose monitors, and other
diabetes devices frequently replace current technology with new models that require the purchase of updated supplies that are often brand and model specific. Some of the market upgrades have been criticized as convenience features that have little bearing on patient outcomes but which significantly increase costs (Rosenthal, 2014). Most states, including all six in New England, have legislation in place requiring health insurers to reimburse diabetes treatment, including the costs of equipment and supplies (Cauchi et al., 2013). Even with comprehensive insurance coverage, however, most consumers are responsible for a portion of treatment costs, which can be significant, particularly for ongoing supplies (Kanakis et al., 2002). Health insurers and consumers are also often pressured to purchase an entire disease management package from manufacturers in order to offer or obtain coverage for specific models of insulin pumps, continuous glucose monitors, and other devices, which can increase costs with unclear added benefit for patients (R. Zavoski, personal communication, 2014).

The price of insulin, which first became available in 1923, has also risen steadily due to the introduction of the newer, costlier analog formulations previously described. Insulin analogs now dominate the diabetes market, with some studies estimating over 90% of insulin-taking type 2 diabetes patients using these formulations (Lipska, 2014). More concentrated versions of insulin (U-500) have also grown more expensive in parallel with an increased demand for formulations that deliver more medication at less volume (Fiore, 2014). The high price of newer medications, including DPP-4 inhibitors and GLP-1 receptor agonists, also contribute to the escalating costs of diabetes disease management.

Investigational and Emerging Treatment Options

Investigational treatments for managing type 2 diabetes include imeglimin, the first new oral antidiabetic drug in the glimins class, as well as insulin degludec, an ultralong-acting basal insulin analog. Imeglimin acts to reduce hepatic glucose production and increase muscle absorption of glucose; early trials have shown an efficacy and safety profile similar to metformin (Pirags, 2012), as well as further reductions in HbA1c for patients not adequately controlled on metformin (Fouqueray, 2013). Limited evidence exists showing superiority of insulin degludec over insulin glargine or detemir for improving glycemic control, and some studies have found a significant benefit in reducing the incidence of hypoglycemia in patients with type 2 diabetes compared to long-acting insulin analogs (Wang, 2012). However, the FDA did not approve an original submission for insulin degludec in February 2013 because of concerns regarding a potential safety signal for cardiovascular events, and requested additional data on these outcomes (Tucker, 2013).

Emerging treatment options that have recently been approved by the FDA for type 2 diabetes management include SGLT2 inhibitors, a new class of oral antidiabetic medications; inhaled human insulin (Afrezza®, MannKind Corporation); and devices for insulin delivery such as the insulin patch...
(OmniPod®, Insulet Corporation) and an “artificial pancreas” device system (MiniMed® 530G System, Medtronic, Inc.). SGLT2 inhibitors work to block reabsorption of filtered glucose by the kidney (Farxiga™, package insert, 2014); three SGLT2s have been approved to treat type 2 diabetes in the U.S. (i.e., dapagliflozin [AstraZeneca plc], canagliflozin [Janssen Pharmaceuticals], and empagliflozin [Boehringer Ingelheim]), and there are several others currently in phase III clinical trials. In June 2014, Afrezza was approved by the FDA as adjunct therapy for type 2 diabetic patients requiring mealtime insulin, and has been shown to significantly reduce HbA1c compared to placebo (Fischer, 2014). The OmniPod insulin patch is designed to benefit certain type 2 subgroups (e.g., elderly patients) because of its small size and simplicity compared to conventional insulin pumps (Pickup, 2012). Finally, the MiniMed 530G System, which can combine an insulin pump and continuous glucose monitor with or without a threshold suspend feature, was approved by the FDA in September 2013, but type 2 patients have not yet been included in clinical trials (Blue Cross Blue Shield Association, 2014)
Table 1. Summary characteristics of select non-insulin medications for the treatment of type 2 diabetes.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Sulfonylureas</th>
<th>GLP-1 receptor agonists</th>
<th>DPP-4 inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Brand and generic name(s)</strong></td>
<td><em>First generation:</em> chlorpropamide (Diabinese®), tolvaptamide (Orinase®)</td>
<td>exenatide (Byetta®)</td>
<td>sitagliptin (Januvia®)</td>
</tr>
<tr>
<td></td>
<td><em>Second generation:</em> glipizide (Glucotrol®), glyburide (Micronase®), glimepiride (Amaryl®)</td>
<td>exenatide extended-release (Bydureon®)</td>
<td>saxagliptin (Onglyza®)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>liraglutide (Victoza®)</td>
<td>linagliptin (Tradjenta®)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dulaglutide (Trulicity®)</td>
<td>alogliptin (Nesina®)</td>
</tr>
<tr>
<td>Administration</td>
<td>Oral tablet</td>
<td>Subcutaneous Injection</td>
<td>Oral tablet</td>
</tr>
<tr>
<td><strong>Use and effects</strong></td>
<td>Typically taken 20 – 30 minutes before mealtime for optimal blood glucose control</td>
<td>Taken weekly, twice daily before mealtimes, or once daily to control blood glucose levels</td>
<td>Taken once daily with or without food to control blood glucose levels</td>
</tr>
</tbody>
</table>
| **Usual effective dose**        | tolbutamide: 500mg – 3000mg  
chlorpropamide: 100mg – 500mg  
glyburide: 1.25mg – 5mg  
glimepiride: 1mg – 8mg  
glipizide: 5mg – 10mg | exenatide (extended-release): 2mg weekly  
exenatide (immediate-release): 10mg – 20mcg twice daily  
liraglutide: 1.2mg – 1.8mg once daily | linagliptin: 5mg once daily  
sitagliptin: 100 mg once daily  
saxagliptin: 5mg or 2.5 mg once daily |
| **Main mechanism of action**    | Lower blood glucose by stimulating production of insulin by the pancreas.     | Slow digestion and lower blood glucose by increasing insulin secretion in presence of elevated glucose levels and suppressing glucagon secretion. | Lowers blood glucose by preventing the degradation of incretin hormones by DPP-4 enzymes, thereby increasing insulin secretion and decreasing the release of glucagon from the pancreas. |
| **Benefits**                    | Generic versions available                                                     | Low risk of hypoglycemia when used as monotherapy; weight loss | Neutral effect on weight; low risk of hypoglycemia when used as monotherapy |
| **Potential risks/most notable adverse events** | Hypoglycemia, weight gain, heartburn, nausea, cardiac events | Nausea, vomiting, diarrhea; may be associated with pancreatitis | Upper respiratory infection, nasopharyngitis, headaches; may be associated with pancreatitis |
| **Price for 30 days of treatment** | $55                                                                          | $233                                                       | $326                                         |

### Table 2. Characteristics of insulin replacement therapies for the treatment of type 2 diabetes

<table>
<thead>
<tr>
<th></th>
<th>Intermediate/Long-Acting Insulin (basal insulin)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Human</td>
<td>Analog</td>
</tr>
<tr>
<td><strong>Brand and Generic Names</strong></td>
<td>Insulin human isophane (NPH) (Humulin N®, Novolin N®)</td>
<td>Insulin detemir (Levemir®) Insulin glargine (Lantus®)</td>
</tr>
<tr>
<td><strong>Administration</strong></td>
<td>Subcutaneous injection</td>
<td>Subcutaneous injection</td>
</tr>
</tbody>
</table>
| **Use and Effects**                | Administered once or twice daily for glycemic control.  
  • Onset: 1.5 hours  
  • Peak: 4-12 hours  
  • Duration: Up to 24 hours | Administered once or twice daily for glycemic control.  
  • Onset: 3-4 hours  
  • Peak: 3-9 hours  
  • Duration: Up to 24 hours |
| **Usual effective dose**           | Individualized                                 | Individualized   |
| **Main mechanism of action**       | Lowers blood glucose by stimulating glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. | Insulin binds to insulin receptors. Facilitates uptake of glucose into skeletal muscle and fat tissue and by inhibiting the output of glucose from the liver. |
| **Advantages**                     | Equally effective as analogs in controlling HbA1C | More predictable than human alternatives; decreased risk of nocturnal hypoglycemia |
| **Potential risks/most notable adverse events** | Hypoglycemia, weight gain | Hypoglycemia, weight gain |
| **Price for 30 days of treatment (when used as adjunct to other antidiabetic medications, based on AWP estimates)** | ~$80 | ~$220 |
3. Coverage Policies

3.1 Medications

**Medicaid**

There are many similarities in Medicaid drug coverage policies across the six New England states (see Table 3 on page 35). Prior authorization is typically not required for generic sulfonylureas, though some programs place restrictions on first-generation formulations. Fast-, intermediate-, and long-acting forms of insulin are covered, both in human and analog formulations, though programs vary in which brands require prior authorization.

Differences in policy primarily involve newer drug classes, such as DPP-4 inhibitors and GLP-1 receptor agonists, both of which are available as branded products only. Four of six New England states restrict coverage by requiring patients to fail or have history of use with older medications. For example, Vermont and Massachusetts require patients to fail with metformin monotherapy or combination therapy with insulin, sulfonylurea, or pioglitazone (an oral agent commonly prescribed for type 2 diabetes) before receiving either a DPP-4 inhibitor or a GLP-1 receptor agonist. Rhode Island and Maine require patients to demonstrate prior use of metformin (or thiazolidinedione, in the case of Rhode Island) for use of DPP-4 inhibitors. In Rhode Island, the same rules for prior history of use also apply to GLP-1 receptor agonists. Maine also utilizes step-therapy, requiring patients to fail with all other oral medications and insulin before attempting GLP-1 receptor agonists.

Other types of restrictions are less common in New England state Medicaid programs. Three out of six states utilize quantity limits for DPP-4 inhibitors and GLP-1 receptor agonists. Supply limits are mostly similar; Maine, Massachusetts, and Vermont each limit patients to one tablet per day for thirty days of treatment, and patients receive one, three, or four pens/vials of GLP-1 receptor agonist treatment per month, depending on the formulation.

New Hampshire and Connecticut are the only state Medicaid programs in New England that cover at least one DPP-4 inhibitor or GLP-1 receptor agonist without restriction.
Regional Private Payers

Diabetes drug policies among major regional private payers in New England are similar to those of Medicaid agencies (see Table 4 on page 37). All identified policies allow for unrestricted use of generic sulfonylureas. Insulin therapies are typically covered without restriction, though generally require higher co-payments than generic medications. ConnectiCare and Neighborhood Health Plan of Rhode Island (NHPRI) are exceptions; both require prior authorization for certain insulin formulations. NHPRI also utilizes quantity limits.

Similar to Medicaid programs, regional private insurers place further restrictions on DPP-4 inhibitors and GLP-1 receptor agonists. Five out of seven payer policies identified utilize prior authorization and/or step therapy for most medications in both drug classes, and some formulations are not covered at all. Regional private insurers also universally restrict use for newer diabetes drug classes through tiered co-payments.

National Private Payers

Like regional payers, national private payers generally do not place restrictions on the use of generic sulfonylureas; only Anthem has dose limits in place, and Cigna requires prior authorization for some formulations. Insulin is also typically covered without restriction, though higher co-payments often apply. Humana is an exception by placing quantity limits on certain rapid-acting insulin analogs. Under Humana’s formulary, patients are limited to 240 units of Humalog 100 unit/mL cartridge or solution per 30 days (Humana, 2014). Also consistent with the approach of regional insurers, national carriers apply stricter coverage criteria to the newest diabetes drug classes. Humana utilizes step therapy for DPP-4 inhibitors and GLP-1 receptor agonists, and four out of five national payer policies identified apply quantity limits to medications within these classes. Full details of quantity limits are described in Table 4 on page 37, but in general insurers tend to define the maximum allowable supply for medication per period using FDA-approved dosing guidelines. In many cases, certain formulations are entirely excluded from coverage. National private payers also apply higher tiered co-payments to newer diabetes drug classes.
3.2 Devices

Medicare

The Centers for Medicare and Medicaid Services (CMS) has a National Coverage Determination in place for external insulin infusion pumps, which provides coverage for patients with type 1 or type 2 diabetes. To be eligible for coverage, patients must have demonstrated hyperglycemia, as shown through a fasting C-peptide test (a blood test that determines the level of insulin the body is producing) of less than or equal to 10%, or a positive beta cell autoantibody test. Patients must also meet the following requirements:

- Completion of comprehensive diabetes education program; and
- Program of multiple daily injections for previous six months, with frequent self-adjustment of insulin; and
- Documented glucose testing at least four times daily for previous two months; and
- Experience of glycemic events (i.e., uncontrolled HbA1c levels, reoccurring hypoglycemia, etc.)

Patients who have utilized an insulin pump prior to enrollment on Medicare and have a documented two month history of frequent glucose self-testing of at least four times daily may also receive coverage for insulin pumps.

CMS also provides coverage for conventional blood glucose monitors for patients with diabetes. No CMS coverage policies were identified for continuous glucose monitors.

Medicaid

Limited information on durable medical equipment was available from the six New England Medicaid programs. The policies identified all included coverage for insulin pumps, with Maine requiring prior authorization, and Massachusetts adopting the same coverage criteria established by CMS (above). Massachusetts also requires patients to initiate treatment with an insulin pump on a three-month trial basis and document continued medical necessity for ongoing coverage. The policies generally also provide coverage for conventional blood glucose monitors, with Maine requiring prior authorization and Rhode Island limiting coverage to patients with poor diabetic control (i.e., frequent episodes of insulin reaction, ketosis, etc.). No coverage policies for continuous glucose monitors were identified.
Regional Private Payers

Of the policies identified, all provided coverage for insulin pumps with the exception of Blue Cross Blue Shield of Massachusetts, which states that insulin pumps are not medically necessary for patients with type 2 diabetes. Blue Cross Blue Shield of Rhode Island requires documentation of continued medical necessity for long-term use. Regional private insurers generally cover conventional blood glucose monitors, though continuous glucose monitor devices are considered investigational and not clinically necessary in this population.

National Private Payers

Like regional insurers, national insurers generally follow the same CMS criteria for coverage of external insulin pumps. Blood glucose monitors are also generally covered. Continuous glucose monitors are not covered in this population by national payers, with the exception of Cigna, who covers continuous glucose monitors for patients with type 2 diabetes who also have renal insufficiency and a history of severe hypoglycemic events despite demonstrated treatment adherence and compliance with monitoring.
<table>
<thead>
<tr>
<th>State</th>
<th>Sulfonylureas</th>
<th>DPP-4 Inhibitors</th>
<th>GLP-1 Receptor Agonists</th>
<th>Insulin (Basal)</th>
<th>Insulin (Bolus)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>chlorpropamide; tolbutamide; glipizide; glyburide; glimepiride</td>
<td>Januvia** Onglyza** Tradjenta**</td>
<td>Byetta** Bydureon** Victoza** Trulicity** Tanzeum**</td>
<td>Humulin N® Novolin N®* Levetiracetam®* Lantus®*</td>
<td>NovoLog®* Apidra®* Humalog®* Humulin R (U-100® and U-500®)* Novolin R**</td>
</tr>
<tr>
<td>MA</td>
<td></td>
<td>PA required: patients must have inadequate response to or adverse event with metformin monotherapy and combination therapy, and have contraindication to or adverse event w/ insulin, sulfonylureas, and pioglitazone</td>
<td>PA required: patients must have inadequate response to or adverse event with metformin monotherapy and combination therapy, and have contraindication to or adverse event w/ insulin, sulfonylureas, and pioglitazone</td>
<td>PA required: patients should first fail with all other available oral medications and insulin</td>
<td>All formulations covered without restriction with the exception of pens and cartridges, which require PA</td>
</tr>
<tr>
<td>ME</td>
<td>PA required for branded formulations (Generic versions covered without restriction)</td>
<td>Januvia and Onglyza are covered in patients with history of metformin use for at least 60 days in previous 18 months</td>
<td>ST and PA required: Januvia: 35 tablets per 35 days Onglyza: 35 tablets per 35 days Tradjenta: 35 tablets per 35 days</td>
<td>Januvia: 30 tablets/month; 100 mg/day Onglyza: 30 tablets/month; 5 mg/day Tradjenta: 30 tablets/month; 5 mg/day Nesina: 30 tablets/month; 25 mg/day</td>
<td>Covered without restrictions with the exception of some bolus formulations that require PA (Apidra, a rapid-acting analog, and Humulin R U-500, a concentrated form of short-acting human insulin).</td>
</tr>
<tr>
<td>CT</td>
<td>Not included on PDL</td>
<td>Januvia and Onglyza covered Nesina not listed.</td>
<td>Byetta, Bydureon, and Victoza covered. Trulicity and Tanzeum not listed.</td>
<td>Covered without restrictions</td>
<td></td>
</tr>
</tbody>
</table>

* Brand-only product, no generic available  
PA: Prior Authorization  
PDL: Preferred Drug List  
QL: Quantity Limits  
ST: Step Therapy

CT: Connecticut  
ME: Maine  
MA: Massachusetts
<table>
<thead>
<tr>
<th>NH</th>
<th>RI</th>
<th>VT</th>
<th>VT</th>
</tr>
</thead>
<tbody>
<tr>
<td>• PA required for branded formulations (Generic versions covered without restriction)</td>
<td>• PA required for branded and first-generation formulations (generic second-generation versions covered without restriction)</td>
<td>• PA required for branded formulations (Generic versions covered without restriction)</td>
<td>• All formulations covered without restriction with the exception of Apidra, which requires PA.</td>
</tr>
<tr>
<td>• Januvia and Onglyza covered without restriction</td>
<td>• Covered in patients with history of metformin or TZD use in previous 90 days</td>
<td>• Januvia and Onglyza covered in patients who have failed with metformin</td>
<td>• Covered for patients who are at least 18 years of age and have failed with metformin</td>
</tr>
<tr>
<td>• PA required for Tradjenta and Nesina</td>
<td>• PA required for Onglyza and Nesina</td>
<td>• Nesina and Tradjenta require additional failure with preferred DPP-4 inhibitors</td>
<td>• PA required for Byetta and Bydureon</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• QL apply:</td>
<td>• QL apply:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Januvia: 1 tablet per day</td>
<td>Bydureon: 4 vials per 28 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Onglyza: 1 tablet per day</td>
<td>Byetta: 1 pen per 30 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tradjenta: 1 tablet per day</td>
<td>Victoza: 3 pens per 30 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nesina: 1 tablet per day</td>
<td>• Length of coverage authorization limited to 1 year</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Length of coverage authorization limited to 1 year</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Trulicity and Tanzeum not listed.</td>
</tr>
<tr>
<td>• Not included on PDL</td>
<td>• Covered in patients with history of metformin or TZD use in previous 90 days</td>
<td>• Length of coverage authorization limited to 1 year</td>
<td>• Trulicity and Tanzeum not listed.</td>
</tr>
<tr>
<td></td>
<td>• PA required for Onglyza and Nesina</td>
<td>• QL apply:</td>
<td>• Trulicity and Tanzeum not listed.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bydureon: 4 vials per 28 days</td>
<td>• Length of coverage authorization limited to 1 year</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Byetta: 1 pen per 30 days</td>
<td>• Trulicity and Tanzeum not listed.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Victoza: 3 pens per 30 days</td>
<td>• All formulations covered without restriction with the exception of Apidra, which requires PA.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Trulicity and Tanzeum not listed.</td>
</tr>
<tr>
<td>• At least one version of human and analog basal or bolus insulin is covered without restriction</td>
<td>• Generally all formulations covered without restriction, with the exception of pens and cartridges, which require PA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 4. Coverage Policies for Type 2 Diabetes Medications: Regional and National Private Insurers.

<table>
<thead>
<tr>
<th>Regional private insurers</th>
<th>Sulfonylureas</th>
<th>DPP-4 Inhibitors</th>
<th>GLP-1 Receptor Agonists</th>
<th>Insulin (Basal)</th>
<th>Insulin (Bolus)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>chlorpropamide; tolbutamide; glipizide; glyburide; glimepiride</td>
<td>Januvia®* Onglyza®* Tradjenta®* Nesina®*</td>
<td>Byetta® Bydureon®* Victoza® Trulicity® Tanzeum®*</td>
<td>Humulin N®, Novolin N®* Levemir®*</td>
<td>NovoLog® Apidra® Humalog® Lantus®* Novolin R®*</td>
</tr>
<tr>
<td>Blue Cross Blue Shield MA (BCBS MA)</td>
<td>* Brand-only product, no generic available</td>
<td>ST and PA required (must fail with other oral medications and insulin) Tier 2</td>
<td>Byetta covered without restriction PA required for Victoza Tier 2 and 3</td>
<td>Covered without restrictions; Tier 2</td>
<td></td>
</tr>
<tr>
<td>Blue Cross Blue Shield Rhode Island (BCBS RI)</td>
<td>Generic versions covered without restriction Tier 1</td>
<td>Januvia and Tradjenta are covered without restriction PA required for Onglyza and Nesina QL apply (details not provided) Tier 2 or 3 Nesina not listed</td>
<td>Byetta covered without restriction Bydureon and Victoza require PA QL apply (details not provided) Tier 2 or 3 Trulicity and Tanzeum not listed</td>
<td>Covered without restriction (some formulations not listed, i.e., Apidra, NovoLog, Novolin); Tier 2</td>
<td></td>
</tr>
<tr>
<td>Blue Cross Blue Shield Vermont (BCBS VT)</td>
<td>Generic versions covered without restriction Tier 1</td>
<td>ST required (patients must fail with metformin) QL apply to Januvia and Onglyza (details not provided) Tier 2 or 3 Nesina not listed</td>
<td>ST required (patients must fail with metformin) QL apply to Byetta, Victoza (details not provided) Tier 2 or 3 Trulicity and Tanzeum not listed</td>
<td>Covered without restrictions; Tier 2 (Apidra is Tier 3)</td>
<td></td>
</tr>
<tr>
<td>ConnectiCare</td>
<td>generics covered without restriction Tier 1</td>
<td>Januvia and Tradjenta covered without restriction ST required for Onglyza and Nesina Tier 2 or 3</td>
<td>ST and QL apply to Byetta, Bydureon, and Victoza; Tier 2 PA and QL apply to Tanzeum; Tier 3 Trulicity not listed</td>
<td>At least one version of human and analog basal or bolus insulin is covered without restriction PA required for some formulations, including: rapid-acting analogs Apidra and Novolog, and human insulin Novolin</td>
<td></td>
</tr>
<tr>
<td>Harvard Pilgrim Health Care (HPHC)</td>
<td>generics covered without restriction Tier 1</td>
<td>ST required for Januvia, Nesina, and Onglyza; Tier 3 Tradjenta covered without restriction; Tier 2</td>
<td>ST required for Byetta, Bydureon, and Victoza; Tier 2 ST and QL apply for Trulicity and Tanzeum (28 day supply); Tier 3</td>
<td>Covered without restrictions; Tier 2</td>
<td></td>
</tr>
</tbody>
</table>
| Neighborhood Health Plan Rhode Island (NHPRI) | generics covered without restriction  
• Tier 1 | PA required: must fail with metformin or sulfonylurea  
Tradjenta, Onglyza, and Nesina not listed | PA required: must fail with metformin or sulfonylurea  
Byetta, Bydureon, Trulicity, and Tanzeum not listed | All formulations covered without restriction with the exceptions of pens and cartridges, and Levemir (a long-acting analog insulin) which requires PA |
| Tufts Health Plan (THP) | generics covered without restriction  
• Tier 1 | Covered without restriction (Onglyza and Nesina not listed)  
• Tier 2 | Covered without restriction  
• Tier 2 or 3  
Victoza and Trulicity not listed | Covered without restrictions  
• Tier 2 |
| National private insurers | * Brand-only product, no generic available | PA: prior authorization  
PDL: Preferred Drug List  
QL: Quantity Limits  
ST: Step therapy |
| Aetna | generics covered without restriction  
• Tier 1 | Covered without restriction  
• Tier 2  
• QL/ST/PA applies for Nesina; Tier 3 | QL apply:  
Bydureon: 1 mL per week  
Byetta: 1 pen/month  
Victoza: 3 pens/month  
• Tier 2 or 3  
Trulicity and Tanzeum not listed | Covered without restrictions  
• Tier 2, except Apidra, NovoLog, and Lantus (analog) and Novolin N and R (human), which are Tier 3 |
| Anthem | QL apply:  
glipizide, glimepiride: 60, 120, or 240 tablets per 30 days, depending on dose.  
tolbutamide: 180 per 30 days  
• Tier 2 or 3 | QL apply  
Januvia: 30, 60, or 100 tablets per 30 days, depending on dose  
Onglyza: 30 or 60 tablets per 30 days, depending on dose  
Nesina: 60 doses per 30 days  
• Tier 3; Tradjenta not listed. | QL apply:  
Bydureon: 4 per week  
Byetta: 1.2 or 2.4 per week, depending on dose  
Victoza: 9 per 30 days  
• Tier 3  
Trulicity and Tanzeum not listed | Covered without restrictions; Tier 3  
• NovoLog, Apidra (analog) and Novolin (human) not listed. |
| Cigna | PA required for chlorpropamide and glyburide; other versions covered without restriction  
• Tier 1 | QL apply  
Januvia: 30 tablets per 30 days  
Tradjenta: 30 per 30 days  
• Tier 3  
Onglyza and Nesina not listed. | QL apply:  
Bydureon: 2.6 mL per 28 days  
Byetta: 3 mL per 30 days  
Victoza: 9 mL per 30 days  
• Tier 3  
Trulicity and Tanzeum not listed | Covered without restrictions; Tier 3  
• NovoLog, Apidra (analog) and Novolin (human) not listed. |
| Humana | generics covered without restriction  
• Tier 1 | ST and QL apply (30 tablets/30 days)  
• Tier 2 or 3 | ST and QL apply:  
Byetta: 1 or 2 pens per 30 days, depending on dosage  
Trulicity: 2 pens for 28 days  
Tanzeum: 4 pens for 28 days  
• Tier 2  
Bydureon and Victoza not listed | QL apply to Humalog vial and cartridge: 240 for 30 days  
• All other formulations covered without restriction  
**Tiers:**  
• Tier 2: Humalog, NovoLog, Levemir, and Lantus (analog); Humulin N and Humulin R (human)  
• Tier 3: Novolin N and R (human) Apidra (analog)
| United Health Care | • generics covered without restriction  
  • Tier 1 | • QL apply (details not provided)  
  • Tier 2 or 3 | • QL apply (details not provided)  
  • Tier 2 or 3  
  *Tulicity not listed* | • Most bolus and basal insulin vials covered without restrictions.  
  • Novolin (human) and NovoLog (analog) are part of special program requiring patients to switch to lower cost insulin alternatives.  
  **Tiers:**  
  • Tier 1: Humalog and Levemir (analog); Humulin N and Humulin R (human)  
  • Tier 3: Apidra and Lantus (analog)  
  • Tier 4: Novolin N and R (human) and NovoLog (analog) |

4.1 Second-Line Medication

American Association of Clinical Endocrinologists (AACE), 2013

Dual therapy should be considered for patients taking metformin (or a metformin alternative when contraindicated) whose HbA1c does not reach target with a single agent. Patients with an initial HbA1c of ≥7.5% can also be considered for dual therapy as first-line treatment. Of the medications included in this review, AACE recommends the following hierarchy of agents to be used in combination with metformin: GLP-1 receptor agonists, DPP-4 inhibitors, Thiazolidinedione (TZD), Sodium glucose cotransporter 2 (SGLT-2) inhibitors, Basal insulin, Colesevelam, Bromocriptine QR, Alpha-glucosidase (AG) inhibitors, and sulfonylureas/glinides. TZD, SGLT-2 inhibitors, Basal insulin, and sulfonylureas should be administered with caution due to associated risks.

American College of Physicians (ACP), 2012

The ACP suggests adding a second agent when lifestyle changes and metformin alone do not bring the patient to a reasonable HbA1c target. They do not offer specific preference as to which agents may be most suitable as second-line options.

American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD), 2012
http://care.diabetesjournals.org/content/35/6/1364.full

Dual therapy should be initiated if the patient does not reach their individualized HbA1c target after 3 months of monotherapy with metformin (or an alternative first-line medication, in patients unable to tolerate metformin). ADA/EASD recommends the addition of either a sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, or basal insulin for dual therapy regimens. They do not offer a suggested hierarchy for second-line prescription but instead emphasize that the decision should be based on individual patient factors and drug characteristics.

International Diabetes Federation (IDF), 2012
http://www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf

When HbA1c targets are not achieved using metformin alone, a sulfonylurea can be added as a second-line oral therapy. In patients who are unlikely to meet their HbA1c goal through monotherapy, initial treatment with dual combination therapy may be recommended. Alternative
agents should be considered in patients who do not tolerate sulfonylureas, including a DPP-4 inhibitor. IDF notes that the evidence shows little difference in efficacy between combination therapies, so selection of a second-line medication should be based on access, cost, and side effects.

National Institute for Health and Care Excellence (NICE), 2009
http://www.nice.org.uk/guidance/cg87/chapter/guidance

If metformin alone is insufficient to bring blood glucose to HbA1c target (typically 6.5%, unless otherwise determined for an individual patient), NICE recommends adding another agent, most commonly a sulfonylurea. A DPP-4 inhibitor can be considered as an alternative second-line medication when a person has a high risk of hypoglycemia or does not tolerate sulfonylureas. When either a DPP-4 inhibitor or TZD is suitable, the choice should be based on patient preference. NICE does not recommend use of GLP-1 receptor agonists or insulin as second-line therapy.

4.2 Third-Line Medication

American Association of Clinical Endocrinologists (AACE), 2013

For patients taking two agents who have an HbA1c <8%, a third-line agent may be beneficial in helping the patient to reach his or her target. The recommended hierarchy of third-line agents is as follows: GLP-1 receptor agonists, TZD, SGLT-2 inhibitors, basal insulin, DPP-4 inhibitors, Colesevelam, Bromocriptine QR, AG Inhibitors, and SU/GLNs. AACE notes that TZDs, SGLT-2s, basal insulin, and SU/GLNs should be used with caution due to associated risks. Insulin should be considered for patients with HbA1c >8%; patients on two or more oral medications or on GLP-1 receptor agonist therapy; and patients with a long disease history, as these groups are not likely to reach their target HbA1c with additional medications.

American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD), 2012
http://care.diabetesjournals.org/content/35/6/1364.full

ADA/EASD suggests that the addition of a third agent may benefit some patients, but that most patients will have the best response with the addition of insulin. Of the medications addressed in this review, ADA/EASD suggests the use of DPP-4 inhibitors, GLP-1 receptor agonists, insulin, or sulfonylureas (in no order of preference) as third-line agents, depending on the choice of second-line agent. To reduce the possibility for adverse effects in combining multiple agents, the third line agent should have a complementary mechanism of action to the agents the patient is already
taking. Insulin should be used in circumstances where the degree of hyperglycemia is sufficiently high that it is unlikely that addition of another oral or injectable agent will be effective.

International Diabetes Federation (IDF), 2012
http://www.idf.org/sites/default/files,IDF-Guideline-for-Type-2-Diabetes.pdf

When the patient does not reach HbA1c target using dual therapy, IDF recommends adding a third agent. AG-inhibitors, DPP-4 inhibitors, TZDs, GLP-1 receptor agonists, basal insulin, or premixed insulin are recommended.

National Institute for Health and Care Excellence (NICE), 2009
http://www.nice.org.uk/guidance/cg87/chapter/guidance

If a combination of metformin and a sulfonylurea is insufficient to lower HbA1c below 7.5%, a DPP-4 inhibitor can be added as a third-line therapy. DPP-4 inhibitors should only be continued if the patient shows a reduction of at least 0.5 percentage points in HbA1c over a period of 6 months. A GLP-1 receptor agonist can be added as third line in patients who have a body mass index (BMI) of at least 35 accompanied by specific psychological or medical problem associated with weight; patients with a BMI of at least 35 when insulin therapy would impose significant occupational implications; or when weight loss would benefit other comorbidities. Insulin should be considered over addition of a third agent for patients on dual therapy with significant hyperglycemia.

4.3 Initiating Insulin and Insulin Choice

American Association of Clinical Endocrinologists (AACE), 2013

Insulin should be considered for patients with HbA1c >8%, patients who are currently on two or more oral medications, patients on GLP-1 receptor agonist therapy, or patients with a long disease history, as these groups are not likely to reach their target HbA1c with additional medications. Patients initially presenting with an HbA1c >9% at time of diagnosis may also be considered for insulin therapy as a first line treatment. AACE recommends that, in general, patients start on a single daily dose of basal insulin in combination with the patient’s existing regimen of medication. Dosing should be individualized and regularly adjusted. Premixed insulin can also be considered, but may pose increased risk for some patients. Basal insulin analogs are recommended over NPH insulin, due to a decreased risk of hypoglycemia.
American Diabetes Association/European Association of for the Study of Diabetes (ADA/EASD), 2012
http://care.diabetesjournals.org/content/35/6/1364.full

ADA/EASD suggest introducing a single daily injection of basal insulin when appropriate. Insulin therapy should be strongly considered at time of diagnosis in cases of significant symptomatic hyperglycemia. Insulin should also be used in place of a third agent in circumstances where the degree of hyperglycemia is sufficiently high that an additional agent is unlikely to bring HbA1c to target. ADA/EASD suggests that insulin analogues may reduce risk of hypoglycemia as compared to NPH, but notes that they have not been shown to differ significantly from human insulin in lowering HbA1c.

International Diabetes Federation (IDF), 2012
http://www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf

Insulin should be added when blood glucose lowering medications and lifestyle interventions are not sufficient to maintain target HbA1c. Insulin should be introduced at low doses, and dosing should be adjusted upwards as necessary. Patients should be started on basal insulin, such as NPH, insulin glargine, or insulin detemir, or on a premixed insulin.

National Institute for Health and Care Excellence (NICE), 2009
http://www.nice.org.uk/guidance/cg87/chapter/guidance

Insulin should be considered over addition of a third pharmacologic agent for patients on dual therapy with significant hyperglycemia. Patients should be started on human NPH insulin injected once or twice daily, depending on need. An insulin analog may be considered if the patient needs assistance from a health care professional for injection, if the person is at high risk of recurrent hypoglycemic episodes, if the person would otherwise need twice-daily NPH insulin in combination with glucose-lowering drugs, or if the person is unable to use devices needed to inject NPH insulin. Patients may switch from NPH to a long acting analog if they experience recurrent hypoglycemia regardless of whether or not they reach their HbA1c target.
4.4 Strategies for Management and Monitoring

**Insulin Pumps**


Insulin pumps may be suitable for some insulin-requiring patients with intensively managed type 2 diabetes. Type 2 diabetes patients should be C-peptide positive, but with poor glycemic control on a basal/bolus injection program. They should also have a significant “dawn phenomenon,” or an overnight surge in hormones that can cause glucose levels to spike. Pumps are intended for patients requiring four or more insulin injections daily, as well as four or more glucose measurements. Pumps may be most useful to patients with an erratic lifestyle, such as individuals who frequently travel long distance, perform shift work, or have unpredictable schedules that result in irregular meal timing. Ideal candidates for an insulin pump are those that are currently adherent to their current therapy but are unable to meet their HbA1c target, are struggling with hypoglycemia, or are looking for more ease and flexibility in achieving their HbA1c target.


IDF suggests that the evidence is insufficient to formulate a recommendation for insulin pump use in type 2 diabetes, though it recognizes its potential on a case by case basis.

**Continuous Glucose Monitoring**


While the Endocrine Society does not offer guidelines specific to type 2 diabetes patients, they do suggest that continuous glucose monitoring may be of benefit to some patients.


The AACE does not offer guidelines specific to the use of continuous glucose monitors in patients with type 2 diabetes.
American Diabetes Association (ADA)

The ADA does not provide clinical guidelines for the use of continuous glucose monitors in patients with type 2 diabetes.
5. Evidence Review

The goal of the evidence review was to evaluate the comparative effectiveness and value of certain treatment options for the management of type 2 diabetes. The sections that follow are organized around five scoping domains of primary interest for this review. These include the comparative effectiveness of (1) use of human insulin versus insulin analogs as add-on therapy with one or more oral medications in patients requiring insulin; (2) second-line pharmacotherapy among patients with inadequate glycemic control on metformin monotherapy; (3) third-line pharmacotherapy among patients with inadequate glycemic control on metformin and sulfonylurea combination treatment; (4) insulin pump therapy versus multiple daily injections; and (5) continuous glucose monitors versus conventional self-monitoring of blood glucose for type 2 diabetes management. The comparisons and outcomes of interest are depicted in the analytic framework below. It was anticipated that most available evidence would be restricted to intermediate outcomes such as HbA1c and changes in body weight, so a series of conceptual links would be required to judge the potential effects on longer-term outcomes such as microvascular and macrovascular complications as well as mortality.

Analytic Framework: Type 2 Diabetes Management
Given the very broad scope of this review, we relied on published and authoritative systematic reviews as a starting point for each research domain, as listed below:

- Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (Horvath [Cochrane], 2009)
- Second-line pharmacotherapy for type 2 diabetes (CADTH, 2013)
- Third-line pharmacotherapy for type 2 diabetes (CADTH, 2013)
- Methods for insulin delivery and glucose monitoring (Golden [AHRQ], 2012)

To supplement these reviews, we also identified any additional RCTs, comparative cohort studies, or case series that have been published within three months prior to the end of each literature search (e.g., February 2012 for the CADTH reviews) through August 2014. Case series were limited to those involving 50 or more patients. Additional study exclusions were individualized to each scoping domain, as listed below. Studies were excluded if in their methods or entry criteria:

- Inadequate glycemic control was defined as HbA1c <6.5% or fasting plasma glucose <7 mmol/L or two-hour postprandial glucose <10 mmol/L for second- and third-line pharmacotherapy
- Treatment durations were less than 24 hours for evaluation of insulin pump therapy or continuous glucose monitoring
- Patients subcutaneously injected insulin less than three times per day for comparisons of insulin pump therapy versus multiple daily injections
- Patients pricked their finger less than three times per day for comparisons of continuous glucose monitoring versus self-monitoring of blood glucose

We sought published studies and systematic reviews of antidiabetic therapy among adult (≥18 years old) patients with type 2 diabetes. We excluded evidence that evaluated therapies for mixed study populations of type 1 and type 2 patients unless outcomes were reported for a type 2 subgroup, or more than half of the subjects were diagnosed with type 2. We did not evaluate studies conducted specifically in pregnant women with previously diagnosed type 2 or gestational diabetes, or children/adolescents. Interventions of interest included any medications classified as a sulfonylurea, DPP-4 inhibitor, GLP-1 receptor agonist, or basal insulin added to metformin monotherapy; any medications classified as a DPP-4 inhibitor, GLP-1 receptor agonist, or basal insulin added to metformin and sulfonylurea combination treatment; NPH insulin or the long-acting insulin analogs detemir or glargine; insulin pumps or multiple daily injections via subcutaneous injection; and continuous glucose monitoring or traditional blood glucose monitoring devices. For the purposes of scoping questions 1 and 2, patients that were inadequately controlled on metformin or metformin+sulfonylurea combination therapy, respectively, were eligible for inclusion. Importantly, the CADTH reviews originally specified class-, individual drug-, and drug/dose-level meta-analyses, but found that treatment effect estimates were comparable across the three types of analyses and
the greatest precision was seen with the class-level meta-analysis (CADTH 2010; CADTH 2013). We therefore adopted a similar approach for our supplemental review and economic model (see Section 6 for economic analyses).

Finally, we did not assess evidence on rapid or short-acting insulins or insulin analogs, as most type 2 patients typically use long-acting insulins as add-on therapy with one or more oral medications.

Primary outcomes of interest included glycemic control as measured by glycosylated hemoglobin (HbA1c); rate of severe hypoglycemic events; changes in body weight/BMI; incidence of diabetes-related complications including microvascular (e.g., retinopathy, neuropathy) and macrovascular (e.g., coronary heart disease) complications, myocardial infarction, stroke, renal failure, or amputations; and mortality. We also collected information on adherence and health-related quality of life where available. Further details on the literature search strategy for each scoping question can be found in Appendix A.

Figure 1. PRISMA diagram.
5.1 Long-acting Insulin Analogs versus NPH Insulin

Long-acting insulin analogs (i.e., insulin glargine and insulin detemir) compared to NPH insulin have shown little added benefit with regard to clinically relevant outcomes for type 2 diabetes. A Cochrane review found no differences between either insulin glargine or detemir compared with NPH insulin for glycemic control, changes in body weight, or adverse events, with the exception of a reduction in nonsevere hypoglycemia (i.e., symptomatic or nocturnal events) for insulin analogs. No evidence regarding the differential impact of long-acting insulin analogs versus NPH insulin on long-term outcomes such as mortality, diabetes-related complications, and health-related quality of life were provided in these RCTs.

A total of eight RCTs were identified in the 2006 Cochrane review comparing NPH insulin to long-acting insulin analogs, with six for insulin glargine and two for insulin detemir (Horvath, 2009). There were no significant between-group differences for HbA1c levels, rates of severe hypoglycemia, or changes in body weight. There was a significant reduction in symptomatic but nonsevere (i.e., with typical symptoms such as palpitations and sweating but without requirement for third-party assistance to restore blood glucose levels) as well as nocturnal hypoglycemia (i.e., recorded nighttime blood glucose ≤70 mg/dl but without symptoms) with insulin analogs; rates for nocturnal hypoglycemia are presented in Figures 2 and 3 on the following page. Approximately one-third of patients in the NPH arms had episodes of nocturnal hypoglycemia versus 18% among those receiving insulin analogs. However, the review also found that all eight RCTs were of relatively poor quality, primarily because of poor reporting of methods of randomization and concealment as well as use of equivalence or noninferiority designs in many of these studies. In addition, no study evaluated the long-term impact of insulin use on diabetes-related complications, mortality, or health-related quality of life. The review concluded that insulin analogs offer a “minor clinical benefit” at best, and suggested a cautious approach to their use in clinical practice.

The relative clinical importance of hypoglycemia and the association of hypoglycemic events of varying severity to mortality, cardiovascular risks, and other long-term outcomes remains a topic of intense debate, as studies of intensive glycemic control in patients with cardiovascular disease have suggested a link between episodes of severe hypoglycemia and excess mortality (Frier, 2011). While nonsevere and asymptomatic nocturnal hypoglycemia have generally been felt to be of lower clinical consequence, some studies have suggested that these events may be correlated with lower productivity and fatigue (Brod, 2013). In addition, other studies have recorded instances of QT prolongation and arrhythmia during nocturnal hypoglycemic episodes (Landstedt-Hallin, 1999; Chow, 2014), but these studies have not documented a connection between episodes of arrhythmia and long-term or lasting damage.
Figure 2. Comparison of rates of nocturnal hypoglycemia – glargine vs. NPH.


Figure 3. Comparison of rates of nocturnal hypoglycemia – detemir vs. NPH.


We identified an additional six RCTs (three each for insulin glargine and insulin detemir) and two large observational studies published after the Cochrane review, as well as a post-hoc analysis of a glargine RCT that was included in the Cochrane review. Major findings are summarized in the sections that follow.
Insulin Glargine versus NPH

Three small RCTs published after the Cochrane review have produced similar findings to the original review with regard to hypo- and hyperglycemic events. One of these studies (Forst, 2010) randomized 28 insulin-naïve type 2 patients with a mean BMI of 30.7 kg/m² and HbA1c of 6.5-8.5% to initiate different formulations of insulin to replace a sulfonylurea as add-on therapy to metformin and found that both HbA1c levels and the rate of hypoglycemia episodes were comparable between NPH and insulin glargine at the end of the three-month study. A cross-over study (De Mattia, 2009) of 20 patients, mean age 59.4 years and a diabetes duration of at least five years, reported statistically-significant reductions in HbA1c from baseline in both arms, but no difference between them; changes in body weight also did not differ between groups. Several cases of hypoglycemia were reported for both groups, but none of the episodes was considered severe.

The third RCT (Wang, 2007), comprising 24 patients, mean age 56 years, with an average diabetes duration of 10 years, found that evening injections of insulin glargine stabilized daily blood glucose fluctuations levels better than NPH insulin and was associated with a decrease in nocturnal hypoglycemic events (6.3% vs. 50.0% for NPH, p=0.028). No significant differences in HbA1c levels were observed in this study.

Finally, a recently published post-hoc analysis (Vahatalo, 2014) of an RCT included in the Cochrane review randomized 109 insulin-naïve patients with poor glycemic control (mean HbA1c of 9.6% with 90% on sulfonylurea and metformin combination therapy) based on fasting or postprandial (post-meal) hyperglycemia to NPH insulin or insulin glargine and found no significant difference with regard to glycemic control or weight gain between the two insulin types. Although more hypoglycemic events were observed in the NPH group during the first 12 weeks of treatment (4 vs. 1.8 per patient for glargine, p=0.05), none of these events was categorized as severe, and the difference in overall events disappeared after three months.

Insulin Detemir versus NPH

We identified three post-Cochrane review RCTs comparing insulin detemir to NPH insulin, one of which was a cross-over study. One RCT (Fajardo Montañana, 2008) evaluated six month outcomes of 271 patients with a mean age of 62 and average diabetes duration of 16 years to determine if NPH in morning and evening doses, or detemir following the same regimen, yielded different outcomes. While detemir was associated with significantly less weight gain (0.4 kg vs. 2.0 kg for NPH, p<0.0001), changes in HbA1c and the proportion of patients reaching target without hypoglycemia did not statistically differ between groups. Another large RCT (Philis-Tsimikas, 2006) compared a pre-breakfast injection of detemir with an evening injection of detemir or NPH insulin among 498 patients (mean age 58.5 years, mean BMI 30 kg/m², average diabetes duration of 10 years), who
were followed for 20 weeks. No between-group differences with regard to HbA1c changes, incidence of severe hypoglycemia, or nocturnal hypoglycemia episodes were reported, but weight gain was 1.2kg, 0.7kg, and 1.6kg for morning detemir, evening detemir, and evening NPH, respectively, with a significant between-group difference for detemir versus NPH when administered as evening doses (p=0.005).

Finally, a small cross-over study (Hendriksen, 2012) in which 24 patients with a mean HbA1c of 7.6% and mean body weight of 93.1kg were initially randomized to treatment with NPH insulin or insulin detemir for 8 weeks and then switched to the opposite treatment for an additional 8 weeks, found significant weight loss for detemir after only one week of treatment compared with NPH insulin (-0.8 ± 0.2kg vs. 0.4 ± 0.2kg, p<0.01). However, in contrast to the previously described RCTs, HbA1c was significantly higher for detemir after 8 weeks of treatment (8.2% vs. 7.6% for NPH, p<0.01).

**Observational Studies**

In addition to the previously described RCTs, we identified two large retrospective cohort studies comparing long-acting insulin analogs to NPH insulin. The first study (Delgado, 2012) identified 1,482 patients on NPH insulin from a Spanish registry (47% men, average age 62.7 years) who were either switched to insulin glargine or maintained on NPH insulin and followed for 4-9 months. Mean HbA1c was significantly but modestly lower with insulin glargine at the end of the study (-0.9% vs. -0.4% for NPH, p<0.001) after adjusting for a higher baseline HbA1c (8.3% vs. 7.9% for NPH) and other potentially confounding factors such as age and BMI. The proportion of patients experiencing severe hypoglycemia was low for both groups, and those in the NPH group experienced significantly more overall hypoglycemic episodes in the month prior to the study visit compared to those who were switched to insulin glargine (47.9% vs. 21.8%, p<0.0001); however, the authors suggested a cautious approach to interpreting these results due to inconsistency in reporting of these events across the study population.

The second study (Gordon, 2010) evaluated 4,337 insulin-naïve patients from a UK database who on average weighed 85.4kg with a mean HbA1c of 9.5% and were initiated on NPH, glargine, detemir, or premixed insulin. All groups saw significant reductions in HbA1c (mean change -1.1%, p<0.001), as well as significant weight gain at the end of 12 months (2.3, 1.7, 1.9, and 3.3 kg on NPH, detemir, glargine and premix, respectively, p<0.001). When comparing NPH with other insulins, the only significant between-group difference was for a reduction in HbA1c vs. insulin glargine (-0.2%, p<0.001).

In summary, evidence from both the original Cochrane review as well as subsequent clinical studies suggest no substantial difference in the clinical benefit of long-acting insulin analogs relative to NPH insulin when used as add-on therapy in patients with type 2 diabetes. Because the true level of harm associated with nocturnal and daytime nonsevere hypoglycemic episodes remains unknown,
the overall comparative net health benefit (i.e., effectiveness and harms taken together) of analog versus human insulin appears comparable or perhaps incremental. The degree of certainty about net benefit is moderate, given that the evidence base of 14 RCTs has produced relatively consistent findings.

5.2 Second-Line Pharmacotherapy

There have been few head-to-head comparative trials of DPP-4 inhibitors, sulfonylureas, GLP-1 receptor agonists, and insulin as second-line agents for patients with continuing hyperglycemia on metformin. A systematic review by the Canadian Agency for Drugs and Technologies in Health (CADTH) of randomized controlled trials found no adequately powered trials to assess differences in mortality or the development of diabetes-related complications. The review did note statistically significant reductions in HbA1c versus placebo across all major drug classes analyzed, with the greatest reductions for GLP-1 receptor agonists and insulin. Although severe hypoglycemic events were uncommon across all treatment combinations (1% or less), the insulins and sulfonylureas were associated with higher rates of severe hypoglycemia. Insulins and sulfonylureas were associated with increases in body weight, whereas GLP-1 receptor agonists and DPP-4 inhibitors were associated with weight-loss and weight-neutral outcomes, respectively. Subsequently published studies have produced similar findings.

An original 2010 CADTH review of second-line pharmacotherapy as well as a 2013 update (CADTH, 2013a) identified a total of 72 placebo- or active-control RCTs involving the agents of interest for this evaluation. Findings from a network meta-analysis of these trials for mean change in HbA1c, change in body weight, and rate of overall hypoglycemia can be found in Figure 4 on page 55. The review found no adequately powered RCTs to assess the impact of second-line pharmacotherapy on diabetes-related complications or mortality.

All drug combinations produced statistically-significant reductions in mean HbA1c levels relative to control therapy. Among the drug classes of interest for this evaluation, GLP-1 receptor agonists (mean change: -0.96%; 95% CI: -1.13%, -0.80%) and basal insulin (-0.91%; 95% CI: -1.16%, -0.67%) produced the greatest reductions, although sulfonylureas and DPP-4 inhibitors also produced substantial average reductions (-0.79% and -0.69%, respectively). Sulfonylureas and basal insulins were associated with the largest levels of weight gain (means of 2.1kg and 1.7kg, respectively), while use of DPP-4 inhibitors did not result in statistically-significant change in weight and GLP-1 receptor agonists were associated with a statistically-significant reduction in body weight (mean: -1.8kg; 95% CI: -2.9, -0.8).
As noted in Figure 4 on page 55, both sulfonylureas and basal insulins were associated with a statistically-significant increase in the rate of overall hypoglycemia (i.e., of any severity), with odds ratios of 7.5 and 4.1, respectively. However, when hypoglycemia events were restricted to those categorized as severe (i.e., requiring medical intervention), the absolute rates were low (1% or less) for all drug classes. In fact, network meta-analysis was not feasible because severe hypoglycemia events were too infrequent. Nevertheless, pairwise comparisons suggested an increased risk for sulfonylureas versus placebo and DPP-4 inhibitors (odds ratios of 2.2 and 12.2, respectively) and a reduced risk for GLP-1 receptor agonists versus placebo and basal insulins (odds ratios of 0.3 for both comparisons). Data were insufficient for any other pairwise comparison.

Findings from more recent studies are summarized in the sections that follow, organized by pharmacologic agent.

**DPP-4 Inhibitors**

We identified one RCT directly comparing two newer second-line agents, an investigational agent in the GLP-1 receptor agonist class and a DPP-4 inhibitor (Bergenstal, 2012). A total of 666 type 2 diabetes patients inadequately controlled on metformin with a mean HbA1c value of 8.0% and average weight of 92.4kg were allocated to three add-on treatment groups; 10mg of the GLP-1 receptor agonist taspoglutide once weekly (QW); 20mg of GLP-1 receptor agonist therapy QW; 100mg of the DPP-4 inhibitor sitagliptin once daily (QD); or placebo. There was a significant reduction in HbA1c for both GLP-1 receptor agonist groups compared to DPP-4 inhibitor (-1.03% and -1.18% vs. -0.66% for DPP-4, p<0.001), as well as a reduction in body weight (-1.6kg and -2.4kg vs. -0.5kg for DPP-4, p<0.001) after 52 weeks. However, discontinuation of GLP-1 receptor agonist therapy due to adverse events (i.e., nausea, vomiting, diarrhea, and upper abdominal pain) was high in this study (21-28% in the two GLP-1 groups vs. 7 and 11% for DPP-4 inhibitor and placebo, respectively). There were no cases of severe hypoglycemia reported.
Figure 4. Forest plot of all antidiabetic drugs added as second-line pharmacotherapy.

CADTH 2010 (●) and Updated Network Meta-Analyses (○) for A1C (%) (A), Weight (kg) (B), and Overall Hypoglycemia (C).

### A

<table>
<thead>
<tr>
<th>Treatment added-on to metformin</th>
<th>NMA Estimate (95% CrI)</th>
<th>CADTH 2010</th>
<th>CADTH 2012</th>
<th>Favours Treatment</th>
<th>Favours Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulfonylureas</td>
<td>-0.79 (-0.95, -0.63)</td>
<td>-0.79 (-0.91, -0.67)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meglitinides</td>
<td>-0.64 (-0.93, -0.37)</td>
<td>-0.64 (-0.91, -0.38)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>-0.82 (-1.00, -0.66)</td>
<td>-0.77 (-0.92, -0.63)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPP-4 inhibitors</td>
<td>-0.80 (-0.95, -0.65)</td>
<td>-0.69 (-0.78, -0.60)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AG inhibitors</td>
<td>-0.74 (-0.90, -0.50)</td>
<td>-0.74 (-0.96, -0.51)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLP-1 analogues</td>
<td>-0.82 (-1.06, -0.59)</td>
<td>-0.98 (-1.13, -0.80)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basal insulin</td>
<td>-0.82 (-1.16, -0.47)</td>
<td>-0.91 (-1.16, -0.67)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biphasic insulin</td>
<td>-0.97 (-1.33, -0.61)</td>
<td>-1.06 (-1.32, -0.80)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### B

<table>
<thead>
<tr>
<th>Treatment added-on to metformin</th>
<th>NMA Estimate (95% CrI)</th>
<th>CADTH 2010</th>
<th>CADTH 2012</th>
<th>Favours Treatment</th>
<th>Favours Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulfonylureas</td>
<td>2.0 (1.1, 2.9)</td>
<td>2.1 (1.3, 2.9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meglitinides</td>
<td>1.8 (0.4, 3.3)</td>
<td>1.8 (0.5, 3.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>2.6 (1.7, 3.6)</td>
<td>2.7 (1.8, 3.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPP-4 inhibitors</td>
<td>0.6 (-0.5, 1.6)</td>
<td>0.3 (-0.4, 1.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AG inhibitors</td>
<td>-0.9 (-2.4, 0.5)</td>
<td>-0.9 (-2.2, 0.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLP-1 analogues</td>
<td>-1.8 (-3.4, -0.1)</td>
<td>-1.8 (-2.9, -0.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basal insulin</td>
<td>1.6 (-0.5, 3.6)</td>
<td>1.7 (0.3, 3.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biphasic insulin</td>
<td>3.0 (1.0, 5.0)</td>
<td>3.1 (1.5, 4.7)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### C

<table>
<thead>
<tr>
<th>Treatment added-on to metformin</th>
<th>NMA Estimate (95% CrI)</th>
<th>CADTH 2010</th>
<th>CADTH 2012</th>
<th>More with Placebo</th>
<th>More with Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulfonylureas</td>
<td>8.22 (4.50, 16.63)</td>
<td>7.51 (4.39, 13.86)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meglitinides</td>
<td>8.59 (3.34, 25.20)</td>
<td>8.30 (3.25, 23.44)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>1.10 (0.64, 2.27)</td>
<td>0.93 (0.48, 1.78)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPP-4 inhibitors</td>
<td>1.06 (0.56, 2.21)</td>
<td>0.93 (0.56, 1.62)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AG inhibitors</td>
<td>0.38 (0.01, 0.77)</td>
<td>0.39 (0.01, 0.66)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLP-1 analogues</td>
<td>1.12 (0.33, 3.90)</td>
<td>1.05 (0.49, 2.30)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basal insulin</td>
<td>5.20 (1.48, 21.46)</td>
<td>4.11 (1.60, 10.73)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biphasic insulin</td>
<td>11.02 (3.46, 40.43)</td>
<td>6.99 (2.83, 18.14)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Several studies comparing a DPP-4 inhibitor to a sulfonylurea have also been published since the most recent CADTH review. One study (Gallwitz, 2012a) randomized 1,519 overweight patients (60.2% male; mean baseline HbA1c 7.7%) to a DPP-4 inhibitor (linagliptin) or a sulfonylurea (glimepiride) plus metformin. The study found that the sulfonylurea was associated with a statistically significant but clinically modest mean reduction in HbA1c relative to DPP-4 inhibitor therapy, but an increased risk of severe hypoglycemia versus the DPP-4. Most importantly, however, DPP-4 inhibitor patients experienced fewer cardiovascular events over two years of active treatment (12 vs. 26 for sulfonylurea; relative risk 0.46, 95% CI 0.23-0.91, p=0.0213); these events were primarily nonfatal MI and nonfatal stroke. The authors acknowledge that the study duration was too short for a comprehensive assessment of the impact of treatment on cardiovascular risks, and that the study was not powered to detect differences in these events. They suggest that possible protective vascular effects of DPP-4 inhibitors as well as the potential for increased cardiovascular risk with sulfonylureas might both be at play in this outcome.

A smaller RCT comparing the DPP-4 inhibitor sitagliptin to a sulfonylurea (glimepiride) in 33 patients (Kim, 2013) found comparable reductions in HbA1c between groups and no statistical differences in the rate of hypoglycemia; the study was underpowered to detect differences in adverse events, however.

Similar outcomes were found in a retrospective comparative cohort (Gitt, 2013). Subjects in this analysis were identified from a registry of 884 patients who were at least 40 years old and divided into two subgroups – one taking a DPP-4 inhibitor and one taking a sulfonylurea, both added to metformin. Although DPP-4 inhibitors were associated with a similar reduction in HbA1c compared to sulfonylurea, at the end of the 12-month study there were fewer hypoglycemic events for DPP-4 inhibitors (OR 0.32, 95% CI: 0.19, 0.54, p=0.05) relative to sulfonylureas, as well as significantly fewer non-fatal cardiovascular events, including stroke and transitory ischemic attacks (0.2 vs. 2.0%; p<0.05).

**GLP-1 Receptor Agonists**

In addition to the above-described direct comparison of GLP-1 receptor agonist and DPP-4 inhibitor therapy (Bergenstal, 2012), we identified one additional RCT (Gallwitz, 2012b) assessing the comparative effectiveness of the GLP-1 receptor agonist exenatide plus metformin versus a sulfonylurea (glimepiride) added to metformin for patients with inadequate glucose control on metformin alone. A total of 1,029 patients with a mean age of 56 and mean HbA1c of 7.5% were followed for an average of two years. Patients in the GLP-1 group were more successful in reducing their HbA1c to less than 7% compared to those receiving sulfonylurea therapy (45% vs. 31%, p<0.0001) and there was a statistically significantly greater reduction in body weight for patients on GLP-1 receptor agonist after four weeks, a difference that was maintained for the study duration
(-3.32kg ± 5.45kg vs. 1.15kg ± 4.18kg for sulfonylurea, p<0.0001). More study participants discontinued therapy in the GLP-1 group than in the sulfonylurea group because of adverse events (9.6% vs. 3.3%, p=0.001); however, the difference was only significant between groups in the first six months of treatment. One case of severe hypoglycemia was reported in the GLP-1 group but the between-group difference was not significant.

**Insulin**

We identified two RCTs published subsequent to the latest CADTH review that compared insulin to an oral antidiabetic agent as add-on to metformin. One RCT (Aschner, 2012) assigned subjects with mean uncontrolled HbA1c of 8.5% to receive either insulin glargine or a DPP-4 inhibitor and found that the mean reduction in HbA1c was significantly greater for patients on insulin after 24 weeks of treatment (-1.72% vs. -1.13% for the DPP-4, p<0.0001); however, the DPP-4 group had a reduction in BMI while those on insulin had an increase (-1.08kg/m² vs. 0.44kg/m², 95% CI 0.93-2.09, p<0.0001). Another RCT (Moon, 2013) assessed patients on metformin with mean BMI 34.3kg/m² and HbA1c 8.8% who received insulin glargine or a sulfonylurea and found a between-group difference for changes in body weight in favor of the sulfonylurea (1.7kg vs. 0.0kg for sulfonylurea, p=0.02), though there was no significant difference between the two groups with respect to reduction in HbA1c.

In addition to the available RCTs, we identified a large retrospective comparative cohort study (Roumie, 2014) that assessed long-term outcomes for nearly 15,000 veterans with type 2 diabetes who added any type of insulin (long-acting, premixed, or short/fast-acting) or a sulfonylurea (glyburide, glipizide, or glimepiride) to metformin over a median follow-up of 14 months. After propensity matching to control for differences in demographic and clinical characteristics between groups, insulin combination therapy was associated with a significantly greater risk of all-cause mortality (33.7 vs. 22.7 per 1000 person-years, HR 1.44, 95% CI 1.15-1.79, p=0.001), as well as an increased risk of a composite of nonfatal MI, stroke-related hospitalization, or death from any cause (42.7 vs. 32.8 per 1000 person-years, HR 1.30, 95% CI 1.07-1.58, p=0.009). Because this was a retrospective study based on datasets with limited clinical information, the authors allow for the possibility that there might have been residual confounding for which they could not control. For example, patients receiving insulin might have had greater frailty or increased diabetes severity in ways that are difficult to measure. However, they also noted that these findings are consistent with those from UKPDS and trials of intensive glycemic control (e.g., ACCORD) that failed to show reduced rates of macrovascular complications with insulin versus oral agents and in some cases, increased risk.
In summary, the evidence suggests that second-line pharmacotherapy with metformin and GLP-1 receptor agonists provides an incremental comparative net health benefit relative to the combination of metformin and sulfonylureas, based on greater reductions in HbA1c levels, favorable impact on body weight, and very low risk of severe hypoglycemia, balanced against a higher rate of discontinuation due to gastrointestinal side effects. DPP-4 inhibitors also carry a low risk of severe hypoglycemia and have little impact on body weight, but appear to have a less pronounced impact on HbA1c, all of which suggests a comparable net health benefit relative to sulfonylureas. Finally, basal insulin with either NPH or insulin analogs appears to lower HbA1c more than sulfonylureas but has similar impacts on body weight and hypoglycemia risk, suggesting a comparable or incremental comparative net health benefit. We consider the level of certainty moderate for all of these comparisons, however, as despite numerous placebo-controlled trials there remains a paucity of head-to-head evidence and, while observational studies suggest differences in cardiovascular and mortality risks with certain treatment strategies in patients inadequately controlled on metformin, such evidence cannot yet be considered conclusive.

5.3 Third-Line Pharmacotherapy

Another CADTH systematic review of randomized control trials comparing third-line pharmacotherapy added to metformin and a sulfonylurea for type 2 diabetes found statistically significant reductions in HbA1c across all drug combinations, with the most significant reduction with insulins. The addition of GLP-1 receptor agonist was associated with reductions in HbA1c similar to those of basal insulin, but with significant weight loss compared to other combination therapies. Basal insulin and DPP-4 inhibitors were associated with a significant excess risk of overall hypoglycemia relative to placebo. However, as with second-line pharmacotherapy, severe hypoglycemia was relatively rare even for three-drug combinations (<2% in most circumstances), and many comparisons could not be made due to a lack of events in one or both study arms.

The literature search conducted by CADTH comparing the addition of a third-line medication to metformin and sulfonylurea combination therapy yielded a total of 3 RCTs for DPP-4 inhibitors, 7 for GLP-1 receptor agonists, and 21 for basal insulin (CADTH, 2013b). There were no significant differences between the classes as add-on to metformin and sulfonylurea; all drugs produced significant reductions in HbA1c, with basal insulin producing the greatest effect (-1.15%, 95% CI: -1.49%, 0.83%) (See Figure 5 on the following page). Basal insulin was associated with a significant increase in body weight (1.9kg, 95% CI: 0.7, 3.0) while DPP-4 inhibitors were not associated with any statistically-significant changes in body weight and GLP-1 receptor agonists produced significant weight loss (-1.6kg, 95% CI: -2.8, -0.4). The incidence of long-term diabetes-related complications were not reported in any included study.
We identified only one additional comparative study published after the CADTH review that focused on the agents of interest as third-line pharmacotherapy. This was a placebo-controlled RCT (Moses, 2013) of the DPP-4 inhibitor saxagliptin added on to metformin and a sulfonylurea in 257 overweight type 2 patients with a mean weight of 81.5kg (BMI 29.2kg/m²) and a baseline HbA1c of 8.3%. The DPP-4 inhibitor produced a statistically-significantly greater reduction in HbA1c from baseline over 24 weeks relative to placebo (between-group difference: -0.66%, 95% CI: -0.86%,
Those on the DPP-4 inhibitor gained a small amount of weight while those on placebo had a small weight loss (mean 0.2kg vs. −0.6kg for placebo, p=0.0272). No severe hypoglycemic events occurred in either group.

In summary, as with second-line pharmacotherapy, the use of GLP-1 receptor agonists in combination with metformin and a sulfonylurea provides a comparable reduction in HbA1c relative to the combination of metformin, a sulfonylurea, and basal insulin, but has a favorable impact on body weight and hypoglycemia risk, suggesting an incremental net comparative health benefit. In contrast, DPP-4 inhibitor-based combinations produce slightly inferior reductions in HbA1c and have similar effects on hypoglycemia risk relative to a third-line combination with basal insulin; although DPP-4 inhibitors do not significantly change body weight (while insulin results in a ~2kg increase on average), the overall net benefit appears comparable. The level of certainty in these judgments of benefit should be considered moderate due to a lack of evidence on the impact of these combinations on long-term outcomes such as diabetes-related complications and mortality.

5.4 Insulin Pump Therapy versus Multiple Daily Injections

Few clinical trials have evaluated the use of insulin pumps compared to multiple daily injections for type 2 diabetes patients on insulin treatment. A recent systematic review and meta-analysis conducted by the Agency for Healthcare Research and Quality (AHRQ) found no differences in glycemic control or weight gain between insulin delivery approaches, and insufficient evidence on the impact of pumps versus multiple daily injections on hypoglycemic events as well as mortality and other clinical outcomes. Although recent trials have provided some evidence of clinical benefit, these have suffered from methodological concerns and use of nonstandard outcomes.

Four RCTs, one of which was a crossover study, were assessed in the AHRQ review comparing insulin pumps with multiple daily injections (MDI) (Golden, 2012). The review concluded that there was moderate evidence of no significant difference in glycemic control between insulin delivery approaches (see Figure 6 on the next page), a low level of evidence suggesting no differences in weight gain or severe hypoglycemia, and insufficient evidence to determine differences in outcome with regard to nocturnal hypoglycemia, diabetes-related complications, or mortality.

We identified four additional RCTs evaluating the use of insulin pumps compared to multiple daily injections, as well as a large case series, since the publication of the AHRQ study. The most recently published RCT (Reznik, 2014) was an open-label study that included 331 patients, mean age 56 years with an average diabetes duration of 15 years, who were inadequately controlled on multiple daily injections of high doses of insulin (on average, four injections daily, up to 220 IU per day). The study found a significant between-group difference for reduction in HbA1c in favor of pump treatment (−0.7%, 95% CI -0.9 to -0.4, p<0.0001). There was no significant difference in changes in
body weight between groups, and only one case of severe hypoglycemia, which occurred in the multiple-injections group. Mean total daily insulin dose for this group was significantly higher than among insulin pump users (112 IU vs. 97 IU, p<0.0001). These results should be viewed with caution, however, as this study was subject to several important limitations. For one, there was substantial study dropout during the pre-randomization “run-in” phase (164 patients) as well as post-randomization (23 patients). In addition, one study center was dropped due to repeated protocol violations. Finally, patients in the multiple-injections group tested their blood glucose less frequently than those in the pump group, suggesting that knowledge of treatment assignment may have affected patients’ interest in maintaining glycemic control (Choudhary, 2014). In addition, in both groups, the average number of daily tests (3.1-3.8) was below the standard of care for patients injecting multiple times daily, which may have also affected study results (Reznik, 2014).

**Figure 6.** Between-group differences in changes in HbA1c for insulin pumps vs. MDI among adults with type 2 diabetes.

![Figure 6](image_url)


The remaining RCTs, all of which were performed in China, did not report reduction in HbA1c or weight gain; time to reach HbA1c goal and mean daily insulin dose were assessed as primary outcomes in two studies, however. One RCT (Lv, 2013) observed 119 patients, mean age 61 years with an average diabetes duration of 10.5 years who were assigned to either one of two multiple-injection groups (insulin glargine and detemir) or a pump group and found that the multiple-injection groups took 2-3 days longer to reach their HbA1c target (7.48 ± 2.51 days and 6.85 ± 2.28 days vs. 4.20 ± 1.34 days for pump, p<0.05). Another RCT (Lian, 2013) randomized 150 subjects with an average age of 54 years and average diabetes duration of 9 years to insulin pump or multiple daily injections and found that both short-term (use of pump until glycemic control
achieved) and long-term (use after control achieved) insulin pump therapy was associated with less time to achieve glycemic control compared to intensive insulin treatment with multiple injections (3.8-3.9 days vs. 6.1-9.1 days for multiple injections, p<0.05). Both studies reported that insulin was administered at lower daily doses for pump groups, although the difference was only significant in one study. No cases of severe hypoglycemia were observed in either trial.

The final RCT (Luo, 2013) of 60 type 2 patients with a mean diabetes duration of 10.2 years and baseline HbA1c of 9% compared a sensor-augmented insulin pump (pump with integrated continuous glucose monitor) to conventional insulin pump therapy and multiple daily injections over six days. Although the sensor-augmented pump group saw a significant decrease in mean daily blood glucose after four days, the conventional pump and multiple-injection groups – including daily injections with basal, prandial, and biphasic insulin – had similar outcomes with regard to total daily insulin dose and mean daily glucose levels. No severe hypoglycemic events occurred during the study.

In addition to the available RCTs, we identified a retrospective case series (Choi, 2013) that selected 521 Korean patients with uncontrolled diabetes (≥7% HbA1c) and mean diabetes duration of 10 years enrolled in a diabetes center who were switched to insulin pump therapy from multiple daily injections and followed for one year. Median HbA1c decreased after 6 months of therapy and was maintained between 6.3%-6.5% for the remainder of the study (p<0.0001), with no reported cases of hypoglycemia. However, BMI significantly and continuously increased at a steady rate over the course of study follow-up (25.7kg vs. 23.6kg at baseline, p<0.0001).

Findings from the evidence base of eight RCTs suggests a moderate level of certainty that insulin pumps provide a comparable net health benefit to multiple daily injections in patients with type 2 diabetes, with similar effects on glycemic control, body weight, and hypoglycemia. While newer RCTs suggest better glucose-control performance with pumps, methodological concerns as well as use of short-term, nonstandard outcomes makes comparisons with older RCTs problematic.

5.5 Continuous Glucose Monitors versus Self-Monitoring of Blood Glucose

Data are extremely limited with regard to the potential added benefits from real-time continuous glucose monitors compared to traditional self-monitoring of blood glucose in patients with type 2 diabetes. A recent systematic review published by the Agency for Healthcare Research and Quality (AHRQ) reported no studies comparing these monitoring strategies in a type 2 population using insulin. We did not identify any subsequent studies in type 2 patients taking insulin, but did identify one industry-sponsored RCT in a population not taking insulin, which is provided for context.
The one RCT of real-time continuous glucose monitoring in a type 2 population (Vigersky, 2012) followed 100 military health beneficiaries with type 2 diabetes not using insulin (mean age 58 years, mean HbA1C 8.3%) to either real-time continuous glucose monitors (rt-CGM) or self-monitoring of blood glucose (SMBG) for 12 weeks; all patients were then followed for an additional 40 weeks at the end of the active monitoring period. There was a significant and consistent difference between the two groups in changes in HbA1c at 12, 24, 38, and 52 weeks, respectively (-1.0, -1.2, -0.8, and -0.8% vs. -0.5, -0.5, -0.5, and -0.2% in the SMBG group, p=0.04), with no severe hypoglycemia or significant between-group differences in body weight reported. Improvement was greatest among patients using the rt-CGM device for at least six weeks. A secondary analysis of this RCT (Fonda, 2013) identified five glucose response patterns of those using a rt-CGM and found that patients who viewed their display more frequently had tighter glycemic control than those who only intermittently viewed their device (23 vs. 15 times/day, p=0.05), suggesting that adherence to monitoring plays a factor into whether HbA1c levels improve.

Given that neither the original AHRQ review nor our subsequent search identified any comparative studies of continuous versus conventional glucose monitoring in type 2 diabetes patients who are taking insulin, the evidence appears insufficient to determine whether continuous monitoring provides added clinical benefit for these patients.
6. Economic Evaluation

6.1 Previously Published Economic Studies

The published literature on the economic impact and potential cost-effectiveness of interventions for type 2 diabetes is vast; our initial search for economic evaluations yielded over 3,500 citations. The availability of long-term epidemiologic data on diabetes from cohorts such as the Framingham Heart Study has also allowed for the development and validation of models to simulate the outcomes and costs of type 2 diabetes management on a lifetime basis. These models have proliferated to such an extent that their ability to predict the development of diabetes-related complications and other events has been explicitly compared on multiple occasions (Palmer, 2013). For most measures, these models appear to perform (a) well when compared with robust external data, and (b) similarly when explicitly compared with each other (Hornberger, 2013). We summarize selected evaluations below, focusing on those sponsored by government agencies or independent academic efforts.

Pharmacotherapy

We did identify economic evaluations specific to the comparisons of interest in our analysis. The CADTH reviews of second- and third-line pharmacotherapy for type 2 diabetes each featured an economic evaluation based on the validated U.K. Prospective Diabetes Study (UKPDS) Outcomes Model (CADTH, 2013 [a]; CADTH, 2013 [b]); costs in both analyses were estimated in 2012 Canadian dollars. The evaluation of second-line treatment options found that sulfonylureas were a cost-effective addition for patients not achieving glycemic control on metformin alone (~$8,500 per quality-adjusted life year [QALY] gained) (CADTH 2013 [a]). However, the model results showed that both DPP-4 inhibitors and all forms of basal insulin (human and analog) were less effective when added to metformin than metformin-sulfonylurea combination therapy, as well as more expensive. While the combination of metformin and GLP-1 receptor agonists produced the greatest number of QALYs in the evaluation, its greater expense yielded a very high incremental cost-effectiveness ratio in comparison to metformin+sulfonylurea (~$560,000 per QALY gained). Findings for the newer agents were similar in the evaluation of third-line treatment options: the combination of metformin+sulfonylurea+DPP-4 inhibitor was less effective and more costly in comparison to metformin+sulfonylurea+basal insulin, and while the GLP-1 receptor agonist combination was slightly more effective than the insulin combination, the increased costs were substantial ($1.8 million per QALY gained).

An earlier evaluation of second-line therapy conducted by the Veteran’s Administration and based on a validated lifetime model from the CDC involved a comparison of the sulfonylurea glyburide,
the DPP-4 inhibitor sitagliptin, and the GLP-1 receptor agonist exenatide (Sinha, 2010). All three agents were found to have comparable effects on long-term diabetes-related complications, but a favorable impact on body weight and hypoglycemia led to greater QALYs for the newer agents (about one month of additional quality-adjusted life expectancy vs. the sulfonylurea strategy). The substantial costs of both new agents led to relatively high cost-effectiveness ratios, however (~$170,000 and ~$280,000 per QALY gained for the DPP-4 inhibitor and GLP-1 receptor agonist agents vs. glyburide, respectively, in 2008 U.S. dollars).

Finally, a recent publication of a joint AHRQ-National Science Foundation-funded effort to develop a new Markov model summarized a comparison of sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, and insulin strategies for second-line therapy (Zhang, 2014). As with other evaluations, the sulfonylurea strategy generated the lowest lifetime costs. In contrast with other analyses, however, the sulfonylurea strategy was also the most effective (i.e., “dominant”), as expressed by a modest gain in QALYs and longest duration of time before third-line insulin was required. As with other analyses, greater risks and disutility were assumed for sulfonylureas relative to hypoglycemia and weight gain, but improvement in HbA1c levels, which was estimated based on observed “real world” changes from a linked health care claims-laboratory dataset, was greater among sulfonylurea recipients than among those treated with the other second-line medications of interest.

**Insulin Choice**

There are many economic evaluations comparing long-acting insulin analogs to NPH insulin and other oral therapies, the overwhelming majority of which are industry-sponsored. A recent exception was an evaluation by the U.K.’s National Institute for Health Research (NIHR) to support the updating of a clinical guideline for the National Institute for Health and Care Excellence (NICE) (Waugh, 2010). In the analysis, both insulin glargine and insulin detemir were associated with very slight gains in quality-adjusted life expectancy vs. NPH insulin (2-5 days), and approximately $3,000-$4,000 in excess costs (2008 dollars, converted from GBP), yielding cost-effectiveness ratios of $300,000-$500,000 per QALY gained. As a result, NICE decided to preserve NPH as the insulin of first choice in type 2 patients who require such therapy (NICE, 2009).

Findings from an earlier CADTH-based evaluation of both short- and long-acting insulin analogs were generated using another validated lifetime model (the CORE Diabetes Model) and involved comparisons of both glargine and detemir to NPH (Cameron, 2009). In this analysis, detemir was found to be clinically inferior to NPH and more costly, while glargine produced 3 additional days of quality-adjusted life expectancy on a lifetime basis with a cost-effectiveness ratio of over $600,000 per QALY gained (2007 Canadian dollars). Overall, insulin analogs were found to produce no to minimal clinical benefit but substantial additional costs relative to NPH insulin.
Insulin Delivery

We identified only one economic evaluation of insulin pump delivery vs. multiple daily injections in type 2 diabetes, another NIHR-based evidence review and economic evaluation to support the updating of a NICE technology appraisal (Cummins, 2010). The study found only weak observational evidence to support the use of the pump in type 2 patients, and so declined to formally model the cost-effectiveness of the pump in this population. The review does note that patients can expect to pay over $2,500 more per year to use the pump vs. multiple daily injections of insulin analogs, driven primarily by the cost of the pump itself as well as disposable equipment.

Continuous Glucose Monitoring

We did not identify any studies evaluating the costs and/or cost-effectiveness of continuous glucose monitoring systems in patients with type 2 diabetes.

6.2 ICER Models

We did not attempt to model the economic impact of either insulin pumps or continuous glucose monitors given the acknowledged dearth of evidence in patients with type 2 diabetes. However, while findings from previous evaluations with respect to second- and third-line pharmacotherapy as well as insulin choice have been quite consistent, we nevertheless felt it important to assess the comparative value of these different management options with a focus on the realities of treatment in the U.S. setting. We conducted a formal cost-effectiveness analysis of second- and third-line pharmacotherapy using a published, validated outcomes model. Because there are no clear clinical differences between insulin analogs and NPH, however, our approach was to simply document the budgetary impact of use of varying distributions of analog vs. human insulins in New England. Methods and results for the comparative value analyses are described in detail in the sections that follow. Our approach for the budgetary impact analysis is described beginning on page 79.
6.3 Cost-Effectiveness Model: Methods

Overview

We used the UKPDS Outcomes Model, version 1.3 (Clarke, 2004) to estimate the lifetime clinical and economic effects of type 2 diabetes and its treatment. While the model is based on data collected entirely in the U.K., predictive equations from the study have been extensively validated against U.S.-based studies such as the Framingham Heart Study and the Wisconsin Epidemiology Study of Diabetic Retinopathy (Kothari, 2002). The model was developed in Microsoft Excel® (Microsoft Corp., Redmond, WA), and generates estimates of the incidence of major diabetes-related complications based on risk equations specific to certain demographic (e.g., age, race/ethnicity, BMI) and clinical (e.g., duration of diabetes, HbA1c, cholesterol) characteristics. In order to more accurately reflect the natural history of type 2 diabetes, model extrapolations also allow for changes in baseline parameters over time; for example, HbA1c and lipid levels tend to rise as patients age (Clarke, 2004). Outcomes of interest in the model include:

- Ischemic heart disease
- Fatal and nonfatal myocardial infarction
- Congestive heart failure (CHF)
- Fatal and nonfatal stroke
- Lower-extremity amputation
- Blindness
- Renal failure
- Diabetes-related and all-cause mortality
- Life expectancy and quality-adjusted life expectancy

Costs incorporated in the model include those of treatment, management of diabetes in the absence of complications, and the initial as well as subsequent annual costs of managing complications. The UKPDS is publicly-available to noncommercial researchers and has been well-validated through comparison to epidemiologic studies and large clinical trials (Palmer, 2013).

The model generates stable estimates of clinical outcomes and costs for a given cohort through the use of multiple “Monte Carlo iterations,” or repeated random samplings of the baseline data for the cohorts. We chose to use 1,000 iterations for our analyses based on the recommendations of the UKPDS developer. The model also generates confidence intervals around each estimate using a bootstrapping technique – we chose 500 iterations for bootstrapping, again based on the developer’s recommendations.
The model generates estimates of clinical outcomes and costs over a 40-year time horizon, which is essentially on a lifetime basis given the assumed age of the cohort (56-58 years, see Table 5 on page 69) and life expectancy for patients with type 2 diabetes (65-70 years).

**Target Population**

Consistent with the approach to the evidence review, the target populations of interest included patients with type 2 diabetes whose blood glucose was (a) inadequately controlled by metformin alone (for second-line therapy); or (b) inadequately controlled by the combination of metformin and a sulfonylurea alone (for third-line therapy). A cohort of 100 patients was assumed in each case; baseline characteristics of each cohort were adapted from the CADTH reviews of second- and third-line therapy, which also used the UKPDS model (CADTH 2013 [a], CADTH 2013 [b]). Characteristics for each analysis can be found in Table 5 on page 69.

**Treatment Strategies**

We considered multiple treatment strategies for this evaluation, consistent with the scope of the evidence review. For second-line pharmacotherapy, medications added to metformin included sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, long-acting insulin analogs, and NPH insulin. Consistent with the approach taken in the evidence review, we assumed that individual drugs within a given class would have identical treatment effects. Given the generic availability of both metformin and sulfonylureas, this combination was considered the “referent,” and all other combinations were compared to it.

For third-line pharmacotherapy, the combination of metformin, a sulfonylurea, and NPH insulin served as the referent management option. This was compared to metformin-sulfonylurea combinations with DPP-4 inhibitors, GLP-1 receptor agonists, and insulin analogs added.

**Perspective**

Consistent with the policy context around CEPAC deliberations, analyses were conducted from the perspective of a state Medicaid agency. As such, cost estimates were limited to direct medical costs only (i.e., costs of drug treatment or insulin, routine diabetes management, and treating diabetes-related complications).
Table 5. Baseline characteristics for hypothetical cohorts of patients with type 2 diabetes who are candidates for second- or third-line pharmacotherapy.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>2(^{nd})-Line Estimate</th>
<th>3(^{rd})-Line Estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (years)</td>
<td>56.1</td>
<td>57.7</td>
</tr>
<tr>
<td>Duration of diabetes (years)</td>
<td>6.7</td>
<td>9.5</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>89.0</td>
<td>89.0</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.7</td>
<td>1.7</td>
</tr>
<tr>
<td>BMI</td>
<td>31.2</td>
<td>31.2</td>
</tr>
<tr>
<td>Sex (% male)</td>
<td>54.0</td>
<td>57.0</td>
</tr>
<tr>
<td>Ethnicity (% Caucasian)</td>
<td>98.0</td>
<td>94.0</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>8.30</td>
<td>8.61</td>
</tr>
<tr>
<td>Smoking status (%)</td>
<td>Current: 16</td>
<td>Current: 16</td>
</tr>
<tr>
<td></td>
<td>Past: 49</td>
<td>Past: 49</td>
</tr>
<tr>
<td></td>
<td>Never: 35</td>
<td>Never: 35</td>
</tr>
<tr>
<td>Cholesterol (mmol/L)</td>
<td>4.50</td>
<td>4.50</td>
</tr>
<tr>
<td>LDL (mmol/L)</td>
<td>3.30</td>
<td>3.30</td>
</tr>
<tr>
<td>HDL (mmol/L)</td>
<td>1.20</td>
<td>1.20</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>139</td>
<td>139</td>
</tr>
<tr>
<td>History of (%):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>9.0</td>
<td>11.0</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>5.0</td>
<td>7.0</td>
</tr>
<tr>
<td>Amputation</td>
<td>0.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Blindness</td>
<td>0.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Renal failure</td>
<td>0.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Stroke</td>
<td>4.0</td>
<td>5.0</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>9.0</td>
<td>9.0</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>4.0</td>
<td>4.0</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>3.0</td>
<td>3.0</td>
</tr>
</tbody>
</table>

Sources: CADTH 2013a, CADTH 2013b
Given the interest in applying results to a Medicaid-relevant population, we conducted sensitivity analyses in which selected characteristics were modified to reflect the more diverse nature of Medicaid patients with Type 2 diabetes; data were derived in part from an analysis of Medicaid claims from a large national database (Best, 2012). Changes included:

- Younger age: (51 and 54 years for 2nd- and 3rd-line respectively)
- Longer duration of disease: (8 and 11 years respectively)
- Higher weight (100 kg for both analyses)
- Greater racial diversity (51% Caucasian, 32% African-American, 17% other)
- More active smokers (65% current, 15% past, 20% never)

In addition to the demographic and clinical changes noted above, we also reduced the cost of branded medications (see Table 6 below) by 23.1%, consistent with the mandated rebate required for Medicaid beneficiaries in all states (Medicaid.gov, 2014).

**Treatment Effects**

The effects of each treatment combination were estimated with respect to reductions in HbA1c levels and changes in body weight. We obtained data on these changes from the network meta-analyses conducted as part of the CADTH reviews (see Table 6 below).

**Table 6. Key model inputs.**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Estimate</th>
<th>Source(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Impact of Treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Second-Line</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metformin/Sulfonylurea</td>
<td>-0.79</td>
<td>+2.1</td>
</tr>
<tr>
<td>Metformin/GLP-1</td>
<td>-0.96</td>
<td>-1.8</td>
</tr>
<tr>
<td>Metformin/DPP-4</td>
<td>-0.69</td>
<td>+0.3</td>
</tr>
<tr>
<td>Metformin/NPH or Insulin Analog</td>
<td>-0.91</td>
<td>+1.7</td>
</tr>
<tr>
<td>Third-Line</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metformin/Sulfonylurea/GLP-1</td>
<td>-1.06</td>
<td>-1.6</td>
</tr>
<tr>
<td>Metformin/Sulfonylurea/DPP-4</td>
<td>-0.72</td>
<td>+0.7</td>
</tr>
<tr>
<td>Metformin/Sulfonylurea/NPH or Insulin Analog</td>
<td>-1.15</td>
<td>+1.9</td>
</tr>
<tr>
<td>Utility Values</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>0.785</td>
<td>Clarke, 2004</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>-0.090</td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>-0.055</td>
<td></td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>-0.108</td>
<td></td>
</tr>
</tbody>
</table>
Stroke               -0.164
Amputation            -0.280
Blindness             -0.074
Renal failure         -0.263

Disutility of Obesity (Sensitivity Analysis Only)

Second-Line
Metformin/Sulfonylurea -0.0047
Metformin/GLP-1        +0.0041
Metformin/DPP-4        -0.0007
Metformin/NPH or Insulin Analog -0.0038

Third-Line
Metformin/Sulfonylurea/GLP-1 +0.0036
Metformin/Sulfonylurea/DPP-4 -0.0016
Metformin/Sulfonylurea/NPH or Insulin Analog -0.0043

Annual Drug Costs (2013$):
Metformin               981
Sulfonylureas           658
GLP-1 receptor agonists 3,912
DPP-4 inhibitors        2,794
Insulin Analogs         2,661
NPH Insulin             986

Complication Costs (2013$):

<table>
<thead>
<tr>
<th></th>
<th>Fatal</th>
<th>Nonfatal</th>
<th>Annual</th>
</tr>
</thead>
<tbody>
<tr>
<td>No complications</td>
<td>---</td>
<td>---</td>
<td>1,000</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>---</td>
<td>8,672</td>
<td>2,241</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>25,015</td>
<td>43,712</td>
<td>2,416</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>---</td>
<td>11,492</td>
<td>3,935</td>
</tr>
<tr>
<td>Stroke</td>
<td>60,199</td>
<td>60,199</td>
<td>20,084</td>
</tr>
<tr>
<td>Amputation</td>
<td>78,480</td>
<td>57,032</td>
<td>10,000</td>
</tr>
<tr>
<td>Blindness</td>
<td>---</td>
<td>1,850</td>
<td>6,101</td>
</tr>
<tr>
<td>Renal failure</td>
<td>80,735</td>
<td>80,735</td>
<td>80,735</td>
</tr>
</tbody>
</table>

Importantly, the UKPDS model does not currently have the ability to estimate the impact of severe hypoglycemic episodes on mortality, costs, or other outcomes. While we did not model this impact explicitly, we report the observed rates of these events by treatment combination as documented in the CADTH reviews to provide further context.
Costs

Costs included those of treatment, management of diabetes in the absence of the complications of interest, and the costs of initial treatment and subsequent management of diabetes-related complications. All costs were estimated in 2013 US dollars; we adjusted these when necessary using the medical care component of the U.S. Consumer Price Index (U.S. Bureau of Labor Statistics, 2014). Treatment costs were estimated based on average wholesale prices (Redbook, 2014) as well as from a recent cost-effectiveness analysis that included median generic and branded prices for certain medications (Zhang, 2014). While we recognize that average wholesale prices may not be reflective of prices that Medicaid pays for medications, we do address this in sensitivity analyses by using the statutory rebate amount (23.1%) that all Medicaid programs receive for branded “innovator” drugs, as described on page 78.

We assumed daily dosing of NPH or insulin analog therapy at 0.3 units per kg of body weight, consistent with recommended dosing levels for add-on therapy. We also assumed an annual cost of diabetes management in the absence of complications of $1,000 for office visits, HbA1c and other laboratory testing, eye exams, and other resources. Complication costs were estimated from multiple sources, the most prominent of which involved use of the CDC simulation model to estimate event-based and subsequent management costs for ischemic heart disease, MI, stroke, amputation, blindness, and renal failure (Zhuo, 2013). In the absence of data, we assumed that follow-on costs post-amputation would be approximately half of those post-stroke ($10,000 per year). Costs of initial and subsequent management of CHF were obtained from a population-based simulation (Heidenreich, 2013) and hospital database analysis (Pfuntner, 2013).

Valuing Patient Outcomes

In addition to rates of diabetes-related complications and mortality, the model expresses effectiveness in terms of the quality-adjusted life year (QALY), which captures both the quality and quantity of life. Utility levels that range between 0 (death) and 1 (perfect health) are used to represent the decrement in quality of life that is associated with any given outcome. We used utility levels from the original paper on the UKPDS Outcomes Model (Clarke, 2004), which were derived from the EuroQoL EQ-5D instrument. Patients with type 2 diabetes were assumed to have a utility of 0.785. Decrements in utility associated with each diabetes-related complication are presented in Table 6, and ranged from -0.055 for MI to -0.280 for amputation.

While BMI is an explicit risk factor in the UKPDS model, it primarily affects CHF risk. To allow for the possibility that treatment-induced weight gain might also adversely affect quality of life, we conducted a sensitivity analysis in which data from a population-based study correlating BMI changes with utility decrements on the EQ-5D were applied (Hunger, 2012). Each single-unit
increase in BMI was associated with a -0.006 decrement in utility, which was then multiplied by the change in BMI from baseline for each treatment strategy evaluated. Resulting utility decrements are presented in Table 6 on page 70.

**Key Model Assumptions**

We made several key assumptions for this analysis. First, we assumed that all clinical outcomes were associated with the initial treatment strategy only; we did not assume switching between strategies, although we acknowledge that patients evaluated over such a long time horizon will likely modify their treatment regimen multiple times. The relative effects of each regimen were assumed to be constant over time, although the absolute effects differed because the UKPDS model accounts for progression of risk factors over time (e.g., HbA1c). Finally, in the absence of any clear evidence of clinical benefit for insulin analogs over NPH insulin, we assumed clinical equivalence (but different costs) for these therapeutic options.
6.4 Cost-Effectiveness Model: Results

Second-Line Pharmacotherapy

All modeled regimens had comparable effects on the rate of diabetes-related complications, although the addition of GLP-1 receptor agonists to metformin resulted in a lower rate of heart failure than the other alternatives. This combination also resulted in the greatest gains in both unadjusted and quality-adjusted life expectancy, but was also by far the most costly, resulting in cost-effectiveness estimates of over $20 million per diabetes death averted and nearly $700,000 per QALY gained vs. metformin+sulfonylurea. The addition of DPP-4 inhibitors to metformin resulted in lower effectiveness and higher costs relative to metformin+sulfonylurea. Clinical gains with metformin+basal insulin were modest; the difference in treatment costs by insulin type resulted in vastly different cost-effectiveness estimates, however (e.g., $160,000 vs. $1 million per QALY gained for NPH insulin and insulin analogs, respectively).

Clinical findings for second-line pharmacotherapy among type 2 diabetes patients can be found in Table 7 below. All regimens were associated with reductions in clinical event rates relative to metformin alone, including approximately one fewer diabetes-related death per 100 patients treated. However, rates of most events were quite comparable across combination regimens. The one exception was congestive heart failure, where the combination of metformin and a GLP-1 receptor agonist resulted in an incidence rate of 11.1% (vs. 11.8-12.4% for other regimens), due to the decrease in body weight associated with GLP-1 receptor agonist therapy.

Table 7. Cumulative lifetime incidence of diabetes-related complications, by second-line treatment option.

<table>
<thead>
<tr>
<th>Event Type</th>
<th>MET Alone (Reference)</th>
<th>MET+SULF</th>
<th>MET+GLP-1</th>
<th>MET+DPP-4</th>
<th>MET+Insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemic heart disease</td>
<td>8.6</td>
<td>7.9</td>
<td>8.1</td>
<td>8.0</td>
<td>8.2</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>29.2</td>
<td>27.9</td>
<td>27.4</td>
<td>28.4</td>
<td>27.6</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>12.4</td>
<td>12.2</td>
<td>11.1</td>
<td>11.8</td>
<td>12.2</td>
</tr>
<tr>
<td>Stroke</td>
<td>14.2</td>
<td>13.1</td>
<td>13.0</td>
<td>13.1</td>
<td>13.1</td>
</tr>
<tr>
<td>Amputation</td>
<td>3.9</td>
<td>3.3</td>
<td>3.2</td>
<td>3.3</td>
<td>3.2</td>
</tr>
<tr>
<td>Blindness</td>
<td>7.2</td>
<td>6.3</td>
<td>6.5</td>
<td>6.5</td>
<td>6.3</td>
</tr>
<tr>
<td>Renal failure</td>
<td>2.3</td>
<td>2.3</td>
<td>2.2</td>
<td>2.3</td>
<td>2.3</td>
</tr>
<tr>
<td>Diabetes-related death</td>
<td>21.5</td>
<td>20.5</td>
<td>20.3</td>
<td>20.8</td>
<td>20.4</td>
</tr>
</tbody>
</table>

MET: Metformin; SULF: Sulfonylurea; GLP-1: Glucagon-like peptide-1 agonist; DPP-4: Dipeptidyl peptidase-4 inhibitor
The cost-effectiveness of second-line pharmacotherapy combinations is presented in Table 8 below. The combination of metformin and GLP-1 receptor agonists produced the greatest life expectancy and QALYs relative to other combinations, and there were also no severe hypoglycemic events observed in available placebo- or active-controlled RCTs of this combination. Lifetime costs for the metformin and GLP-1 receptor agonist combination were substantially higher than those for metformin+sulfonylurea (~$117,000 vs. $77,000, respectively). The incremental cost per diabetes death averted for metformin+GLP-1 receptor agonist vs. metformin+sulfonylurea was over $20 million, driven by a modest difference in this outcome (0.2%). The cost per QALY gained was estimated to be nearly $700,000, as the difference in quality-adjusted life expectancy between these two combinations was only about 20 days. Combination therapy with the other newer agent (DPP-4 inhibitors) resulted in slightly lower effectiveness and higher cost relative to the metformin+sulfonylurea combination, as the modeled impact on HbA1c was greater for the latter.

As noted previously, we assumed equivalent effectiveness of NPH insulin and insulin analogs for this evaluation. When given with metformin, both insulins produced slightly more QALYs than metformin+sulfonylurea (8.45 vs. 8.43, respectively), but an increased cost. Costs were about $4,000 higher for the NPH strategy vs. the sulfonylurea combination, yielding an incremental cost-effectiveness ratio of approximately $160,000 per QALY gained. The wider difference in lifetime costs for the insulin analog strategy ($102,000 vs. $77,000 for the sulfonylurea strategy) yielded a cost-effectiveness estimate of over $1 million per QALY gained.

Table 8. Cost-effectiveness of second-line treatments added to metformin for type 2 diabetes.

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Life Expectancy (years)</th>
<th>QALYs</th>
<th>Diabetes Death (%)</th>
<th>Severe Hypoglycemia (%)*</th>
<th>Total Costs</th>
<th>Costs per Death Averted</th>
<th>Costs per QALY Gained</th>
</tr>
</thead>
<tbody>
<tr>
<td>MET Alone (Ref)</td>
<td>11.01</td>
<td>8.33</td>
<td>21.5</td>
<td>N/A</td>
<td>$70,494</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>MET+SULF</td>
<td>11.11</td>
<td>8.43</td>
<td>20.5</td>
<td>1.0</td>
<td>$76,956</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>MET+GLP-1</td>
<td>11.17</td>
<td>8.49</td>
<td>20.3</td>
<td>No events</td>
<td>$117,184</td>
<td>$20,114,146</td>
<td>$689,850</td>
</tr>
<tr>
<td>MET+DPP-4</td>
<td>11.10</td>
<td>8.42</td>
<td>20.8</td>
<td>&lt;0.1</td>
<td>$104,026</td>
<td>†</td>
<td>†</td>
</tr>
<tr>
<td>MET+Insulin Analog</td>
<td>11.13</td>
<td>8.45</td>
<td>20.4</td>
<td>0.9</td>
<td>$101,839</td>
<td>$24,883,051</td>
<td>$1,020,313</td>
</tr>
<tr>
<td>MET+NPH Insulin</td>
<td>11.13</td>
<td>8.45</td>
<td>20.4</td>
<td>0.9</td>
<td>$80,817</td>
<td>$3,861,003</td>
<td>$158,318</td>
</tr>
</tbody>
</table>

*Not from model; pooled findings from RCTs in CADTH review
†Less effective, more expensive
MET: Metformin; SULF: Sulfonylurea; GLP-1: Glugacon-like peptide-1 agonist; DPP-4: Dipeptidyl peptidase-4 inhibitor
Third-Line Pharmacotherapy

As with second-line pharmacotherapy, third-line combinations had comparable impacts on development of all diabetes-related complications with the exception of heart failure, where lower rates were generated for the combination of metformin, a sulfonylurea, and a GLP-1 receptor agonist. In comparison to the referent combination of metformin+sulfonylurea+NPH insulin, the GLP-1 receptor agonist combination averted 6 diabetes-related deaths per 1,000 treated and resulted in a slight improvement in quality-adjusted life expectancy (6 days). Costs were significantly higher, however, resulting in incremental costs per diabetes death averted and per QALY gained of approximately $5 million and $1.8 million, respectively. Cost-effectiveness ratios could not be generated for DPP-4 inhibitor- or insulin analog-based regimens due to equivalent or lower effectiveness and higher cost.

Clinical results for third-line pharmacotherapy combinations can be found in Table 9 below. As with second-line combinations, all regimens of interest improved clinical outcome relative to metformin+sulfonylurea alone, and prevented 1-2 diabetes-related deaths per 100 persons treated. Consistent with findings from the second-line model, differences between third-line combinations in clinical event rates were modest, with the exception of congestive heart failure. Incidence with the GLP-1 combination was 10.6%, vs. 11.5% and 11.6% for the DPP-4 inhibitor- and insulin-based regimens, respectively.

Table 9. Cumulative lifetime incidence of diabetes-related complications, by third-line treatment option.

<table>
<thead>
<tr>
<th>Event Type</th>
<th>MET+SULF (Reference)</th>
<th>MET+SULF +GLP-1</th>
<th>MET+SULF +DPP-4</th>
<th>MET+SULF +Insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemic heart disease</td>
<td>7.2</td>
<td>7.0</td>
<td>6.8</td>
<td>6.8</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>27.9</td>
<td>26.3</td>
<td>26.7</td>
<td>26.3</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>12.4</td>
<td>10.6</td>
<td>11.5</td>
<td>11.6</td>
</tr>
<tr>
<td>Stroke</td>
<td>13.4</td>
<td>12.0</td>
<td>12.5</td>
<td>12.1</td>
</tr>
<tr>
<td>Amputation</td>
<td>3.9</td>
<td>2.5</td>
<td>3.1</td>
<td>2.5</td>
</tr>
<tr>
<td>Blindness</td>
<td>6.4</td>
<td>5.6</td>
<td>5.9</td>
<td>5.4</td>
</tr>
<tr>
<td>Renal failure</td>
<td>1.9</td>
<td>1.9</td>
<td>1.9</td>
<td>2.0</td>
</tr>
<tr>
<td>Diabetes-related death</td>
<td>24.6</td>
<td>23.0</td>
<td>23.8</td>
<td>23.6</td>
</tr>
</tbody>
</table>

MET: Metformin; SULF: Sulfonylurea; GLP-1: Glucacon-like peptide-1 agonist; DPP-4: Dipeptidyl peptidase-4 inhibitor
Cost-effectiveness findings can be found in Table 10 below. In this analysis, the GLP-1 receptor agonist- and insulin-based combinations were essentially equally effective, producing approximately seven years of quality-adjusted life expectancy. In contrast to findings for second-line pharmacotherapy, rates of severe hypoglycemia (1.1-1.5%) were similar across all treatment strategies, in all likelihood because sulfonylureas are included in every combination. The one exception was the DPP-4 inhibitor combination (2.6%). This finding should be interpreted with great caution, however, as only two RCTs of third-line therapy with DPP-4 inhibitors were identified in the CADTH review, and severe hypoglycemic events were observed in only one.

Cost-effectiveness ratios could not be generated for the DPP-4 inhibitor- and insulin analog-based combinations, as the former was less effective and more expensive than the NPH insulin-based combination, and the latter was equally effective and more expensive. The cost per diabetes death averted for metformin+sulfonylurea+GLP-1 receptor agonist was approximately $5.2 million relative to metformin+sulfonylurea+NPH insulin. The cost-effectiveness of this combination relative to the NPH-based referent combination was approximately $1.8 million per QALY gained, as lifetime costs were over $30,000 greater and the difference in QALYs was slightly more than 0.01, or about six days of quality-adjusted life expectancy.

Table 10. Cost-effectiveness of third-line treatments added to metformin+sulfonylurea for type 2 diabetes.

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Life Expectancy (years)</th>
<th>QALYs</th>
<th>Diabetes Death (%)</th>
<th>Severe Hypoglycemia (%)*</th>
<th>Total Costs</th>
<th>vs. MET+SULF+NPH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cost per Death Averted</td>
</tr>
<tr>
<td>MET+SULF (Ref)</td>
<td>9.02</td>
<td>6.82</td>
<td>24.6</td>
<td>N/A</td>
<td>$81,773</td>
<td>---</td>
</tr>
<tr>
<td>MET+SULF+NPH Insulin</td>
<td>9.21</td>
<td>7.00</td>
<td>23.6</td>
<td>1.1</td>
<td>$91,025</td>
<td>---</td>
</tr>
<tr>
<td>MET+SULF+GLP-1</td>
<td>9.23</td>
<td>7.01</td>
<td>23.0</td>
<td>1.5</td>
<td>$122,181</td>
<td>$5,192,565</td>
</tr>
<tr>
<td>MET+SULF+DPP-4</td>
<td>9.13</td>
<td>6.92</td>
<td>23.8</td>
<td>2.6</td>
<td>$111,048</td>
<td>††</td>
</tr>
<tr>
<td>MET+SULF+Insulin Analog</td>
<td>9.21</td>
<td>7.00</td>
<td>23.6</td>
<td>1.1</td>
<td>$108,717</td>
<td>✠</td>
</tr>
</tbody>
</table>

*Not from model; pooled findings from RCTs in CADTH review
†Less effective, more expensive
‡Equally effective, more expensive
MET: Metformin; SULF: Sulfonylurea; GLP-1: Glugacon-like peptide-1 agonist; DPP-4: Dipeptidyl peptidase-4 inhibitor
Obesity-Related Sensitivity Analysis

The results of our sensitivity analysis, in which we applied a change in utility to correspond with treatment-induced changes in body weight, can be found in Appendix B. For second-line therapy, the gap in effectiveness widened between the combination of metformin and GLP-1 receptor agonist therapy vs. metformin+sulfonylurea (8.53 vs. 8.38 QALYs). However, the increased costs of the GLP-1 receptor agonist combination still resulted in a cost-effectiveness ratio of over $250,000 per QALY gained. Cost-effectiveness was also improved with DPP-4 inhibitor- and insulin analog-based regimens, as these resulted in less weight gain than the referent combination, but incremental cost-effectiveness ratios were still over $700,000 per QALY gained. The cost-effectiveness of the NPH-based regimen was also improved somewhat, to approximately $110,000 per QALY gained.

In analyses of third-line pharmacotherapy, the addition of a GLP-1 receptor agonist to metformin and sulfonylurea also improved outcome relative to the NPH insulin-based referent combination (7.05 vs. 6.96 QALYs, respectively), resulting in a cost-effectiveness ratio of approximately $350,000 per QALY gained. However, as in primary analyses, cost-effectiveness ratios could not be generated for DPP-4 inhibitor-based treatment or insulin analogs given equivalent or lower effectiveness in relation to the NPH referent and higher costs in both instances.

Medicaid Sensitivity Analysis

Findings from our sensitivity analysis using Medicaid-relevant demographics, clinical characteristics, and costs can be found in Appendix D. As with basecase analyses, adding DPP-4 inhibitors to metformin remained slightly less effective and more costly than metformin+sulfonylurea. Similar to the obesity sensitivity analysis above, cost-effectiveness improved with GLP-1s and insulin analogs (~$340,000 and ~$270,000 per QALY gained respectively vs. ~$690,000 and ~$1 million in basecase analyses), but remained higher than commonly-accepted thresholds for cost-effectiveness. Cost-effectiveness with the combination of metformin and NPH insulin improved to under $60,000 per QALY gained vs. metformin+sulfonylurea.

Results of sensitivity analyses for third-line combinations showed very comparable performance in terms of QALYs gained (7.3-7.4 for all combinations). However, because the QALY estimates were highest for the addition of insulin to metformin and a sulfonylurea in this analysis (likely as a result of greater reductions in HbA1c without the attendant effects of weight gain/loss seen in the obesity analysis above), both GLP-1 receptor agonist and DPP-4 inhibitor based combinations were less effective and more expensive than insulin, and cost-effectiveness ratios could not be generated.
6.5 Budget Impact Analysis: Methods

As described at the beginning of this section, our intent was to document the one-year budgetary impact of changes in the distribution of NPH insulin vs. insulin analogs in type 2 patients using insulin as add-on therapy to other antidiabetic drugs. In keeping with assumptions made for the cost-effectiveness analysis, we assumed no difference in major clinical outcomes by insulin type; we do present estimates of the numbers of patients who would experience nocturnal hypoglycemia at different distributions, however. While the clinical significance of this outcome remains uncertain, it was the one variable that differed materially in head-to-head RCTs of NPH and insulin analogs. Annual costs of NPH and insulin analogs were estimated as in the cost-effectiveness analysis, based on typical add-on dosing (0.3 u/kg) for an individual weighing 89kg.

The prevalence of type 2 diabetes in New England was estimated based on age-specific prevalence estimates from the Centers for Disease Control. Estimates were 4.1%, 16.2%, and 25.9% for persons age 18-44, 45-64, and 65 years and older, respectively. We assumed that 95% of these individuals would have type 2 disease. The proportion of type 2 patients using insulin was estimated to be approximately 15% from an analysis of a large insurer health claims database (Lipska, 2014). That same analysis described the current prevalent levels of insulin glargine (64%) and detemir (16%) use among type 2 diabetics, a pattern that has been shown to be similar in other settings. Our baseline for insulin analog vs. NPH insulin use was therefore 80% and 20%, respectively.

6.6 Budget Impact Analysis: Results

Based on our estimates, of the 11 million adults currently residing in New England, approximately 1.4 million (12%) have type 2 diabetes. Of these individuals, slightly more than 200,000 are currently using insulin to help manage their condition.

At baseline, the number of patients experiencing nocturnal hypoglycemia is estimated to total 209 per 1,000 patients treated. Reductions in the proportion of individuals receiving insulin analogs would increase the number experiencing nocturnal hypoglycemia, as the rate of these events with NPH insulin is nearly double that of insulin analogs. If 65% of patients were receiving insulin analogs, an additional 18 patients per 1,000 treated would experience nocturnal hypoglycemia (an increase of 9%). If this distribution were to be reversed (i.e., 65% of patients receiving NPH insulin), the number would grow by an additional 56 patients over baseline (a 27% increase). As mentioned previously, there is great uncertainty regarding the clinical significance of nocturnal hypoglycemia, but these data provide context for considerations of the type of insulin used in the region.
In contrast, the impact of changes in the distribution of insulin type on insulin-related expenditures is quite clear. As shown in Figure 7 below, the high percentage of insulin analog recipients, coupled with prices that are approximately threefold higher for insulin analogs vs. NPH (i.e., $2,661 vs. $986 annually) results in annual expenditures in the region of nearly $500 million, 92% of which is driven by insulin analog costs. Reducing the percentage of patients using insulin analogs to 65% from 80% would result in $52 million in savings (11%). A further reduction to 50% would increase these savings to over $100 million (21.6%). If 80% of insulin use were NPH-based, cost savings would exceed $200 million. Simply put, for every 1,000 patients treated with insulin, a switch from insulin analogs to NPH insulin would result in approximately $1.7 million in cost savings.

**Figure 7. Budgetary impact of shifts in the distribution of insulin analog vs. NPH insulin use in New England.**
6.7 Limitations

We note some limitations of our analyses. First, while the UKPDS Outcomes Model has been extensively tested and externally validated, we cannot rule out the possibility that small differences in clinical benefit could have been the result of sampling error during model simulations. In addition, as previously noted, we were not able to explicitly model the clinical impact and cost of hypoglycemia, the risk of which appears to be lessened with newer antidiabetic agents. Nevertheless, while estimates differ somewhat, our findings are congruent with all of the independently-conducted economic evaluations highlighted at the beginning of this section, including at least one that suggests somewhat better “real world” effectiveness for generic sulfonylureas (Zhang, 2014). While we await the publication of the impact of these treatment alternatives on long-term outcomes from the Mini-Sentinel and other initiatives, we nevertheless take comfort in the knowledge that the direction of our model findings is similar to those of other efforts that have used independently-validated simulation models.

We also did not model the contribution of changes in weight gain to clinical outcomes and costs other than for congestive heart failure, a link already established in the UKPDS. The cohort characteristics used in our basecase analyses also did not necessarily reflect those of a Medicaid population with type 2 diabetes. We did conduct sensitivity analyses to address both issues, however, including utility associated with treatment-induced weight gain or loss in one, and Medicaid-relevant demographic and clinical characteristics as well as prices in another. In both sets of analyses, while incremental gains in effectiveness and differential costs did change somewhat, our conclusions did not—namely, the least expensive second- and third-line pharmacotherapy options offer good value for money.

6.8 Summary

The results of our cost-effectiveness analysis of second-line pharmacotherapy suggest that, given the best available knowledge of current clinical evidence, use of a treatment regimen of metformin and a sulfonylurea in patients inadequately controlled on metformin alone produces outcomes nearly as good as with newer agents at a much lower cost. While GLP-1 receptor agonists produced the best overall clinical outcomes, including consideration of weight gain, hypoglycemia, and blood sugar control, among all available combinations, gains in total quality-adjusted life expectancy were small, while costs were over 50% higher, yielding a cost-effectiveness ratio of nearly $700,000 per QALY gained. Findings were similar for insulin analogs, but a combination of metformin and less expensive NPH insulin produced a more reasonable cost-effectiveness ratio (~$160,000 per QALY gained).
Similar results were seen in analyses of third-line pharmacotherapy options. Again, the least expensive treatment option (metformin+sulfonylurea+NPH insulin) was nearly as effective as the GLP-1 receptor agonist-based combination, which resulted in a very high cost-effectiveness ratio (~$1.8 million per QALY gained) for the latter.

Our budget impact analysis is also illustrative. Without clear evidence favoring insulin analogs over NPH insulin in type 2 patients, our results suggest that payers in New England may be overspending by as much as $200 million per year for more expensive analogs. While we do acknowledge that many other regions and systems are encountering the same phenomenon, we note that this is not universally true. For example, a recent comparison of insulin use among Veteran’s Affairs and Medicare Part D patients showed that only a little more than a quarter (27%) of type 2 diabetes patients on insulin in the VA system were using insulin analogs for their treatment (Gellad, 2013).

In summary, the current state of the evidence suggests that the use of newer oral antidiabetic agents and insulin analogs may offer small clinical improvements over generic sulfonylureas and human insulin in patients with type 2 diabetes who are inadequately controlled on metformin, but the high costs of these agents call their potential cost-effectiveness into question. In contrast, the less expensive agents appear to provide good value for those patients who would be considered good candidates for such therapy.
7. Questions and Discussion

**About the CEPAC Process**

The New England Comparative Effectiveness Public Advisory Council (CEPAC) is an independent forum in which clinical and public policy experts publicly deliberate on evidence reviews of the clinical effectiveness and value of health care services. Through these deliberations, CEPAC provides guidance on how the existing evidence can best be applied to improve the quality and value of health care services across New England. CEPAC is composed of 17 members, a mix of clinicians, economists, and public representatives from each New England state that meet strict conflict of interest criteria (described in Appendix F). Representatives of state Medicaid programs and of regional private payers are included as ex-officio members of CEPAC. CEPAC members are recruited through an open public nomination process, and are selected on the basis of their experience and training in the interpretation and application of medical evidence in health care delivery.

Council members are intentionally elected to represent a range of expertise and diversity in perspective, and are therefore not pre-selected based on the topic being addressed to maintain the objectivity of the Council and ground the conversation in the interpretation of the published evidence rather than anecdotal experience or expert opinion. Acknowledging that any judgment of evidence is strengthened by real life clinical and patient perspective, subject matter experts are invited to participate in each meeting to serve as a resource to the Council during their deliberation, and to help form recommendations with CEPAC on ways the evidence can be applied to policy and practice. Clinical experts also provide input to Council members before the meeting to help clarify CEPAC’s understanding of the different interventions being analyzed in the evidence review.

Led by the Institute for Clinical and Economic Review (ICER), CEPAC was originally funded by a federal grant from the Agency for Healthcare Research and Quality (AHRQ), but is now supported by a broad coalition of state Medicaid leaders, integrated provider groups, public and private payers and patient representatives. For more information on CEPAC, please visit cepac.icer-review.org.

At the October 29, 2014 meeting, CEPAC discussed issues regarding the comparative benefit of different management approaches for type 2 diabetes, as well as the benefit of devices to support insulin delivery and glucose monitoring in this patient population. CEPAC votes and discussion are intended to support the dialogue needed for successful action to improve the quality and value of health care services. The key questions are developed by the ICER research team for each appraisal, with input from the CEPAC Advisory Board to ensure that the questions are framed to address the issues that are most important in applying the evidence to support clinical practice and medical policy decisions. The sections below include the results of the votes of CEPAC on these key evidence questions. In addition, we present policy considerations highlighted by CEPAC and by a Roundtable of regional clinical experts, patient advocates, and health insurance representatives that discussed the implications of CEPAC votes for clinical practice, and payer policies. The meeting agenda, including Roundtable panelists, are shown in Appendix E.
7.1 Summary of the Votes and Considerations for Policy

Following the evidence presentation and public comments, CEPAC voted on questions concerning the comparative clinical effectiveness and comparative value of second- and third-line treatment options for type 2 diabetes, as well as devices to support insulin delivery and the monitoring of blood glucose. We present below the voting results along with comments reflecting the most important considerations mentioned by CEPAC members during the voting process.

When voting on comparative value, CEPAC was asked to assume the perspective of a state Medicaid program that must make resource decisions within a relatively fixed budget for care. CEPAC is not given prescribed boundaries or thresholds for budget impact or incremental cost-effectiveness ratios to guide its judgment of low, reasonable, or high value. However, CEPAC did make use of a series of value categories designed by ICER to assist the Council in assigning an overall value rating (see Figure 8 below). CEPAC members who vote “no” on comparative clinical effectiveness are designated to a special “low” value vote category for lack of evidence to demonstrate comparative clinical effectiveness. Because all of the voting questions asked whether a particular drug or device was equivalent to or better than a comparator, CEPAC did not have the option to vote for two of the categories shown in the value matrix below, as these categories refer to a drug or device that has “worse outcomes”.

Figure 8. Evidence Categories for Ratings of Low, Reasonable/Comparative, and High Value

<table>
<thead>
<tr>
<th>Low Value</th>
<th>Reasonable/Comparable Value</th>
<th>High Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Worse outcomes; Higher or equivalent cost</td>
<td>Worse outcomes; Lower cost</td>
<td>Comparable outcomes; Lower cost</td>
</tr>
<tr>
<td>Comparable outcomes; Higher costs</td>
<td>Comparable outcomes; Comparable cost</td>
<td>Promising but inconclusive evidence of better outcomes; Lower cost</td>
</tr>
<tr>
<td>Promising but inconclusive evidence of better outcomes; Higher cost</td>
<td>Promising but inconclusive evidence of better outcomes; Comparable cost</td>
<td>Better outcomes; Lower or comparable cost</td>
</tr>
<tr>
<td>Better outcomes; Too high a cost</td>
<td>Better outcomes; Reasonable higher cost</td>
<td>Better outcomes; Slightly higher cost</td>
</tr>
</tbody>
</table>
Insulin choice for adjunctive therapy:

*Human insulin vs. insulin analogs*

1. Is the evidence adequate to demonstrate that NPH insulin (intermediate-acting human insulin) is functionally equivalent to long-acting insulin analogs for most patients with type 2 diabetes?

   *CEPAC Vote:*
   
   9 yes (100%) 0 no (0%)

2. If yes, from the perspective of a state Medicaid program, would you judge the value of NPH insulin compared to long-acting insulin analogs to be high, reasonable, or low?

   *CEPAC Vote:*
   
   9 high (100%) 0 reasonable (0%) 0 low (0%)

*Comments:* A majority of CEPAC members voted that NPH insulin provides comparable outcomes at a lower cost, while some voted that there is promising but inconclusive evidence of better outcomes at a lower cost. CEPAC members emphasized that their high value votes do not mean that all patients are well-suited to treatment with NPH insulin. The decreased risk of hypoglycemia associated with long-acting insulin analogs may be of significant benefit to some patients. Choice of insulin should be guided in part by individual risk for hypoglycemia and cannot be based solely on comparative value.

Second-line pharmacotherapy options for patients with inadequate glycemic control from metformin monotherapy:

*Combination therapy with Metformin plus DPP-4 inhibitor or sulfonylurea*

3. Is the evidence adequate to demonstrate that combination therapy with metformin + DPP-4 inhibitor is superior to metformin + sulfonylurea for most patients with type 2 diabetes for whom metformin monotherapy provides inadequate glycemic control?

   *CEPAC Vote:*
   
   1 yes (11%) 8 no (89%)
Note: CEPAC did not place a vote comparing the value of metformin plus a DPP-4 inhibitor versus metformin plus a sulfonylurea since a majority of the Council voted that there is insufficient evidence to demonstrate the superior effectiveness of DPP-4s relative to sulfonylureas.

**Combination therapy with Metformin plus GLP-1 receptor agonist or sulfonylurea**

4. Is the evidence adequate to demonstrate that combination therapy with metformin + GLP-1 receptor agonist is superior to metformin + sulfonylurea for most patients with type 2 diabetes for whom metformin monotherapy provides inadequate glycemic control?

**CEPAC Vote:**

6 yes (67%) 3 no (33%)

**Comments:** Members of CEPAC voting yes pointed to the reduced risks for hypoglycemia and benefits of weight loss for patients with type 2 diabetes as evidence of the clinical advantage of GLP-1 receptor agonists over sulfonylureas. Members voting no suggested that the specific sulfonylureas reviewed in the evidence were mostly older agents, and that more current versions may potentially perform better against GLP-1 receptor agonists.

5. If yes, from the perspective of a state Medicaid program, would you judge the value of metformin + GLP-1 receptor agonist compared to metformin + sulfonylurea to be high, reasonable, or low?

**CEPAC Vote:**

0 high (0%) 0 reasonable (0%) 6 low (100%)

**Comments:** CEPAC members voted that the evidence demonstrates either better outcomes at too high of a cost, or promising but inconclusive evidence of better outcomes at a higher cost, making GLP-1 receptor agonists low value as compared to sulfonylureas for second line medication.
Third-line pharmacotherapy options for patients with inadequate glycemic control from metformin combination therapy with sulfonylurea:

**Combination therapy with Metformin plus sulfonylurea + either DPP-4 inhibitor or insulin**

6. Is the evidence adequate to demonstrate that combination therapy with *metformin + sulfonylurea + DPP-4 inhibitor* is superior to *metformin + sulfonylurea + NPH insulin* for most patients with type 2 diabetes with inadequate glycemic control?

    **CEPAC Vote:**
    
    0 yes (0%)  9 no (100%)

Note: CEPAC did not place a vote comparing the value of metformin plus sulfonylurea and a DPP-4 inhibitor versus metformin plus sulfonylurea and insulin since a majority of the Council voted that there is insufficient evidence to demonstrate the superior effectiveness of DPP-4s relative to insulin as a third-line option.

**Combination therapy with Metformin plus sulfonylurea + either GLP-1 receptor agonist or insulin**

7. Is the evidence adequate to demonstrate that combination therapy with *metformin + sulfonylurea + GLP-1 receptor agonist* is superior to *metformin + sulfonylurea + NPH insulin* for most patients with type 2 diabetes with inadequate glycemic control?

    **CEPAC Vote:**
    
    6 yes (67%)  3 no (33%)

8. If yes, from the perspective of a state Medicaid program, would you judge the value of *metformin + sulfonylurea + GLP-1 receptor agonist* compared to *metformin + sulfonylurea + NPH insulin* to be high, reasonable, or low?

    **CEPAC Vote:**
    
    0 high (0%)  0 reasonable (0%)  6 low (100%)
**Comments:** CEPAC members voted that GLP-1 receptor agonists have low comparative value, with some members voting that the evidence was promising but inconclusive of better outcomes at too high a cost, while others indicated that they felt the evidence suggested better outcomes at too high a cost.

**Insulin delivery:**

**Insulin pumps vs. multiple daily injections**

9. Is the evidence adequate to demonstrate that any clinical subpopulation of patients with type 2 diabetes does better with *insulin pumps* compared to *multiple daily injections*?

**CEPAC Vote:**

|   | 0 yes (0%) | 9 no (100%) |

**Comments:** CEPAC noted that this vote was based on an overarching lack of studies comparing insulin pump therapy to multiple daily injections in the type 2 population. While there may be some patients that could benefit from an insulin pump, more research is needed to produce evidence sufficient to support this claim.

**Glucose monitoring:**

**Self-monitoring of blood glucose vs. Continuous glucose monitors**

10. Is the evidence adequate to demonstrate that any clinical subpopulation of patients with type 2 diabetes does better with *continuous glucose monitors* compared to *self-monitoring of blood glucose*?

**CEPAC Vote:**

|   | 0 yes (0%) | 9 no (100%) |

**Comments:** CEPAC noted that some populations may be well-suited to continuous glucose monitoring and more research is needed to identify subpopulations that may perform better with CGMs, but there is not currently enough evidence to support their clinical utility for patients with type 2 diabetes.
7.3 Roundtable Discussion and Key Policy Conclusions

Following CEPAC’s deliberation on the evidence and subsequent voting, the Council engaged in a moderated discussion with a Roundtable composed of clinical experts, a patient advocate, and regional health insurers. The participants in the Roundtable discussion are shown below.

Table. 11 Policy Roundtable Participants

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Francis Basile, Jr., MD</td>
<td>Chief of the Division of Primary Care, University Medicine, Inc.</td>
</tr>
<tr>
<td></td>
<td>Clinical Associate Professor, Warren Alpert School of Medicine at Brown University</td>
</tr>
<tr>
<td>Barbara Henry, RPh</td>
<td>Senior Clinical Pharmacy Coordinator, Harvard Pilgrim Health Care</td>
</tr>
<tr>
<td>Peter Hollmann, MD</td>
<td>Medical Director, Blue Cross Blue Shield of Rhode Island</td>
</tr>
<tr>
<td>Robert Smith, MD</td>
<td>Professor of Medicine, Warren Alpert School of Medicine at Brown University Chair, U.S. FDA Endocrinologic and Metabolic Drugs Advisory Committee Former Director, Hallett Center for Diabetes at Rhode Island Hospital</td>
</tr>
<tr>
<td>Rev. Albert Whitaker, MA</td>
<td>Director, Mission Delivery, American Diabetes Association, New England Chapter</td>
</tr>
<tr>
<td>Robert Zavoski, MD, MPH</td>
<td>Medical Director, Connecticut Department of Social Services</td>
</tr>
</tbody>
</table>

The Roundtable discussion explored the implications of CEPAC’s votes for clinical practice and medical policy, considered real life issues critical for developing best practice recommendations in this area, and identified potential avenues for applying the evidence to improve patient care. The main themes and recommended best practices from the conversation are summarized in the sections below. The Policy Expert Roundtable discussion reflected multiple perspectives and opinions and therefore none of the recommendations below should be taken as a consensus view held by all participants.

1. Clinicians should make treatment decisions with a consideration of the psycho-social context in which medications are being used. Health care teams that integrate nurse case managers, community health workers, behavioral health providers, pharmacists, and diabetes educators are ideal for providing comprehensive management of the condition and ensuring that different treatment approaches are feasible given each patient’s unique circumstances.

The Policy Roundtable discussion emphasized that diabetes is embedded in broader socioeconomic issues related to public health and health care access. Experts on the Roundtable noted that for many patients the disease will not be controlled nor treatment successful without first addressing
the underlying issues that affect an individual’s ability to maintain a healthy lifestyle, access medication, and adhere to a complicated treatment regimen that can often be costly. CEPAC members and Policy Roundtable participants stressed the importance of building health care teams that can more comprehensively manage a patient’s condition. Nurse case managers, community health workers, pharmacists, and diabetes educators were all recognized as important potential members of health teams that help transition patients across different therapies, monitor glycemic control, and educate and provide support to patients as treatment strategies become more complicated and patients have more options to consider. By adopting a multiple-disciplinary care team approach, there are more opportunities to reach patients inside or outside of the practice setting to increase education and to better engage patients in their treatment choices. CEPAC members and Roundtable participants also emphasized how comprehensive health care teams are better equipped to intervene early when there are issues with treatment, thereby improving patient adherence. For example, some patients are unable to test blood sugar levels multiple times a day so are noncompliant to treatment regimens that require multiple daily injections and more frequent monitoring schedules. Nurse case managers and community health workers in particular can better account for the psycho-social context in which medications are being used and determine the feasibility of different management approaches given each patient’s unique circumstances. As ACOs and global payment systems become more prominent, payers should ensure funding that adequately supports the provision of team-based services.

2. **Consideration of pharmacotherapy for patients with type 2 diabetes should be only one component of a broader management plan that emphasizes lifestyle changes and behavioral support.**

CEPAC members highlighted that the focus of the CEPAC meeting and this report only address a subset of the diabetes problem, and that for many patients, the disease has been managed through lifestyle changes and other public health approaches. CEPAC and Policy Roundtable members agreed that decisions of medication choice should be considered within a broader treatment strategy that prioritizes patient education, diet, and exercise. The patient representative on the Roundtable emphasized the essential role that education plays in helping patients understand their disease, the appropriate level of activity and carbohydrate intake, and consequences of diabetes if left uncontrolled.

3. **To the extent possible, clinicians should determine appropriate HbA1c targets based on individual factors.**

CEPAC and Roundtable panelists discussed at length the extent to which diabetes care can be personalized to achieve treatment goals. The philosophy of diabetes management heretofore has been to bring patients to a specific HbA1c target of ≤7%. However, clinical experts on the
Roundtable noted that the drive for blood glucose levels less than 7% will not be appropriate for many patients. Treatment aims should always reflect a balance between the goals of reducing long-term adverse clinical events and managing hypoglycemia and other side effects of treatment.

The Roundtable and Council members also agreed that patient preferences should inform decisions of treatment goals and pharmacotherapy choice. For many patients with type 2 diabetes, comorbid conditions are a major concern. Even a marginal increase in weight may require some patients to go back on blood pressure medication, complicating treatment regimens. Other patients may be unable to intervene independently to manage their risk of hypoglycemia, for example patients with disability. Council members and the patient representative on the Roundtable therefore underscored the importance of explaining the relative risks and benefits associated with different pharmacotherapy options in terms that are acceptable and understandable to patients, and developing HbA1c targets and other treatment aims with individual patient factors and the relative advantages and disadvantages of each treatment alternative in mind.

4. Based on the best available evidence, clinicians and payers should consider aligning patient education, practice standards, and payment policies to start patients who require insulin on human formulations first, unless there are contraindications or other factors suggesting that initiation on insulin analogs would be preferred.

The available evidence suggests that most patients with type 2 diabetes can achieve equal levels of glycemic control with regular human insulin (NPH) or long-acting analog formulations. The research demonstrates that NPH use does not result in higher levels of weight gain nor does it cause more adverse events, except for “nonsevere” hypoglycemia. Patients treated with NPH insulin may more often require twice daily injections than patients treated with long-acting insulin analogs. The possibility that this could adversely affect adherence to the insulin regimen and thus diabetes control has not been adequately evaluated. Accounting for both the evidence on clinical effectiveness and costs, CEPAC determined that human insulin offers high value compared to long-acting analog alternatives for many type 2 diabetes patients. CEPAC members and Roundtable panelists suggested that human insulin is potentially being underutilized and that more should be done by payers and provider organizations to promote its use in appropriate patients. Prior authorization and step-therapy requirements were offered as potential mechanisms to direct patients towards trying NPH first, with opt-out provisions for patients with co-morbid conditions, job conditions, or other factors that would elevate the risk that nonsevere hypoglycemia would produce significant effects on health or quality of life. CEPAC and Roundtable members cautioned, however, that any step therapy policies would have to be flexible in design and application to ensure the ability to rapidly switch patients to insulin analogs if needed.
Patient and clinical representatives suggested that additional patient education can help reduce the perceived concerns regarding hypoglycemia and adherence with NPH. Roundtable panelists advocated for more targeted education instructing patients on how to prevent and manage hypoglycemia, and pointed to existing guidelines from the American Diabetes Association that outline minimum standards for diabetes self-education and support. Roundtable panelists once again advocated for a team-based approach to managing diabetes that utilizes nurse case managers, community health care workers, and other health care professionals, particularly for patients on complicated medication regimens that include insulin.

5. **Health plans and provider organizations should promote the use of high value drug treatment options while crafting approaches that are flexible enough to allow for personalized care that can meet individual patient needs. Specifically:**

- **First-line therapy:** Nearly all patients requiring pharmaceutical treatment should be started on metformin as first-line therapy, and the use of metformin should be optimized before considering the addition of other options.

- **Second-line therapy:** For many patients who do not reach adequate blood sugar control with metformin monotherapy, second-line therapy with sulfonylureas is a reasonable choice. Although CEPAC voted that GLP-1 receptor agonists offer incremental clinical benefits related to reduced weight gain and incidence of hypoglycemia – benefits that will be of greater potential importance for some patients than others – CEPAC felt that the balance of the clinical benefits versus the high per-patient incremental cost made GLP-1 receptor agonists a “low value” second-line therapy compared to sulfonylureas. The evidence was not considered adequate to demonstrate clinical advantages of DPP-4 inhibitors over less-expensive sulfonylureas as second-line therapy.

- **Third-line therapy:** For patients who need additional therapy after metformin plus sulfonylureas, the evidence suggests that adding NPH insulin is a reasonable choice. As with second-line treatment, CEPAC voted that GLP-1 receptor agonists offer incremental clinical benefits versus NPH insulin related to reduced weight gain and incidence of hypoglycemia, benefits that will be of greater potential importance for some patients than others. Here too, CEPAC felt that the balance of the clinical benefits versus the high per-patient incremental cost made GLP-1 receptor agonists a “low value” third-line therapy compared to NPH insulin. The evidence was inadequate to demonstrate clinical advantages of DPP-4 inhibitors over less-expensive NPH insulin as a third-line therapy.
CEPAC and Roundtable panelists discussed at length the options available for incentivizing the use of high value treatment options that may be underutilized in some settings. Council members highlighted the need for measures that ensure that patients are not unnecessarily receiving more expensive agents first, and pointed to the experience of MassHealth (Massachusetts Medicaid), which implements tight preauthorization controls over costly new drug therapies. In the case of second-line treatment options, the Council acknowledged that there are some patients for whom sulfonylureas may not be appropriate, but that it is a minority of patients. Clinical protocols and medical policy should therefore encourage consideration of initial second-line therapy with a sulfonylurea. CEPAC members agreed with payers on the Roundtable, however, that policies should not prevent the possibility of individualized treatment, and that exceptions must be made to allow patients that may benefit more from specific agents access to these therapies. For instance, some patients will benefit more from GLP-1 receptor agonists as initial second-line therapy due to the drugs’ positive effect on body weight. When developing policy, health plans and provider organizations must balance the mutual goals of maximizing health system value while creating an environment in which clinicians can provide individualized treatment as necessary without undue difficulty.

6. **The policy and clinical community should support the development of evidence and future research in the following areas:**

- Further study of insulin pumps and continuous glucose monitors is needed to understand if certain patient subpopulations with type 2 diabetes may benefit from these technologies. For future research to be relevant, additional regulation may be required from the FDA since at present, devices change and are upgraded so frequently that conducting meaningful long-term studies is impossible. CEPAC members recognized the challenge to developing a robust evidence base for devices as it is more difficult to perform a blinded study and there may be issues regarding confounding.

- Further research is needed to understand the heterogeneity of treatment effects, specifically for identifying patient subpopulations whose risk of significant hypoglycemia should lead to initial treatment with insulin analogs, GLP-1 receptor agonists, or DPP-4 inhibitors. Many important patient subpopulations are excluded from clinical trials, so little is known at present about treatment effects in patient groups that are not well studied.

- The research community should develop study designs that reflect patient preferences and analyze treatment regimens that are feasible for patients to maintain. Further studies should also be framed around more patient-centered questions, like the percentage of patients that achieve reductions in HbA1c levels without experiencing an adverse event. Conceptualized this way, research will more helpfully inform treatment decisions by addressing the questions that matter most to patients.
• Additional long-term studies are also needed that analyze primary rather than intermediate outcomes. Patient and clinical communities want to know the effect new medications have on mortality, myocardial infarction, stroke, and other long term complications of diabetes (e.g. retinopathy, neuropathy). Evidence on long-term outcomes exist for sulfonylureas, but are still lacking for newer medications.
References


Bell D. Do sulfonylurea drugs increase the risk of cardiac events? Can Med Assoc J. 2006;174(2):185-186.


Bydureon® (exenatide extended release for injectable suspension) Full Prescribing Information, AstraZeneca Pharmaceuticals LP, Wilmington DE, May 2014.

Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ. 2009 Feb 17;180(4):400-7.


Farxiga™ (dapagliflozin) Full Prescribing Information, AstraZeneca Pharmaceutical LP, Wilmington DE, August 2014.


Appendix A: Literature Search and Synthesis Strategy

Type 2 Diabetes Management – Literature Search and Synthesis Strategy

• Separate searches will be conducted for each domain in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials

1. Insulin choice: *neutral protamine Hagedorn (NPH) insulin vs. long-acting insulin analogs*

   Data Source: Long-acting insulin analogs vs. NPH insulin (Horvath [Cochrane]; 2009)
   Date Range: September 2006 – August 2014
   Population Type: Adult T2D patients requiring basal insulin treatment
   Interventions/Comparators: NPH insulin vs. insulin detemir or glargine
   Included Studies: RCTs, comparative cohorts, single-arm studies of ≥50 patients

2. Second-line medication options: metformin two-drug combination therapy with *sulfonylureas vs. DPP-4 inhibitors vs. GLP-1 receptor agonists vs. insulin*

   Data Source: Second-line pharmacotherapy for type 2 diabetes (CADTH; 2013)
   Date Range: February 2012 – August 2014
   Population Type: Adult T2D patients inadequately controlled on metformin monotherapy
   Interventions/Comparators: Metformin plus one of the following: sulfonylurea, GLP-1 receptor agonist, DPP-4 inhibitor, or basal insulin
   Included Studies: RCTs, comparative cohorts, single-arm studies of ≥50 patients

3. Third-line medication options: metformin three-drug combination therapy with sulfonylurea and *DPP-4 inhibitors vs. GLP-1 receptor agonists vs. insulin*

   Data Source: Third-line pharmacotherapy for type 2 diabetes (CADTH; 2013)
   Date Range: February 2012 – August 2014
   Population Type: Adult T2D patients inadequately controlled on metformin and sulfonylurea combination therapy
   Interventions/Comparators: Metformin and sulfonylurea plus one of the following: GLP-1 receptor agonist, DPP-4 inhibitor, or basal insulin
   Included Studies: RCTs, comparative cohorts, single-arm studies of ≥50 patients
4. Intensive insulin administration strategies: *multiple daily injections (MDI)* vs. *continuous subcutaneous insulin infusion (CSII)*

Data Source: Methods for insulin delivery and glucose monitoring (Golden [AHRQ]; 2012)

Date Range: April 2011 – August 2014

Population Type: Adult T2D patients on insulin treatment

Interventions/Comparators: Multiple daily injections vs. insulin pump therapy

Included Studies: RCTs, comparative cohorts, single-arm studies of ≥50 patients

5. Intensive glucose monitoring strategies: *continuous glucose monitors (CGM)* vs. *self-monitoring of blood glucose (SMBG)*

Data Source: Methods for insulin delivery and glucose monitoring (Golden [AHRQ]; 2012)

Date Range: April 2011 – August 2014

Population Type: Adult T2D patients on insulin treatment

Interventions/Comparators: Continuous glucose monitoring vs. conventional blood glucose monitoring

Included Studies: RCTs, comparative cohorts, single-arm studies of ≥50 patients
Appendix B: Results of Obesity-Related Sensitivity Analyses

Table B1. Cost-effectiveness of second-line treatments added to metformin for type 2 diabetes, with consideration of obesity-related utility values.

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Life Expectancy (years)</th>
<th>QALYs</th>
<th>Severe Diabetes Death (%)</th>
<th>Severe Hypoglycemia (%)*</th>
<th>Total Costs</th>
<th>vs. MET+SULF</th>
</tr>
</thead>
<tbody>
<tr>
<td>MET Alone (Ref)</td>
<td>11.01</td>
<td>8.33</td>
<td>21.5</td>
<td>N/A</td>
<td>$ 70,494</td>
<td>---</td>
</tr>
<tr>
<td>MET+SULF</td>
<td>11.11</td>
<td>8.38</td>
<td>20.5</td>
<td>1.0</td>
<td>$ 76,956</td>
<td>---</td>
</tr>
<tr>
<td>MET+GLP-1</td>
<td>11.17</td>
<td>8.53</td>
<td>20.3</td>
<td>No events</td>
<td>$ 117,184</td>
<td>$ 20,114,146</td>
</tr>
<tr>
<td>MET+DPP-4</td>
<td>11.10</td>
<td>8.41</td>
<td>20.8</td>
<td>&lt;0.1</td>
<td>$ 104,026</td>
<td>‡</td>
</tr>
<tr>
<td>MET+Insulin Analog</td>
<td>11.13</td>
<td>8.41</td>
<td>20.4</td>
<td>0.9</td>
<td>$ 101,839</td>
<td>$ 24,883,051</td>
</tr>
<tr>
<td>MET+NPH Insulin</td>
<td>11.13</td>
<td>8.41</td>
<td>20.4</td>
<td>0.9</td>
<td>$ 80,817</td>
<td>$ 3,861,003</td>
</tr>
</tbody>
</table>

*Not from model; pooled findings from RCTs in CADTH review
‡Less effective, more expensive

MET: Metformin; SULF: Sulfonylurea; GLP-1: Glugacon-like peptide-1 agonist; DPP-4: Dipeptidyl peptidase-4 inhibitor

Table B2. Cost-effectiveness of third-line treatments added to metformin+sulfonylurea for type 2 diabetes, with consideration of obesity-related utility values.

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Life Expectancy (years)</th>
<th>QALYs</th>
<th>Severe Diabetes Death (%)</th>
<th>Severe Hypoglycemia (%)*</th>
<th>Total Costs</th>
<th>vs. MET+SULF+NPH</th>
</tr>
</thead>
<tbody>
<tr>
<td>MET+SULF (Ref)</td>
<td>9.02</td>
<td>6.82</td>
<td>24.6</td>
<td>N/A</td>
<td>$ 81,773</td>
<td>---</td>
</tr>
<tr>
<td>MET+SULF+NPH Insulin</td>
<td>9.21</td>
<td>6.96</td>
<td>23.6</td>
<td>1.1</td>
<td>$ 91,025</td>
<td>---</td>
</tr>
<tr>
<td>Insulin</td>
<td>9.21</td>
<td>6.96</td>
<td>23.6</td>
<td>1.1</td>
<td>$ 91,025</td>
<td>---</td>
</tr>
<tr>
<td>MET+SULF+GLP-1</td>
<td>9.23</td>
<td>7.05</td>
<td>23.0</td>
<td>1.5</td>
<td>$ 122,181</td>
<td>$ 5,192,565</td>
</tr>
<tr>
<td>MET+SULF+DPP-4</td>
<td>9.13</td>
<td>6.91</td>
<td>23.8</td>
<td>2.6</td>
<td>$ 111,048</td>
<td>‡</td>
</tr>
<tr>
<td>MET+SULF+Insulin Analog</td>
<td>9.21</td>
<td>6.96</td>
<td>23.6</td>
<td>1.1</td>
<td>$ 108,717</td>
<td>‡</td>
</tr>
</tbody>
</table>

*Not from model; pooled findings from RCTs in CADTH review
†Less effective, more expensive
‡Equally effective, more expensive

MET: Metformin; SULF: Sulfonylurea; GLP-1: Glugacon-like peptide-1 agonist; DPP-4: Dipeptidyl peptidase-4 inhibitor
### Appendix C: Summary Evidence Tables

#### Table 1C. Long-acting Insulin Analogs vs. NPH Insulin.

<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Country</th>
<th>Study Design/ Treatment Duration</th>
<th>Comparators/ Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia *</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forst T 2010</td>
<td>Germany</td>
<td>RCT 3 months</td>
<td>Metformin + 1) insulin glargine 2) NPH insulin (1x daily evening injections for both)</td>
<td>1) 14 2) 14 N=28</td>
<td>Mean Age: 61.5  Gender: 79% male  Mean Baseline A1c: 7.1%  Mean Baseline BMI: 30.7kg/m²</td>
<td>1) -0.02 2) -0.03 p=NS</td>
<td>Not reported</td>
<td>None in either group</td>
<td>Daily insulin dose (IU): 1) 23.6 2) 23.3 p=NS Hypoglycemia events: 1) 1 2) 1</td>
</tr>
<tr>
<td>De Mattia G 2009</td>
<td>Italy</td>
<td>Cross-over 3 months</td>
<td>Metformin + sulfonylurea + 1) insulin glargine 2) NPH insulin (1x daily evening injections for both)</td>
<td>1) 10 2) 10 N=20</td>
<td>Mean Age: 59.4  Gender: 70% male  Mean Baseline A1c: 9.3%  Mean Baseline BMI: 29.5kg/m²</td>
<td>1) -1.7 2) -1.6 p=NS</td>
<td>Not significant for both</td>
<td>None in either group</td>
<td>Daily insulin dose (IU): 1) 28.8 2) 34.7 p=NR Hypoglycemia events: 1) 13 2) 15</td>
</tr>
<tr>
<td>Fritsche A 2003</td>
<td>Multinational</td>
<td>RCT 24 weeks</td>
<td>Sulfonylurea + 1) morning glargine insulin 2) evening glargine insulin 3) evening NPH insulin</td>
<td>1) 236 2) 227 3) 232 N=695</td>
<td>Mean Age: 61  Gender: 53.7% male  Mean Baseline A1c: 9.1%  Mean Baseline BMI: 28.7kg/m²</td>
<td>1) -1.24 2) -0.96 3) -0.84 1 vs. 3: p=0.001 2 vs. 3: p=0.008</td>
<td>1) +3.9 2) +3.7 3) +2.9 p=NS</td>
<td>1) 2.1% 2) 1.8% 3) 2.6% p=NS</td>
<td>Nocturnal hypoglycemia: 1) 39 (17%) 2) 52 (23%) 3) 89 (38%) 1 &amp; 2 vs. 3: p&lt;0.001</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.*
<table>
<thead>
<tr>
<th>Author/Year Country</th>
<th>Study Design/Treatment Duration</th>
<th>Comparators/Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eliaschewitz FG 2006 Latin America</td>
<td>RCT 24 weeks</td>
<td>Sulfonylurea + 1) glargine insulin 2) NPH insulin (1x daily evening injections for both)</td>
<td>1) 231 2) 250 N=481</td>
<td>Mean Age: 56.6 Gender: 40.3% male Mean Baseline A1c: 9.2% Mean Baseline BMI: 27.3kg/m²</td>
<td>1) -1.38 2) -1.44 p=NS</td>
<td>Not reported</td>
<td>1) 2.6% 2) 4.4% p=NS</td>
<td>Nocturnal hypoglycemia: 1) 16.9% 2) 30% p&lt;0.01 Patients reaching ≤7.0% A1c w/o hypoglycemia: 1) 27% 2) 17% p=0.014</td>
</tr>
<tr>
<td>Fonseca V 2004 United States</td>
<td>Subgroup analysis of Rosenstock 2001 28 weeks Subgroup of patients previously treated with NPH</td>
<td>1) insulin glargine (1x daily) 2) NPH insulin (1x or 2x daily)</td>
<td>1) 52 2) 48 N=100</td>
<td>Mean Age: 57.9 Gender: 57% male Mean Baseline A1c: 8.39% Mean Baseline BMI: 29.81kg/m²</td>
<td>1) -0.41 2) -0.46 p=NS</td>
<td>1) +.4 2) +1.4 p&lt;0.0007</td>
<td>1) 0.0% 2) 2.1% p=NR</td>
<td>Nocturnal hypoglycemia: 1) 8 (15%) 2) 13 (27%) p&lt;0.01</td>
</tr>
<tr>
<td>Massi Benedetti M 2003 Multinational</td>
<td>RCT 52 weeks</td>
<td>Combination therapy with OAD(s) + 1) insulin glargine 2) NPH insulin (1x daily evening injections for both)</td>
<td>1) 289 2) 281 N=570</td>
<td>Mean Age: 59.5 Gender: 53.7% male Mean Baseline A1c: 8.9% Mean Baseline BMI: 29.1kg/m²</td>
<td>1) -0.46 2) -0.38 p=NS</td>
<td>1) +2.01 2) +1.88 p=NS</td>
<td>1) 1.1% 2) 1.7% p=NR</td>
<td>All-cause mortality: 1) 1 2) 6 Nocturnal hypoglycemia: 1) 12% 2) 24% p=0.002</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.
<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Study Design/ Treatment Duration</th>
<th>Comparators/ Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Riddle MC 2003 United States and Canada</td>
<td>RCT 24 weeks</td>
<td>Combination therapy with OAD(s) + 1) insulin glargine 2) NPH insulin (1x daily evening injections for both)</td>
<td>1) 367 2) 389 N=756</td>
<td>Mean Age: 56 Gender: 55.3% male Mean Baseline A1c: 8.6% Mean Baseline BMI: 32.4kg/m²</td>
<td>1) -1.44 2) -2.03 p=NS</td>
<td>1) +2.8 2) +3.0 p=NS</td>
<td>1) 2.5% 2) 1.8% p=NR</td>
<td>Patients reaching ≤7.0% A1c w/o nocturnal hypoglycemia: 1) 33.2% 2) 26.7% p&lt;0.05 Daily insulin dose (IU): 1) 47.2 2) 41.8 p&lt;0.005</td>
</tr>
<tr>
<td>Rosenstock J 2001 United States</td>
<td>RCT 28 weeks</td>
<td>1) insulin glargine (1x daily) 2) NPH insulin (1x or 2x daily)</td>
<td>1) 259 2) 259 N=518</td>
<td>Mean Age: 59.3 Gender: 60% male Mean Baseline A1c: 8.5% Mean Baseline BMI: 30.5kg/m²</td>
<td>1) -0.41 2) -0.59 p=NS</td>
<td>1) +0.4 2) +1.4 p&lt;0.0007</td>
<td>1) 0.4% 2) 2.3% p=0.0581</td>
<td>Nocturnal hypoglycemia: 1) 26.5% 2) 35.5% p=0.0136</td>
</tr>
<tr>
<td>Wang XL 2007 China</td>
<td>RCT 3 months</td>
<td>Sulfonylurea + 1) insulin glargine 2) NPH insulin (1x daily evening injections for both)</td>
<td>1) 16 2) 8 N=24</td>
<td>Mean Age: 56 Gender: 50% male Mean Baseline A1c: 8.79% Mean Baseline BMI: 24.3kg/m²</td>
<td>1) -1.15 2) -1.32 p=NS</td>
<td>1) +1.47 2) +1.20 p=NS</td>
<td>None reported</td>
<td>Daily insulin dose (IU): 1) 19.0 2) 18.5 p&gt;0.05 Nocturnal hypoglycemia: 1) 6.3% 2) 50.0% p=0.028</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.
<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Study Design/ Treatment Duration</th>
<th>Comparators/ Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vahätälo MA 2013</td>
<td>Post-hoc analysis of Yki-Järvinen 2006 36 weeks</td>
<td>Metformin + insulin glargine or NPH insulin (1x daily evening injections for both) grouped according to hyperglycemia type (fasting or post-prandial)</td>
<td>1) 57 with FPG ≥1.3 (fasting) 2) 52 with FPG &lt;1.3 (post-prandial) N=109</td>
<td>Mean Age: 56 Gender: 63.6% male Mean Baseline A1c: 9.6% Mean Baseline BMI: 31.7kg/m²</td>
<td>1) -2.1 2) -2.0 p=NS (no difference between insulin groups)</td>
<td>1) +4.0 2) +2.0 p=0.02 (no difference between insulin groups)</td>
<td>None in either group</td>
<td>Daily insulin dose (IU/kg): 1) 0.77 2) 0.57 p=0.001 Hypoglycemic events (per patient): 1) 1.0 2) 2.0 p=NS</td>
</tr>
<tr>
<td>Yki-Järvinen H 2006</td>
<td>RCT 36 weeks</td>
<td>Metformin + 1) insulin glargine 2) NPH insulin (1x daily evening injections for both)</td>
<td>1) 49 2) 61 N=110 (intent-to-treat)</td>
<td>Mean Age: 56 Gender: 63.6% male Mean Baseline A1c: 9.6% Mean Baseline BMI: 31.7kg/m²</td>
<td>1) -2.0 2) -2.1 p=NS</td>
<td>1) +2.6 2) +3.5 p=NS</td>
<td>None in either group</td>
<td>Daily insulin dose (IU): 1) 68 2) 70 p=NS</td>
</tr>
<tr>
<td><strong>Insulin Detemir vs. NPH</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fajardo Montanana C 2008</td>
<td>RCT 26 weeks</td>
<td>Metformin + 1) insulin detemir 2) NPH insulin (1x daily evening injections for both)</td>
<td>1) 125 2) 146 N=271</td>
<td>Mean Age: 62 Gender: 40.6% male Mean Baseline A1c: 8.9% Mean Baseline BMI: 32kg/m²</td>
<td>1) -1.1 2) -1.0 p=NS</td>
<td>1) +.4 2) +1.9 p=0.0001</td>
<td>1) 0 2) 3 p=NR</td>
<td>Daily insulin dose (IU/kg): 1) 0.59 2) 0.47 p=0.001</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.*
<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Study Design/Treatment Duration</th>
<th>Comparators/Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philis-Tsimikas A 2006</td>
<td>RCT 20 weeks</td>
<td>OAD combo therapy with 1) insulin detemir (morning) 2) insulin detemir (evening) 3) NPH insulin (evening)</td>
<td>1) 165 2) 169 2) 164 N=498</td>
<td>Mean Age: 58.5 Gender: 56.5% male Mean Baseline A1c: 9.0% Mean Baseline BMI: 30kg/m²</td>
<td>1) -1.58 2) -1.48 3) -1.74 p=NS</td>
<td>1) +1.2 2) +0.7 3) +1.6 p=0.005 for evening detemir vs. NPH</td>
<td>1) 0 2) 2 3) 0 p=NR</td>
<td>Mortality (due to stroke): Detemir – 1 NPH – 1</td>
</tr>
<tr>
<td>Hendricksen KV 2012</td>
<td>Cross-over 17 weeks</td>
<td>1) insulin detemir 2) NPH insulin</td>
<td>N=24</td>
<td>Mean Age: 62 Mean Baseline A1c: 7.6% Mean Baseline Weight: 93.1kg</td>
<td>After 8 weeks 1) +1.2 2) 0 p&lt;0.01</td>
<td>After 1 week 1) -0.8 2) +0.4 p&lt;0.01</td>
<td>None reported</td>
<td></td>
</tr>
<tr>
<td>Haak T 2005</td>
<td>RCT 26 weeks</td>
<td>Premeal insulin aspart + 1) insulin detemir 2) NPH insulin (1x or 2x daily)</td>
<td>1) 341 2) 164 N=505</td>
<td>Mean Age: 60.4 Gender: 51.1% male Mean Baseline A1c: 7.9% Mean Baseline BMI: 30.4kg/m²</td>
<td>1) -0.2 2) -0.4 p=NS</td>
<td>1) +1 2) +1.8 p=0.017</td>
<td>&lt;2% overall</td>
<td>All-cause mortality: 1) 1 2) 0 Nocturnal hypoglycemia: 1) 52 (15.8%) 2) 38 (23.6%) p=NS</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.
<table>
<thead>
<tr>
<th>Author/Year Country</th>
<th>Study Design/ Treatment Duration</th>
<th>Comparators/ Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hermansen K 2006 Denmark</td>
<td>RCT 24 weeks</td>
<td><strong>OAD combo therapy with</strong> 1) insulin detemir 2) NPH insulin (2x daily for both)</td>
<td>N=476</td>
<td>Mean Age: 61 Gender: 43.3% male Mean Baseline A1c: 8.6% Mean Baseline BMI: 28kg/m²</td>
<td>1) -1.8 2) -1.9 p=NR</td>
<td>1) +1.2 2) +2.8 p&lt;0.001</td>
<td>None reported</td>
<td>Patients reaching ≤7.0% A1c w/o hypoglycemia: 1) 26% 2) 16% p=0.008</td>
</tr>
<tr>
<td>Delgado E 2012 Spain</td>
<td>Retrospective comparative cohort 4-9 months Patients on NPH insulin switched to insulin glargine or maintained on NPH insulin</td>
<td>1) insulin glargine 2) NPH insulin</td>
<td>1) 976 2) 506 N=1,482</td>
<td>Mean Age: 62.7 Gender: 46.6% male Mean Baseline A1c: 7.6% Mean Baseline BMI: 29kg/m²</td>
<td>1) -0.874 2) -0.363 p&lt;0.001</td>
<td>Not reported</td>
<td>1) 0.2% 2) 1.8% p=NR</td>
<td>Hypoglycemic events: 1) 213 (21.8%) 2) 241 (47.9%) p&lt;0.001</td>
</tr>
<tr>
<td>Gordon J 2010 United Kingdom</td>
<td>Retrospective comparative cohort 12 months Insulin-naïve patients initiating insulin treatment</td>
<td>1) insulin glargine 2) insulin detemir 3) NPH insulin 4) premix</td>
<td>1) 968 2) 114 3) 727 4) 2,528 N=4,337</td>
<td>Mean Age: 60.8 Gender: 45.6% male Mean Baseline A1c: 9.5% Mean Baseline Weight: 85.3kg</td>
<td>1) -1.2 2) -1.0 3) -0.9 4) -1.2 p&lt;0.001 change from baseline 1 vs. 3: p&lt;0.001</td>
<td>1) +1.9 2) +1.7 3) +2.3 4) +3.3 p&lt;0.001 change from baseline No between-group difference</td>
<td>None reported</td>
<td>Daily insulin dose (IU/kg): 1) 0.56 2) 0.61 3) 0.64 4) 0.76 Hypoglycemic events (per patient year): 1) 0.18 2) 0.12 3) 0.14 4) 0.25</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.
### Table 2C. Second-line pharmacotherapy in combination with metformin\(^1\).

<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Study Design/ Treatment Duration</th>
<th>Comparators/ Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bergenstal 2012</td>
<td>Multinational RCT 24 weeks, 28 weeks (first extension), 104 weeks (second extension)</td>
<td>1) GLP-1 taspoglutide (10mg) 2) GLP-1 taspoglutide (20mg) 3) DPP-4 sitagliptin 4) placebo</td>
<td>1) 190 1) 198 3) 185 4) 93 N=666</td>
<td>Mean Age: 55.9 Gender: 52.9% male Mean Baseline A1c: 7.96% Mean Baseline Weight: 92.4kg</td>
<td>1) -1.23 2) -1.30 3) -0.89 4) -0.10 p&lt;0.001</td>
<td>1) -1.8 2) -2.6 3) -0.9 4) -0.5 p&lt;0.001</td>
<td>None in either group</td>
<td>Discontinuation Rate: 1) 21% 2) 28% 3) 7% 4) 11% Non-severe Hypoglycemia: 1) 21 (11.2%) 2) 15 (7.8%) 3) 18 (9.8%) p=NR</td>
</tr>
<tr>
<td>Berndt-Zipfel C 2013</td>
<td>Germany RCT 24 weeks</td>
<td>1) DPP-4 vildagliptin 2) sulfonylurea glimepiride</td>
<td>1) 22 2) 22 N=44</td>
<td>Mean Age: 58.5 Gender: 63.6% male Mean Baseline A1c: 7.4% Mean Baseline BMI: 34kg/m(^2)</td>
<td>1) -0.67 2) -0.71 p=NR</td>
<td>1) -1.7 2) +1.8 p=NR</td>
<td>None in either group</td>
<td>Symptomatic hypoglycemic events: 1) 2 2) 29 p=NR</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.

\(^1\) Summary data from the studies included in the CADTH review are publically available here: [http://www.cadth.ca/media/pdf/OP0512_DiabetesUpdate_Second-line_e.pdf](http://www.cadth.ca/media/pdf/OP0512_DiabetesUpdate_Second-line_e.pdf)
<table>
<thead>
<tr>
<th>Author/Year Country</th>
<th>Study Design/Treatment Duration</th>
<th>Comparators/Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gallwitz B 2012a Multinational</td>
<td>RCT ~3 years</td>
<td>1) DPP-4 linagliptin 2) sulfonylurea glimepiride</td>
<td>1) 776 2) 775 N=1,551</td>
<td>Mean Age: 59.8 Gender: 60.2% male Mean Baseline A1c: 7.7% Mean Baseline BMI: 30.2kg/m²</td>
<td>1) -0.16 2) -0.36 p=0.0004</td>
<td>1) -1.4 2) +1.3 p&lt;0.001</td>
<td>1) 1.7% 2) 4.3% p=NR</td>
<td>Cardiovascular Events: 1) 12 (2%) 2) 26 (3%) RR 0.46 CI 0.23-0.91 Hypoglycemic events: 1) 58 (7%) 2) 280 (36%) p&lt;0.0001</td>
</tr>
<tr>
<td>Gitt AK 2013 Germany</td>
<td>Retrospective Cohort 1 year</td>
<td>1) DPP-4 2) sulfonylurea</td>
<td>1) 628 2) 256 N=884</td>
<td>Mean Age: 66.2 Gender: 49.8% male Mean Baseline A1c: 7.4% Mean Baseline Weight: 88.3kg</td>
<td>1) -0.6 2) -0.5 p=NS</td>
<td>1) -1.2 2) -0.4 p=NS</td>
<td>None reported</td>
<td>Non-fatal cardiovascular events: 1) 0.2% 2) 2.0% p&lt;0.05 Hypoglycemic events: 1) 5.5 2) 15.2 p=0.05 OR 0.32 95% CI 0.19-0.54</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.
<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Study Design/ Treatment Duration</th>
<th>Comparators/ Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Göke B 2013 Multinational</td>
<td>Secondary analysis of Göke 2010 1 year extension</td>
<td>1) DPP-4 saxagliptin 2) sulfonylurea glipizide</td>
<td>1) 428 2) 430 N=858</td>
<td>Mean Age: 57.6 51.7% male Mean Baseline A1c: 7.7% 31.4kg/m²</td>
<td>1) -0.41 2) -0.35 95% CI -0.17 to 0.06</td>
<td>1) -1.5 2) +1.3 95% CI -3.32 to -2.20</td>
<td>None reported</td>
<td>Patients reaching &lt;7.0% A1c w/o hypoglycemia: 1) 72 (22.2%) 2) 43 (13.4%) p=NR</td>
</tr>
<tr>
<td>Kim HS 2013 Korea</td>
<td>RCT 3 weeks</td>
<td>1) DPP-4 sitagliptin 2) Sulfonylurea glimepiride</td>
<td>1) 16 2) 17 N=33</td>
<td>Mean Age: 57.7 57.6% male Mean Baseline A1c: 7.2% 25.6kg/m²</td>
<td>1) -0.4 2) -0.4 p=NS</td>
<td>Not reported</td>
<td>None reported</td>
<td></td>
</tr>
<tr>
<td>Koren S 2012 Israel</td>
<td>Cross-over 3 months</td>
<td>1) DPP-4 sitagliptin 2) sulfonylurea glibenclamide</td>
<td>1) 20 2) 20 N=40</td>
<td>Mean Age: 59 62.5% male Mean Baseline A1c: 8.3% 31kg/m²</td>
<td>1) -0.6 2) -1.0 p=0.01</td>
<td>BMI change: 1) -0.01kg/m² 2) +0.50kg/m² p&lt;0.001</td>
<td>None in either group</td>
<td>Hypoglycemia: 1) 1 (2.6%) 2) 14 (37%) p=NR</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.
<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Country</th>
<th>Study Design/Treatment Duration</th>
<th>Comparators/Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Krobot KJ 2012</td>
<td>Multinational</td>
<td>Secondary analysis of Nauck 2007 52 weeks Evaluate risk of hypoglycemia after adjusting for most recent A1c value</td>
<td>1) DPP-4 sitagliptin 2) sulfonylurea glipizide</td>
<td>1) 588 2) 584 N=1,172</td>
<td>Mean Age: 57 Gender: 59% male Mean Baseline A1c: 7.7% Mean Baseline BMI: 31.3kg/m²</td>
<td>1) -0.67 2) -0.67 p=NS 95% CI -0.75 to -0.67</td>
<td>1) -1.5 2) +1.1 p&lt;0.001 95% CI -3.1 to -2.0</td>
<td>1) 2 2) 22 p=0.005 HR 0.08 95% CI 0.01 – 0.47</td>
<td>Risk of confirmed hypoglycemic events: 1) 31 2) 448 p&lt;0.001 HR 0.05 95% CI 0.03 -0.09</td>
</tr>
<tr>
<td>Morgan CL 2012</td>
<td>United Kingdom</td>
<td>Retrospective cohort 12 months</td>
<td>1) DPP-4 2) sulfonylurea</td>
<td>1) 1,455 2) 15,377</td>
<td>Variable depending on treatment Improvement s for both, but not &lt;7.0%</td>
<td>Not reported</td>
<td>None reported</td>
<td>Switching to combo therapy: 1) highest BMI (mean 34.2 kg/m2) 2) highest baseline HbA1c (mean 8.7%)</td>
<td></td>
</tr>
<tr>
<td>Rathman W 2013</td>
<td>Germany</td>
<td>Retrospective cohort 2 years</td>
<td>1) DPP-4 2) sulfonylurea</td>
<td>1) 19,184 2) 31,110 N=50,294</td>
<td>Mean Age: 66.7 Gender: 52.9% male Mean Baseline A1c: 7.7% Mean Baseline BMI: 31.5kg/m²</td>
<td>Not reported</td>
<td>Not reported</td>
<td>None reported</td>
<td>Incidence of macrovascular outcomes: 1) 10.3% 2) 14.3% Hypoglycemic events: 1) 0.18% 2) 1.0% OR 0.22 95% CI 0.13 - 0.36</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.
<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Study Design/ Treatment Duration</th>
<th>Comparators/ Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Srivastava S 2012 India</td>
<td>RCT 18 weeks</td>
<td>1) DPP-4 sitagliptin 2) sulfonylurea glimepiride</td>
<td>1) 25 2) 25 N=50</td>
<td>Mean Baseline A1c: 8.3% Mean Baseline BMI: 25.9kg/m²</td>
<td>1) -0.636 2) -1.172 p&lt;0.001</td>
<td>1) -0.102 2) +0.493 p&lt;0.01</td>
<td>None reported</td>
<td>Hypoglycemic events: 1) 1 (4%) 2) 2 (8%) Patients reaching &lt;7.0% A1c w/o hypoglycemia: 1) 12% 2) 36% p=NR</td>
</tr>
<tr>
<td>Gallwitz B 2012b Multinational</td>
<td>RCT ~2 years</td>
<td>1) GLP-1 agonist exenatide 2) sulfonylurea glimepiride</td>
<td>1) 515 2) 514 N=1,029</td>
<td>Mean Age: 56 Gender: 53.6% male Mean Baseline A1c: 7.5% Mean Baseline BMI: 32.4kg/m²</td>
<td>1) -0.37 2) -0.20 p=0.002</td>
<td>1) -3.32 2) +1.15 p&lt;0.0001</td>
<td>1) 0.2% 2) 0.0% p=NS</td>
<td>Discontinued treatment due to adverse event (first 6 months only): 1) 49 (9.6%) 2) 17 (3.3%) p=0.001 Patients reaching ≤7.0% A1c w/o hypoglycemia: 1) 45% 2) 31% p&lt;0.0001</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.
<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Study Design/ Treatment Duration</th>
<th>Comparators/ Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nauck M 2013</strong></td>
<td>Multinational 18 month extension</td>
<td>1) GLP-1 liraglutide (0.6mg) 2) GLP-1 liraglutide (1.2mg) 3) GLP-1 liraglutide (1.8mg) 4) sulfonylurea glimepiride 5) metformin monotherapy</td>
<td>1) 242 2) 241 3) 242 4) 244 5) 122 N=1,091</td>
<td>Mean Age: 56.6 Gender: 58.1% male Mean Baseline A1c: 8.4% Mean Baseline BMI: 31.06kg/m²</td>
<td>1) -0.4 2) -0.6 3) -0.5 4) -0.3 1 or 2 or 3 vs. 5: p&lt;0.0001 p&lt;0.0001</td>
<td>1) -2.1 2) -3.0 3) -2.9 4) +0.7 5) -1.8 1 or 2 or 3 vs. 5: p&lt;0.0001 2 vs. 4: p&lt;0.0001</td>
<td>1) 0 2) 1 3) 0 4) 0 5) 0 p=NR</td>
<td>Patients reaching ≤7.0% A1c w/o hypoglycemia or weight gain: 1) 13.2% 2) 23.3% 3) 25.6% 4) 6.6% 5) 8.3% 3 vs. 4: p=0.0493</td>
</tr>
<tr>
<td><strong>Insulin</strong></td>
<td></td>
<td></td>
<td></td>
<td>Mean Age: 53.6 Gender: 51% male Mean Baseline A1c: 8.5% Mean Baseline BMI: 31.1kg/m²</td>
<td>1) -1.72 2) -1.13 p&lt;0.0001</td>
<td>1) +0.44 2) -1.08 p&lt;0.0001 95% CI 0.93-2.09</td>
<td></td>
<td>Patients reaching ≤7.0% A1c w/o hypoglycemia: 1) 152 (68%) 2) 104 (42%) p&lt;0.0001</td>
</tr>
<tr>
<td><strong>Aschner P 2012</strong></td>
<td>RCT 6 months</td>
<td>1) glargine insulin 2) DPP-4 sitagliptin</td>
<td>1) 250 2) 265 N=515</td>
<td>Mean Age: 53.6 Gender: 51% male Mean Baseline A1c: 8.5% Mean Baseline BMI: 31.1kg/m²</td>
<td>1) -1.72 2) -1.13 p&lt;0.0001</td>
<td>1) +0.44 2) -1.08 p&lt;0.0001 95% CI 0.93-2.09</td>
<td>1) 1.2% 2) 0.4% p=NS</td>
<td></td>
</tr>
<tr>
<td><strong>Moon JS 2014</strong></td>
<td>RCT 1 year</td>
<td>1) glargine insulin 2) sulfonylurea glimepiride</td>
<td>1) 38 2) 36 N=74</td>
<td>Mean Age: 53.1 Gender: 39.2% male Mean Baseline A1c: 8.8% Mean Baseline BMI: 25kg/m²</td>
<td>1) -1.8 2) -1.8 p=NS</td>
<td>1) +1.7 2) 0.0 p=0.02</td>
<td>None in either group</td>
<td>Hypoglycemic events: 1) 26.3% 2) 55.9% p=0.01</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.*
<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Study Design/Treatment Duration</th>
<th>Comparators/Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roumie CL 2014 United States</td>
<td>Retrospective cohort ~14 months</td>
<td>1) insulin 2) sulfonylurea</td>
<td>1) 2,436 2) 12,180 N=14,616</td>
<td>Mean Age: 60 Gender: 94.6% male Mean Baseline A1c: 8.1% Mean Baseline BMI: 32.5kg/m²</td>
<td>1) -1.1 2) -1.2 p=NS</td>
<td>Not reported</td>
<td>None reported</td>
<td>All-cause mortality (per 1000 person-years): 1) 33.7 2) 22.7 p=0.001 HR 1.44 95% CI 1.15-1.79 Cardiovascular events and death (per 1000 person-years): 1) 42.7 2) 32.8 p=0.009 HR 1.30 95% CI 1.07 -1.58</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.
Table 3C. Third-line pharmacotherapy in combination with metformin and a sulfonylurea.

<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Study Design/ Treatment Duration</th>
<th>Comparators/ Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moses RG 2013</td>
<td>Multinational RCT 24 weeks</td>
<td>1) DPP-4 sitagliptin 2) placebo</td>
<td>N=257</td>
<td>Mean Age: 57 Gender: 59.9% male Mean Baseline A1c: 8.3% Mean Baseline BMI: 29.2kg/m²</td>
<td>1) -0.74 2) -0.08 p&lt;0.0001 95% CI -0.86 to -0.47</td>
<td>1) +0.2 2) -0.6 p=0.0272</td>
<td>None in either group</td>
<td>Patients reaching ≤7.0% A1c w/o hypoglycemia: 1) 3 (7.7%) 2) 0 (0%) p=NR</td>
</tr>
</tbody>
</table>

Table 4C. Insulin Pump Therapy vs. Multiple Daily Injections.

<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Study Design/ Treatment Duration</th>
<th>Comparators/ Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choi SB 2013</td>
<td>Retrospective case series 30 months</td>
<td>Patients with A1c ≥7% and diabetes duration ≥1 year initiating insulin pump therapy</td>
<td>N=521</td>
<td>Mean Age: 60 Gender: 51.2% male Mean Baseline A1c: 8.7% Mean Baseline BMI: 23.6kg/m²</td>
<td>-2.4 p&lt;0.0001 Patients maintained between 6.3%-6.5% for all time points vs. baseline (p&lt;0.0001)</td>
<td>+2.1 p&lt;0.0001</td>
<td>None reported</td>
<td>Patients reaching ≤7.0% A1c: 371 (71.2%) p=NR</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.

---

2 Summary data from the studies included in the CADTH review are publically available here: [http://www.cadth.ca/media/pdf/OP0512_Diabetes%20Update_Third-line_e.pdf](http://www.cadth.ca/media/pdf/OP0512_Diabetes%20Update_Third-line_e.pdf)

3 Summary data from the studies included in the AHRQ review are publically available here: [http://effectivehealthcare.ahrq.gov/ehc/products/242/749/CER57_Insulin-Delivery_FinalReport_20120703.pdf](http://effectivehealthcare.ahrq.gov/ehc/products/242/749/CER57_Insulin-Delivery_FinalReport_20120703.pdf)
<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Study Design/Treatment Duration</th>
<th>Comparators/Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lian G 2013 China</td>
<td>RCT 3 months</td>
<td>1) pump – long-term 2) pump – short-term 3) MDI – insulin glargine + aspart/lispro 4) MDI – aspart/lispro 5) MDI – human insulins</td>
<td>1) 30 2) 30 3) 30 4) 30 5) 30 N=150</td>
<td>Mean Age: 54.1 Gender: 48% male Mean Baseline A1c: 11%</td>
<td>1) -6.3 2) -4 3) -5.6 to -5.8 4) -3.8 to -5 5) -4.4 to -4.5 p&lt;0.05 (1 vs. 2)</td>
<td>Not reported</td>
<td>Not reported</td>
<td>Days to arrive at target: 1) 3.8 2) 3.9 3) 6.2 4) 7.7 5) 8.9 p&lt;0.05 (1 &amp; 2 vs. 3-5)</td>
</tr>
<tr>
<td>Luo P 2013 China</td>
<td>RCT 6 days</td>
<td>1) sensor-augmented pump 2) traditional pump 3) multiple daily injections</td>
<td>1) 20 2) 20 3) 20 N=60</td>
<td>Mean Age: 55.1 Gender: 63.3% male Mean Baseline A1c: 9.14% Mean Baseline BMI: 25.7kg/m²</td>
<td>Not reported</td>
<td>Not reported</td>
<td>None in either group</td>
<td>Mean daily blood glucose (mmol/L): 1) 7.18 2) 8.38 3) 9.43 p=0.01 (1 vs. 2 or 3) Mean daily insulin dose (IU): 1) 40.74 2) 34.09 3) 39.55 p=NS</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.
<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Country</th>
<th>Study Design/ Treatment Duration</th>
<th>Comparators/ Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia*</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lv WS 2013</td>
<td>China</td>
<td>RCT</td>
<td>1) pump with insulin aspart 2) multiple daily injections with insulin glargine 3) multiple daily injections with insulin detemir</td>
<td>1) 40 2) 40 3) 39  N=119</td>
<td>Mean Age: 61.1  Gender: 40.3% male  Mean Baseline A1c: 9.56%  Mean Baseline BMI: 25.07kg/m²</td>
<td>Not reported</td>
<td>Not reported</td>
<td>None in either group</td>
<td>Days to arrive at target: 1) 4.20 2) 7.48* 3) 6.85* <em>p&lt;0.05 (versus group A) Daily insulin dose (IU): 1) 40.25 2) 49.35</em> 3) 49.21* *p&lt;0.05 (versus group A)</td>
</tr>
<tr>
<td>Reznik Y 2014</td>
<td>Multinational</td>
<td>RCT</td>
<td>1) pump 2) multiple daily injections</td>
<td>1) 168 2) 163  N=331</td>
<td>Mean Age: 56  Gender: 54.4% male  Mean Baseline A1c: 9%  Mean Baseline BMI: 33.3kg/m²</td>
<td>1) -1.1 2) -0.4 p&lt;0.0001 95% CI -0.9 to -0.4</td>
<td>1) 1.5 2) 1.1 p=NS</td>
<td>1) 0 2) 1 p=NR</td>
<td>Daily insulin dose (IU): 1) 97 2) 122 p&lt;0.0001</td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.
Table 4C. Continuous Glucose Monitors vs. Self-Monitoring of Blood Glucose.

<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Study Design/Treatment Duration</th>
<th>Comparators/Interventions</th>
<th>Number of Patients</th>
<th>Patient Characteristics</th>
<th>Mean change in A1c (%)</th>
<th>Change in Body Weight (kg)</th>
<th>Frequency of Severe Hypoglycemia *</th>
<th>Other Outcomes of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fonda RA 2013</td>
<td>Secondary analysis of Vigersky 2012</td>
<td>1) favorable response but with high and variable glucose 2) tight control 3) worsening glycemia 4) incremental improvement 5) no response</td>
<td>1) 7 2) 14 3) 6 4) 11 5) 7 N=45</td>
<td>Mean Age: 55.8 Gender: 64.4% male Mean Baseline A1c: 8.3% Mean Baseline BMI: 32.1kg/m²</td>
<td>1) -0.6 2) -2.0 3) -1.3 4) -1.4 5) +0.1</td>
<td>Not reported</td>
<td>None reported</td>
<td>Display viewing frequency (per day): 1) 8x 2) 23x 3) 5x 4) 15x 5) 11x p=0.05</td>
</tr>
<tr>
<td>United States</td>
<td>Glucose response patterns among the rt-CMG cohort over 12 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vigersky RA 2012</td>
<td>RCT 12 weeks of active treatment and 40 weeks of follow-up</td>
<td>1) real-time continuous glucose monitors 2) self-monitoring of blood glucose</td>
<td>1) 50 2) 50 N=100</td>
<td>Mean Age: 57.8 Gender: 55% male Mean Baseline A1c: 8.3% Mean Baseline BMI: 32.3kg/m²</td>
<td>12 weeks 1) -1.0 2) -0.5 24 weeks 1) -1.2 2) -0.5 38 weeks 1) -0.8 2) -0.5 52 weeks 1) -0.8 2) -0.2 p=0.04</td>
<td>1) -4.1 2) -2.0 p=NS</td>
<td>None reported</td>
<td>Patients initiated on insulin during study: 1) 6 2) 14 p=0.05</td>
</tr>
<tr>
<td>United States</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Expressed as proportion of patients experiencing at least one event, or number of episodes.
### Appendix D: Results of Medicaid Sensitivity Analyses

#### Table C1. Cost-effectiveness of second-line treatments added to metformin, using prices and demographics reflective of a Medicaid population with Type 2 diabetes (sensitivity analysis).

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Life Expectancy (years)</th>
<th>QALYs</th>
<th>Diabetes Death (%)</th>
<th>Severe Hypoglycemia (%)*</th>
<th>Total Costs</th>
<th>vs. MET+SULF</th>
<th>Cost per Death Averted</th>
<th>Cost per QALY Gained</th>
</tr>
</thead>
<tbody>
<tr>
<td>MET+SULF</td>
<td>11.93</td>
<td>9.07</td>
<td>17.0</td>
<td>1.0</td>
<td>$ 72,055</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>MET+GLP-1</td>
<td>12.05</td>
<td>9.17</td>
<td>16.8</td>
<td>No events</td>
<td>$ 106,702</td>
<td>$ 27,067,972</td>
<td>$ 341,416</td>
<td></td>
</tr>
<tr>
<td>MET+DPP-4</td>
<td>11.92</td>
<td>9.06</td>
<td>17.0</td>
<td>&lt;0.1</td>
<td>$ 95,667</td>
<td>‡</td>
<td>‡</td>
<td>‡</td>
</tr>
<tr>
<td>MET+Insulin Analog</td>
<td>12.05</td>
<td>9.16</td>
<td>16.7</td>
<td>0.9</td>
<td>$ 94,528</td>
<td>$ 8,918,150</td>
<td>$ 267,060</td>
<td></td>
</tr>
<tr>
<td>MET+NPH Insulin</td>
<td>12.05</td>
<td>9.16</td>
<td>16.7</td>
<td>0.9</td>
<td>$ 76,888</td>
<td>$ 1,917,919</td>
<td>$ 57,433</td>
<td></td>
</tr>
</tbody>
</table>

*Not from model; pooled findings from RCTs in CADTH review
‡Less effective, more expensive
MET: Metformin; SULF: Sulfonylurea; GLP-1: Glugacon-like peptide-1 agonist; DPP-4: Dipeptidyl peptidase-4 inhibitor

#### Table C2. Cost-effectiveness of third-line treatments added to metformin+sulfonylurea, using prices and demographics reflective of a Medicaid population with Type 2 diabetes (sensitivity analysis).

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Life Expectancy (years)</th>
<th>QALYs</th>
<th>Diabetes Death (%)</th>
<th>Severe Hypoglycemia (%)*</th>
<th>Total Costs</th>
<th>vs. MET+SULF+NPH</th>
<th>Cost per Death Averted</th>
<th>Cost per QALY Gained</th>
</tr>
</thead>
<tbody>
<tr>
<td>MET+SULF+NPH Insulin</td>
<td>9.69</td>
<td>7.37</td>
<td>18.3</td>
<td>1.1</td>
<td>$ 67,255</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>MET+SULF+GLP-1</td>
<td>9.68</td>
<td>7.37</td>
<td>18.3</td>
<td>1.5</td>
<td>$ 90,915</td>
<td>$ 15,565,769</td>
<td>‡</td>
<td>‡</td>
</tr>
<tr>
<td>MET+SULF+DPP-4</td>
<td>9.67</td>
<td>7.34</td>
<td>18.6</td>
<td>2.6</td>
<td>$ 83,404</td>
<td>‡</td>
<td>‡</td>
<td>‡</td>
</tr>
<tr>
<td>MET+SULF+Insulin Analog</td>
<td>9.69</td>
<td>7.37</td>
<td>18.3</td>
<td>1.1</td>
<td>$ 81,109</td>
<td>‡</td>
<td>‡</td>
<td>‡</td>
</tr>
</tbody>
</table>

*Not from model; pooled findings from RCTs in CADTH review
‡Less effective, more expensive
≡Equally effective, more expensive
MET: Metformin; SULF: Sulfonylurea; GLP-1: Glugacon-like peptide-1 agonist; DPP-4: Dipeptidyl peptidase-4 inhibitor
Appendix E: Meeting Agenda and List of Participants

**Controversies in Type 2 Diabetes Management**

**Wednesday ● October 29, 2014 ● 10:00AM – 4:00PM**

**Agenda**

Brown University

Petteruti Lounge ● Stephen Robert ’62 Campus Center

75 Waterman Street ● Providence, RI 02912

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30AM – 10:00AM</td>
<td>Registration</td>
</tr>
</tbody>
</table>
| 10:00AM – 10:15AM | • Meeting convened and opening remarks:  
                       Steve Pearson, MD, MSc, President,  
                       Institute for Clinical and Economic Review |
| 10:15AM – 11:30AM | • Presentation of the Evidence:  
                            Daniel Ollendorf, PhD, Chief Review Officer,  
                            Institute for Clinical and Economic Review  
                            ● CEPAC Q&A                                |
| 11:30AM – 12:00PM | • Public Comments and Discussion:  
                                Members of the public pre-registered to deliver oral remarks |
| 12:00PM – 12:30PM | • Break for Lunch                                                        |
| 12:30PM – 2:00PM | • CEPAC Deliberation and Votes:  
                             ICER staff, clinical experts, and a patient representative will be available for  
                             questions from the Council during deliberation. |
| 2:00PM – 3:50PM | • Policy Roundtable:  
                             Consideration by CEPAC and Roundtable of Best Practice Recommendations  
                             (Panelists listed on back) |
<p>| 3:50PM – 4:00PM | • Meeting Adjourned                                                       |</p>
<table>
<thead>
<tr>
<th>CEPAC Members</th>
<th>Policy Roundtable Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert H. Aseltine, Jr., PhD</td>
<td>Francis Basile, Jr., MD*</td>
</tr>
<tr>
<td>Professor, Division of Behavioral Sciences and Community Health,</td>
<td>Chief of the Division of Primary Care, University Medicine, Inc.</td>
</tr>
<tr>
<td>University of Connecticut Health Center</td>
<td>Clinical Associate Professor, Warren Alpert School of Medicine at Brown University</td>
</tr>
<tr>
<td>Deputy Director, Center for Public Health and Health Policy</td>
<td></td>
</tr>
<tr>
<td>Director, Institute for Public Health Research, University of Connecticut</td>
<td></td>
</tr>
<tr>
<td>R. William Corwin, MD</td>
<td>Barbara Henry, RPh</td>
</tr>
<tr>
<td>Physician Champion, Co-Lead, Epic Acute Care Implementation Lifespan</td>
<td>Senior Clinical Pharmacy Coordinator, Harvard Pilgrim Health Care</td>
</tr>
<tr>
<td>Austin Frakt, PhD</td>
<td>Peter Hollmann, MD</td>
</tr>
<tr>
<td>Health Economist, VA Boston Healthcare System</td>
<td>Medical Director, Blue Cross Blue Shield of Rhode Island</td>
</tr>
<tr>
<td>Associate Professor, Boston University School of Public Health</td>
<td></td>
</tr>
<tr>
<td>Associate Professor, Boston University School of Medicine</td>
<td></td>
</tr>
<tr>
<td>Claudia B. Gruss, MD, FACP, FACG, CNSC (Chair)</td>
<td>Robert Smith, MD</td>
</tr>
<tr>
<td>Physician, ProHealth Physicians</td>
<td>Professor of Medicine, Warren Alpert School of Medicine at Brown University</td>
</tr>
<tr>
<td></td>
<td>Chair, U.S. FDA Endocrinologic and Metabolic Drugs Advisory Committee</td>
</tr>
<tr>
<td></td>
<td>Former Director, Hallett Center for Diabetes at Rhode Island Hospital</td>
</tr>
<tr>
<td>Claudio Gualtieri, JD</td>
<td>Albert Whitaker, MA*</td>
</tr>
<tr>
<td>Associate State Director of Advocacy</td>
<td>Director, Mission Delivery, American Diabetes Association, New England Chapter</td>
</tr>
<tr>
<td>Connecticut AARP</td>
<td></td>
</tr>
<tr>
<td>Christopher Jones, PhD</td>
<td>Rob Zavoski, MD</td>
</tr>
<tr>
<td>Assistant Professor, Department of Surgery</td>
<td>Medical Director, Connecticut Department of Social Services</td>
</tr>
<tr>
<td>Director, Global Health Economics Unit,</td>
<td></td>
</tr>
<tr>
<td>Center for Clinical and Translational Science,</td>
<td></td>
</tr>
<tr>
<td>University of Vermont College of Medicine</td>
<td></td>
</tr>
<tr>
<td>Stephen Kogut, PhD, MBA, RPh</td>
<td></td>
</tr>
<tr>
<td>Professor, University of Rhode Island College of Pharmacy</td>
<td></td>
</tr>
<tr>
<td>Julie Rothstein Rosenbaum, MD**</td>
<td></td>
</tr>
<tr>
<td>Associate Professor, Yale School of Medicine</td>
<td></td>
</tr>
<tr>
<td>Cynthia N. Rosenberg, MD (ex-officio)</td>
<td></td>
</tr>
<tr>
<td>Senior Medical Director, Harvard Pilgrim Health Care</td>
<td></td>
</tr>
<tr>
<td>Jeanne Ryer, MS</td>
<td></td>
</tr>
<tr>
<td>Director, New Hampshire Citizens Health Initiative</td>
<td></td>
</tr>
<tr>
<td>Tom Simpatico, MD (ex-officio)</td>
<td></td>
</tr>
<tr>
<td>Chief Medical Officer, Vermont Department of Health Access</td>
<td></td>
</tr>
<tr>
<td>Keith A. Stahl, MD</td>
<td></td>
</tr>
<tr>
<td>Physician and Medical Director, Catholic Medical Center</td>
<td></td>
</tr>
<tr>
<td>Mitchell Stein, MBA (Vice-Chair)</td>
<td></td>
</tr>
<tr>
<td>Independent Health Care Consultant</td>
<td></td>
</tr>
</tbody>
</table>

*No conflict of interest to report  ** Will be recused from voting during this meeting
Appendix F: CEPAC Conflict of Interest Policy for Voting Members

Conflict of Interest Policy for CEPAC Members

Voting CEPAC members do not represent the views of their employer, and must meet strict conflict of interest standards to serve on the Council. CEPAC members, excluding ex-officio members, cannot work for any of the New England state agencies or regional private payers, and are expected to be free from financial conflicts of interest and are required to disclose financial ties to any private health care organization. While issues of financial influence are handled on a case-by-case basis, as a guideline, CEPAC members, excluding ex-officio members, may not have substantial financial interests in the health care industry, defined as the following:

- A specific financial association, such as individual health care stock ownership (including those held by spouse or minor child) in excess of $25,000 during the previous year from any one health care manufacturer or insurer
- Financial association, such as individual health care stock ownership (including those held by spouse or minor child) in excess of $50,000 in aggregate during the previous year from health care manufacturers or insurers.

Any Council member with a direct financial association with the particular product or service being evaluated at a CEPAC meeting shall also recuse themselves from voting at that CEPAC meeting. “Direct financial association” is defined as individual health care stock ownership (including those held by spouse or minor child) in or health care consultancy income from the manufacturer of the product being evaluated in excess of $5,000 during the previous year.